1 How to drug a cloud? Targeting intrinsically disordered proteins

2 Vladimir N. Uversky ^{1,*}

5

6

- 4 Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA

Downloaded from pharmrev.aspetjournals.org at ASPET Journals on December 20, 2024

- 8 **Running Title:** Intrinsically disordered proteins as drug targets
- 9 **Corresponding author**: Vladimir N. Uversky, 120901 Bruce B. Downs Blvd., MDC07, Tampa,
- 10 Florida 33612, USA; phone: 1-813-974-5816; Fax: 1-813-974-7357; email: <u>vuversky@usf.edu</u>
- 11 The number of text pages: 131 (68 without references and figure legends)
- **The number of tables**: 0
- 13 The number figures: 14

- **The number of references:** 472
- 15 The number of words in the *Abstract*: 230

17	Abbreviations:	
18	Ab	antibody
19	AD	Alzheimer's disease
20	AI	artificial intelligence
21	ALS	amyotrophic lateral sclerosis
22	BC	biomolecular condensate
23	bHLHe39	basic helix-loop-helix protein
24	bHLHZip	basic region/helix-loop-helix/leucine zipper
25	СВ	Cajal body
26	CBP	CREB-binding protein
27	CDR	complementarity determining region
28	СР	chimeric polypeptide
29	CPP	cell penetrating peptide
30	cpSG	chloroplast stress granule
31	DBD	DNA-binding domain
32	Dox-CP	doxorubicin-conjugated chimeric polypeptide
33	ELP	elastin-like polypeptide
34	ESFT	Ewing's sarcoma family of tumors
35	EWS	Ewing's sarcoma
36	EWSR1	EWS breakpoint region 1
37	HCV	hepatitis C virus
38	HIV-1	human immunodeficiency virus-1
39	HLB	histone locus body
40	HMGB1	high mobility group protein B1
41	HRMT1L2	protein arginine N-methyltransferase 1
42	HSV	herpes simplex viruse
43	HTS	high-throughput screening
44	IDR	intrinsically disordered region

45	IDP	intrinsically disordered protein
46	IFN	interferon
47	ITF	inducible transcription factor
48	LBD	ligand binding domain
49	LLPS	liquid-liquid phase separation
50	LIMT	metallothionein from Littorina littorea
51	mAb	monoclonal antibody
52	Max	Myc-associated factor X
53	ML	machine learning
54	MLO	membrane-less organelle
55	MoRF	molecular recognition feature
56	MT	metallothionein
57	NAFLD	nonalcoholic fatty liver disease
58	nSB	nuclear stress body
59	OPT	Oct1/PTF/transcription
60	PcG	polycomb group
61	PD	Parkinson's disease
62	PDB	protein data bank
63	PML	progressive multifocal leukoencephalopathy
64	PNC	perinucleolar compartment
65	POD	PML oncogenic domains,
66	PPI	protein-protein interaction
67	PTM	posttranslational modification
68	RHA	RNA helicase A
69	RNP	ribonucleoprotein
70	SG	stress granule
71	SNB	Sam68 nuclear body
72	SNP	single nucleotide polymorphism

	U
	Ō,
	ᢓ
	'nloaded from pharmr
	ွှ
	ಹ
	লূ
	-
	亞
	Ξ
	\Box
۲	ᆵ
	a
	≒
	☱
	œ,
	:<
	as
۲	ğ
	œ.
٠	♂.
	Ĕ
	3
	<u> </u>
	$\overline{\mathbf{s}}$
	9
	Ξ
(, ,
(2
(at .
(at A
(at ASI
(at ASPE
(at ASPET
(g at ASPET J
(at ASPET Jo
(g at ASPET Jour
(g at ASPET Journa
•	g at ASPET Journal
•	at ASPET Journals
•	at ASPET Journals or
(at ASPET Journals on l
(at ASPET Journals on De
	ournals on De
	at ASPET Journals on Decer
	at ASPET Journals on December
	at ASPET Journals on Decembe
	at ASPET Journals on December
	at ASPET Journals on December 20
	at ASPET Journals on December 20.
,	at ASPET Journals on December 20, 2
	at ASPET Journals on December 20, 202
	at ASPET Journals on December 20, 2024
`	at ASPET Journals on December 20, 2024

73	SSD	signal sensing domain
74	TAD	transactivation domain
75	TF	transcription factor
76	TPPP/p25	tubulin polymerization promoting protein
77		

Abstract

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

Biologically active proteins/regions without stable structure (i.e., intrinsically disordered proteins and regions (IDPs and IDRs)) are commonly found in all proteomes. They have a unique functional repertoire that complements the functionalities of ordered proteins and domains. IDPs/IDRs are multifunctional promiscuous binders capable of folding at interaction with specific binding partners on a template- or context-dependent manner, many of which undergo liquid-liquid phase separation, leading to the formation of membrane-less organelles and biomolecular condensates. Many of them are frequently related to the pathogenesis of various human diseases. All this defines IDPs/IDRs as attractive targets for the development of novel drugs. However, their lack of unique structures, multifunctionality, binding promiscuity, and involvement in unusual modes of action preclude direct use of traditional structure-based drug design approaches for targeting IDPs/IDRs, and make disorder-based drug discovery for these "protein clouds" challenging. Despite all these complexities there is continuing progress in the design of small molecules affecting IDPs/IDRs. This article describes the major structural features of IDPs/IDRs and the peculiarities of the disorder-based functionality. It also discusses the roles of IDPs/IDRs in various pathologies, and shows why the approaches elaborated for finding drugs targeting ordered proteins cannot be directly used for the intrinsic disorder-based drug design, and introduces some novel methodologies suitable for these purposes. Finally, it emphasizes that regardless of their multifunctionality, binding promiscuity, lack of unique structures, and highly dynamic nature, "protein clouds" are principally druggable.

Significance Statement

Intrinsically disordered proteins and regions are highly abundant in nature, have multiple important biological functions, are commonly involved in the pathogenesis of a multitude of human diseases, and are therefore considered as very attractive drug targets. Although dealing with these unstructured multifunctional protein/regions is a challenging task, multiple innovative approaches have been designed to target them by small molecules.

106	Table of Contents
107	I. Introduction dancing protein clouds:
108	I.A. Functions beyond the classic "lock-and-key"
109	I.B. Spatio-temporal heterogeneity of IDPs: Structural dissection of dancing protein clouds
110	I.C. Intrinsic disorder and structure-function continuum
111	I.D. Intrinsic disorder and liquid-liquid phase separation
112	II. Diseases and disorder-based protein complexity: Too many ways to get something wrong
113	III. How to target a dancing protein cloud
114	III.A. Why one would want to target an IDP?
115	III.B. Some general strategies for targeting IDPs
116	III.C. Targeting transcription factors
117	III.C.1. General considerations
118	III.C.2. Crucial hybrids: Order and intrinsic disorder in transcription factors
119	III.C.3. Transcription factors as potential and actual drug targets
120	III.C.4. Targeting ordered domains of transcription factors
121	III.C.5. Disorder-based rational drug design: the p53-Mdm2 story
122	III.C.6. cMyc-Max journey
123	III.C.7. Targeting EWS-FLI1 and other oncogenic translocation-generated fusion proteins

124	III.C.8. Androgen receptor
125	III.D. Irrational drug design: Targeting functionally misfolded IDPs/IDRs
126	III.E. Targeting aggregating IDPs/IDRs
127	III.F. Disorder-based development of consensus interferons
128	III.G. Unstructural vaccinology: Fighting fire with fire
129	III.H. Targeting liquid-liquid phase separation
130	III.I. Self-assembling "smart" IDP-based containers for targeted drug delivery
131	III.J. Pharmacological chaperones
132	IV. Concluding remarks: Clouds in clouds
133	
134	
135	
136	
137	

I. Introduction

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

I.A. Introducing dancing protein clouds: Functions beyond the classic "lock-and-key" Most biochemistry textbooks use the "lock-and-key" model to describe the molecular principles of protein functionality, which depicts an enzyme as a lock, its active site as a key-hole, and a substrate as a key, and which claims that only the correctly shaped/sized substrate (key) could fit into the key-hole (active site) of the particular lock (enzyme). This theory was proposed in 1894 by German chemist Hermann Emil Louis Fischer (1852-1919) to explain why in the enzymatic hydrolysis of glucoside multimers, one enzyme could hydrolyze α - but not β -glycosidic bonds, whereas a similar enzyme could hydrolyze β - but not α -glycosidic bonds (Fischer, 1894; Lemieux and Spohr, 1994). This highly mechanistic model was exceptionally fruitful and actually served as a "big-bang" moment of the creation of the universe of modern protein science, since most of the knowledge generated in the field by the end of the last century was in one way or another rooted in the lock-and-key principle and the associated sequence-structurefunction paradigm, according to which a unique amino acid sequence of a protein defines its unique 3D structure, which is crucial for unique protein function (Uversky, 2002a). Furthermore, the ever-increasing content of the protein data bank (PDB), where, as of June 08, 2024, unique 3D structures determined by X-ray diffraction are reported for over 185,000 proteins, provides compelling support for the static view of a functional protein structure. However, the situation changed drastically at the turn of the century, when it was recognized that not all biological functions of proteins require stable well-defined structure in solution, with many functions originating from the lack of ordered structure in a protein molecule (Dunker et al., 2001; Dunker and Obradovic, 2001; Dunker et al., 2008a; Dunker et al., 2008b; Dyson and

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

Wright, 2005; Tompa, 2002b; Uversky, 2002a; b; Uversky and Dunker, 2010b; Uversky et al., 2000a; Wright and Dyson, 1999b). These intrinsically disordered proteins and regions (IDPs and IDRs, respectively) exist as structural ensembles either at the secondary or at the tertiary structure level. Curiously, although the origin of "unfoldomics" (Dunker et al., 2008a; Uversky, 2024) is attributed to a handful of papers published in the early 2000s (Dunker et al., 2001; Dunker and Obradovic, 2001; Tompa, 2002b; Uversky, 2002a; b; Uversky et al., 2000a; Wright and Dyson, 1999b), these biologically active proteins without unique structures were actually discovered and rediscovered multiple times. This lengthy prehistory generated a wide trail of terms used for the description of these proteins, which were depicted in literature as floppy, pliable, rheomorphic (Holt and Sawyer, 1993), flexible (Pullen et al., 1975), mobile (Cary et al., 1978), partially folded (Linderstrom-Lang and Schellman, 1959), natively denatured (Schweers et al., 1994), natively unfolded (Uversky et al., 2000b; Weinreb et al., 1996), natively disordered (Daughdrill et al., 2005), intrinsically unstructured (Tompa, 2002a; Wright and Dyson, 1999a), intrinsically denatured, (Schweers et al., 1994) intrinsically unfolded (Weinreb et al., 1996), intrinsically disordered (Dunker et al., 2001), vulnerable (Chen et al., 2008), chameleon (Uversky, 2003a), malleable (Fuxreiter et al., 2008), 4D proteins (Tsvetkov et al., 2008), protein clouds (Dunker and Uversky, 2010), dancing proteins (Livesay), proteins waiting for partners (Janin and Sternberg, 2013), and several other names often representing different combinations of 'natively, naturally, inherently, and intrinsically' with 'unfolded, unstructured, disordered, and denatured' among several other terms (Dunker et al., 2013). Earlier, the "dancing protein cloud" term was introduced by superimposing the aforementioned "dancing proteins" and "protein clouds" descriptors (Uversky, 2016a). It was also emphasized: "Although the phrase "dancing protein clouds" sounds like a parody, the term actually has deep meanings. The presence of a

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

unique structure in a given protein means that when one would look at the sample containing this protein, s/he would find that all protein molecules are alike, that the structure of an individual molecule barely changes over time, and that the ensemble-averaged (or time-averaged) structure is identical, or at least very similar, to the structures of all individual protein molecules in that sample. In other words, if one would overlay all those individual structures, a crisp and clear image would be generated, similar to those found in the PDB, and this ensemble-averaged structure would not change much over time. On the other hand, the lack of a unique structure in a given protein would create a highly dynamic ensemble, members of which would possess very different structures at any given moment, and the structure of any given molecule would change dramatically over time (therefore the "dancing protein" analogy). If one would try to overlay all those structures, all those dancing protein molecules, a cloud-like, fuzzy entity would be generated, and the shape of this cloud would not be static, dramatically changing with time and in response to subtle environmental perturbations" (Uversky, 2016a). This idea is illustrated by **Figure 1** showing the NMR solution structure of one of the IDPs, barnacle (*Megabalanus rosa*) cement protein MrCP20 (PDB ID: 6LEK; (Mohanram et al., 2019)), where 10 models are overlaid, generating a complex conformational ensemble that clearly resembles a fuzzy cloud. Although originally considered as being rather rare exceptions, IDPs/IDRs, which fail to form unique 3D-structures under physiological conditions, are highly abundant in different proteomes (Dunker et al., 2000; Tokuriki et al., 2009; Uversky, 2010a; Ward et al., 2004; Xue et al., 2012; Xue et al., 2010), and are especially prevalent in eukaryotes (Dunker et al., 2000; Oldfield et al., 2005a; Uversky, 2010a; Ward et al., 2004; Xue et al., 2012). The natural abundance of intrinsic disorder can be understood via a unique usefulness of this feature for some proteins functions (Daughdrill et al., 2005; Dunker et al., 2002a; Dunker et al., 2002b; Dunker et al., 2005; Dunker

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

et al., 1998; Dunker et al., 2001; Dunker and Obradovic, 2001; Dyson and Wright, 2005; Tompa, 2002b; 2005; Tompa and Csermely, 2004; Uversky, 2002a; b; 2003b; Uversky and Dunker, 2010b; Uversky et al., 2000a; Uversky et al., 2005; Vucetic et al., 2007; Wright and Dyson, 1999b; Xie et al., 2007). Since the disorder-based functionality cannot be described within the frame of the traditional structure-function paradigm, a more comprehensive view of the protein structure/function relationships is needed, where the disorder-based functionality complements the functions of ordered proteins (Vucetic et al., 2007; Xie et al., 2007). In fact, the majority of signaling proteins contain significant levels of intrinsic disorder (Dunker et al., 2002a), and IDPs/IDRs, being capable of interactions with multiple partners and being involved in highspecificity/low-affinity interactions, often play central roles in regulation and control of numerous cellular signaling pathways and in promoting the assembly of supra-molecular complexes (Dunker et al., 2005; Uversky et al., 2005). IDPs are multifunctional proteins capable of promiscuous interactivity with numerous and often unrelated partners. This makes them crucial organizers and controllers of complex protein-protein interaction (PPI) networks, in which IDPs/IDRs often act as hubs (Daughdrill et al., 2005; Dosztanyi et al., 2006; Dunker et al., 2005; Ekman et al., 2006; Haynes et al., 2006; Oldfield et al., 2008; Patil and Nakamura, 2006; Singh et al., 2007; Uversky, 2011b). Below is a list of some of the most important functional advantages of intrinsic disorder (Brown et al., 2002; Cortese et al., 2008; Daughdrill et al., 2005; Dunker et al., 2002a; Dunker et al., 2002b; Dunker et al., 2005; Dunker et al., 1998; Dunker et al., 2001; Dunker and Obradovic, 2001; Dunker et al., 1997; Dyson and Wright, 2002a; 2005; Iakoucheva et al., 2002; Mollica et al., 2016; Plaxco and Gross, 1997; Pontius, 1993; Romero et al., 2001; Schulz, 1979; Uversky, 2013a; Uversky et al., 2005; Wright and Dyson, 1999b):

- 1) Most IDPs/IDRs are characterized by multifunctionality, which is based on their mosaic architecture, where multiple relatively short and differently folded or disordered functional elements are spread within the amino acid sequences (DeForte and Uversky, 2016; Uversky, 2013a; d; 2016a; 2019).
 - 2) Multifunctionality of 'moonlighting' proteins (i.e., proteins that perform multiple unrelated functions, each being independently regulated) relies on the presence of IDRs (Tompa et al., 2005).
 - 3) Biological activities and functions of IDPs/IDRs (due to their high accessibility) are easily modulated by various enzymatically catalyzed posttranslational modifications (PTMs), such as acetylation, glycosylation, phosphorylation, sumoylation, and ubiquitination. (Darling and Uversky, 2018; Iakoucheva et al., 2004; Pejaver et al., 2014).
 - 4) IDPs/IDRs are efficiently regulated via rapid proteolytic degradation.

- 5) IDPs/IDRs are commonly subjected to alternative splicing, which results in the production of diverse forms and thereby represents an important means for regulation and redirection.
- 6) IDPs/IDRs can undergo disorder-to-order transitions under a variety of conditions
 (Dunker et al., 2002a; Dunker et al., 2005; Dunker et al., 2001; Dyson and Wright,
 2002a; 2005; Fink, 2005; Iakoucheva et al., 2002; Oldfield et al., 2005b; Oldfield et al.,
 2008; Tompa, 2002b; Uversky, 2002a; b; Uversky et al., 2000a; Uversky et al., 2005;
 Wright and Dyson, 1999b). Besides changes in the protein environment, such folding can
 also be promoted by interaction with binding partners, such as other proteins, nucleic

- acids, membranes, or small molecules (Daughdrill et al., 2005; Dunker et al., 2002a; Dunker et al., 2002b; Dunker et al., 2005; Dunker et al., 2001; Dunker and Obradovic, 2001; Dyson and Wright, 2002a; 2005; Iakoucheva et al., 2002; Plaxco and Gross, 1997; Pontius, 1993; Schulz, 1979; Spolar and Record, 1994; Uversky et al., 2005; Wright and Dyson, 1999b). The protein regions capable of such binding-induced folding are known as molecular recognition features (MoRFs) (Cheng et al., 2007; Mohan et al., 2006; Oldfield et al., 2005b; Vacic et al., 2007a). They are known to play crucial roles in various biological processes, such as cell signaling, recognition, and regulation (Disfani et al., 2012).
- 7) Many IDRs can act as morphing MoRFs, which fold differently at interaction with different partners (Hsu et al., 2012; Oldfield et al., 2008), and many IDPs/IDRs can readily bind to multiple partners by changing shape (Dunker et al., 2001; Karush, 1950; Kriwacki et al., 1996). All this defines the unique disorder-based binding plasticity, where, depending on the template provided by binding partners, IDPs/IDRs can mold into specific bound conformations (which can be very different).
- 8) IDPs/IDRs commonly contain short linear motifs (SLiMs) and eukaryotic linear motifs (ELMs) with a typical length between 5 and 25 residues. These linear motifs are characterized by noticeable conservation (the presence of a short consensus pattern, with conserved residues that are interspersed with rather freely exchangeable, variable positions). Being dynamic switch-like elements, which are frequently generated and erased in evolution, these short linear motifs can often be involved in mediating specific protein-protein interactions (Fuxreiter et al., 2007b; Linding et al., 2003; Neduva and Russell, 2005; Puntervoll et al., 2003).

9) Many IDPs and IDRs contain transient elements of secondary structure, pre-structured motifs (PreSMos) (Chi et al., 2007; Lee et al., 2012), which were shown to pre-exist (Lee et al., 2000) or be pre-formed prior to their binding to targets (Zitzewitz et al., 2000). Therefore, PreSMos, which are also known by other names, such as pre-organized (Bienkiewicz et al., 2002), pre-ordered (Sayers et al., 2000), or local structural elements (Lee et al., 2000), transient structure (Ramelot et al., 2000), preformed structural element (PSE) (Fuxreiter et al., 2004), primary contact site (PCS) (Csizmok et al., 2005), and linear motifs (Fuxreiter et al., 2007b), act as active sites of IDPs/IDRs that mediate target protein binding in many, if not all, extended IDPs/IDRs (Lee et al., 2012).

- 10) The bound forms of IDPs could be either relatively non-compact (i.e., remain substantially disordered or fuzzy) (Dosztanyi and Tompa, 2008; Fuxreiter and Tompa, 2012; Uversky, 2011b; 2013b) or be tightly folded (Tompa and Fuxreiter, 2008; Uversky, 2002b; 2011b).
- 11) To accommodate the peculiarities of interaction with various partners, IDPs/IDRs employ binding fuzziness based on the utilization of different binding mechanisms, such as stabilization of the binding-competent secondary structure elements within the contact region, establishing long-range electrostatic interactions, involvement in the transient physical contacts with the partner, or formation of highly disordered complexes without any apparent ordering.
- 12) IDPs/IDRs can be involved in cascade interactions (or "binding chain reactions:), where binding to a first partner induces partial folding of an IDP/IDR, causing the formation of

a new binding site suitable for interaction with a second partner(Fuxreiter et al., 2014; Uversky, 2013c).

- 13) The presence of intrinsic disorder allows decoupling specificity and affinity of binding, which is central for the formation of specific but weak complexes involved in reversible signaling processes, where turning a signal off is as important as turning it on (Dunker et al., 2001; Schulz, 1979).
- 14) IDPs/IDRs, being extended and flexible, are characterized by a greater capture radius, which allows them to have faster kinetics of interaction and spatially search through a wider interaction space. Due to their conformational pliability, they are also able to overcome steric restrictions.
- 15) Due to their extended linear conformations, IDPs/IDRs are capable of holding overlapping binding sites.
- 16) IDPs/IDRs also have increased interaction (surface) area per residue that broadens their binding mechanisms and enables larger interaction surfaces in protein-protein and protein-ligand complexes than those obtained between rigid partners.
- 17) The large interaction surfaces allow some IDPs/IDRs to form very stable intertwined complexes.
- 18) IDPs/IDRs can form transient encounter complexes, which makes spatial orientation requirements less stringent.

19) The structural flexibility and conformational dynamics of IDPs/IDRs provides important means for masking (or not) of interaction sites and allows interaction between bound partners.

- 20) IDPs/IDRs can be engaged in one-to-many binding, where a single IDP/IDR is capable of binding to several structurally diverse partners.
- 21) IDPs/IDRs also participate in many-to-one binding, where many different IDPs/IDRs interact with a single ordered protein.
- 22) IDPs/IDRs are characterized by a broad variability of their evolutionary conservation, with some of them being highly conserved and others possessing very high evolutionary rates and rapidly evolving into sophisticated and complex interaction centers (scaffolds) that can be easily tailored to the needs of different organisms.
- 23) Some IDPs/IDRs have functions that are entropic in nature that not only do not require any folding (Dunker et al., 2002a; Dunker et al., 2002b; Dunker et al., 2001; Tompa, 2002b; 2005; Uversky, 2002a; b; Uversky and Dunker, 2010b) but actually originate from the lack of stable well-defined structure in a protein molecule or a protein region (Dunker et al., 2001; Dunker and Obradovic, 2001; Dunker et al., 2008a; Dunker et al., 2008b; Dyson and Wright, 2005; Tompa, 2002b; Uversky, 2002a; b; Uversky and Dunker, 2010b; Uversky et al., 2000a; Wright and Dyson, 1999b).

In relation to the disorder-based signaling and regulatory interactions (as well as to the related roles of IDPs/IDRs in the pathogenesis of different diseases), one of the major functional advantages of IDPs/IDRs is their ability to undergo disorder-to-order transitions upon binding

that gives them a possibility, during the formation of "signaling" complexes characterized by high specificity and low affinity, to decouple the specificity and affinity of binding (Dunker et al., 2001; Schulz, 1979). Also, many IDPs/IDRs can act as shape-shifters capable of interaction with partners by changing shape or undergoing partner-specific folding (Dunker et al., 2001; Hsu et al., 2012; Hsu et al., 2013; Karush, 1950; Kriwacki et al., 1996; Oldfield et al., 2008; Uversky, 2013b; d). Numerous other advantages of intrinsic disorder for signaling, regulation, and control-related protein functions have been systemized in several dedicated studies (Brown et al., 2002; Cortese et al., 2008; Dunker et al., 1998; Dunker et al., 2001; Dunker et al., 1997; Romero et al., 2001; Uversky, 2013a; Wright and Dyson, 1999b) and are schematically summarized in **Figure** 2.

I.B. Spatio-temporal heterogeneity of IDPs: Structural dissection of dancing protein clouds

The characteristic feature of IDPs/IDRs is their inability to spontaneously fold under conditions which trigger folding of ordered proteins/domains. The ability or inability of a protein to spontaneously fold under physiological conditions is defined by the peculiarities of its amino acid sequence. Therefore, based on the sequence-structure relationships, the universe of protein amino acid sequences can be divided into at least two very different categories: sequences that naturally fold into ordered proteins or domains, and sequences that yield IDPs/IDRs (Uversky, 2013a; Wathen and Jia, 2009). In fact, multiple features can differentiate amino acid sequences coding for IDPs/IDRs from sequences encoding ordered globular proteins/domains. These features include, but are not limited to, the amino acid composition, charge, evolutionary conservation, flexibility, hydrophobicity, and sequence complexity. For example, ordered and

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

disordered proteins and regions can be differentiated based on the peculiarities of their amino acid compositions, as IDPs/IDRs are enriched in so-called disorder-promoting residues A, G, D, M, K, R, S, O, P, and E, and are depleted in order-promoting amino acids C, W, Y, I, F, V, L, H, T, and N, many of which would commonly be found in the hydrophobic cores of folded globular proteins (Dunker et al., 2001; Radivojac et al., 2007; Vacic et al., 2007b; Williams et al., 2001) (see **Figure 3A**). Various disorder predictors utilize these and other sequence differences. Due to the complexity of the protein intrinsic disorder phenomenon and because of the multiple features that are used by different tools to differentiate ordered and disordered sequences, a more complete representation of the disorder status of an individual protein of interest or of a protein dataset can be achieved by comparing and combining several predictors (Bourhis et al., 2007; Dosztanyi et al., 2007; Dosztanyi and Tompa, 2008; Esnouf et al., 2006; Ferron et al., 2006; He et al., 2009; Huang et al., 2012; Oldfield et al., 2005a; Uversky, 2017a). It was also pointed out that the inability of IDPs/IDRs to spontaneously fold and the requirement for some of them to bind to specific partners in order to gain more ordered structures indicated that their amino acid sequences do not contain an entire "folding code" defining the ability of foldable proteins to spontaneously gain their unique biologically active structures. Since many IDPs/IDRs can fold at interaction with specific partners, it seems that these binding partner(s) can supplement at least part of the missing portion of their "folding code". Importantly, this feature also defines an important difference between ordered and disordered proteins in the molecular principles of their functions, where ordered proteins first undergo spontaneous folding and then bind their partners, whereas IDPs/IDRs remain disordered until they find and bind to their partners (Uversky, 2013a; d; Uversky and Dunker, 2013). Furthermore, many disorderbased functions do not require any folding (Dunker et al., 2002a; Dunker et al., 2002b; Dunker et

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

al., 2001; Tompa, 2002b; 2005; Uversky, 2002a; b; Uversky and Dunker, 2010b), and some IDPs/IDRs preserve significant amount of disorder in their bound states, forming so-called fuzzy complexes (Fuxreiter and Tompa, 2012; Tompa and Fuxreiter, 2008). On the other hand, the removal of the restrictions posed by the need to spontaneously fold into ordered structure dramatically increases the sequence space available to IDPs/IDRs (at least those which either do not fold at all, or do not completely fold at binding) in comparison with the sequence space available to foldable proteins and domains (Uversky, 2013a; d). These considerations are illustrated by Figure 3B showing the difference in the dimensions of the sequence spaces encoding for ordered/compact and extended intrinsically disordered proteins within the chargehydropathy phase space. Importantly, the structural heterogeneity of IDPs/IDRs is not limited by the aforementioned peculiarities of their amino acid sequences, being further extended due to the capability of different parts of a protein to be (dis)ordered to different degrees, and the overall ability of IDPs/IDRs to have different levels and depth of disorder (Uversky et al., 2005). In fact, even at the whole molecule level, intrinsic disorder can be found in three different forms, as IDPs can exist in the collapsed (molten globule-like), or extended (coil- or pre-molten globule-like) forms (Daughdrill et al., 2005; Dunker et al., 2001; Turoverov et al., 2010; Uversky, 2002a; b; 2003b; Uversky and Dunker, 2010b; Uversky et al., 2000a; Williams et al., 2001). Furthermore, the structural heterogeneity does not stop there, as not only the entire protein molecule but its different parts can be (dis)ordered to different degrees as well (Uversky, 2013a; d), indicating that foldability (or structure-coding potential) is non-homogeneously distributed within the amino acid sequences of IDPs/IDRs. As a result, different parts of a molecule are ordered or disordered to different degrees, and a typical IDP/IDR normally contains potentially foldable,

partially foldable, differently foldable, or not foldable at all protein segments (Uversky, 2013a; d). Therefore, IDPs/IDRs can be more or less compact and possess smaller or larger amounts of flexible secondary/tertiary structure (Dunker et al., 2001; Dunker and Obradovic, 2001; Uversky, 2002a; b; Uversky and Dunker, 2010b; Uversky et al., 2000a).

Furthermore, this distribution of differently (dis)ordered regions is constantly changing in time, and a given segment of a protein molecule can potentially show different structures or lack of structure at different time points. As a result, at any given moment, an IDP/IDR has a structure different from what was seen at another moment (Uversky, 2013a; d). Clearly, this consideration represents another way to end up with the "dancing protein cloud" view of a dynamic protein structure. One should also keep in mind that many proteins exist as complex structural hybrids possessing ordered and differently disordered domains, thereby defining another level of structural heterogeneity crucial for their functions (Dunker et al., 2013).

I.C. Intrinsic disorder and structure-function continuum

The previous section draws a complex picture of a highly dynamic and very heterogeneous protein structure, where only the entire protein molecules are expected to be disordered to different degrees, but various protein segments (even rather short ones) can be differently disordered as well (DeForte and Uversky, 2016; Uversky, 2013a; d; 2016a; e; 2019). The resulting mosaic architecture of a protein molecule includes foldons (regions capable of spontaneous folding), non-foldons (segment that do not fold), semi-foldons (regions that are always in a semi-folded state), inducible foldons (segments that can gain structure (at least partially fold) at interaction with binding partners), inducible morphing foldons (regions capable

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

of folding to the different structures at interaction with different binding partners), and unfoldons (important less stable parts of ordered proteins that must unfold (or undergo order-disorder transition, at least partially) in order to make protein active) (DeForte and Uversky, 2016; Uversky, 2013a; d; 2016a; e; 2019). Again, the entire protein has a highly dynamic and morphing structure, which is not rigid or crystal-like, and where at different time moments, different parts of a molecule can be (dis)ordered to different degrees (DeForte and Uversky, 2016; Uversky, 2013a; d; 2016a; 2019). Furthermore, it is also very clear that the classification of proteins as ordered and disordered is an obvious oversimplification, as the structure-disorder space of a protein represents a continuum, with no obvious boundary between ordered and disordered proteins (DeForte and Uversky, 2016; Uversky, 2013a). It is also important to emphasize here that a protein molecule is an inherently flexible entity, and even the most ordered proteins do not resemble crystals or "solid rocks", possessing instead some degree of flexibility, which is crucial for their biological activities (Ma et al., 1999). This complex mosaic-like structural organization of proteins, where different regions are dynamically (dis)ordered to different degrees and constantly undergo conformational exchange, not only defines their highly flexible and heterogeneous "anatomy" but serves as a very important foundation of the unique disorder-based "physiology". This idea is illustrated by Figure 4 showing that all the aforementioned differently (dis)ordered structural segments of proteins might have very different functions. Therefore, although based on the classical structure-function paradigm, where a unique protein function is determined by a unique protein structure, the structural "floppiness" (or the presence of intrinsic disorder) would be incompatible with protein functionality, and in reality many protein functions originate from the lack of ordered structure in a protein molecule. Furthermore, since all those foldons, semi-

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

foldons, non-foldons, inducible foldons, inducible morphing foldons, and unfoldons can be found within one protein molecules, it is clear that a protein with such heterogeneous structure is inherently multifunctional. In other words, protein structural continuum defines protein multifunctionality. This indicates that at the global level, protein functionality depends on comprehensive structure/function relationships and cannot be described within the frames of the traditional structure-function paradigm. In fact, the protein sequence-function relationships are best described using a two-pathway approximation, where the traditional sequence-to-structureto-function pathway is used to describe the functionality of enzymes and membrane transport proteins, whereas a new sequence-to-disordered ensemble-to-function pathway should be added for proteins and protein regions involved in signaling, regulation, and control (Dunker et al., 2002a; Dunker et al., 2002b; Dunker et al., 2001; Dunker and Obradovic, 2001; Uversky, 2002a; b). Furthermore, the biological complexity is directly linked to the size of a functional proteome and not to the size of the corresponding genome (Schluter et al., 2009). Originally, this increase in the functional proteome was ascribed to the allelic variations (i.e., single or multiple point mutations, indels, single nucleotide polymorphisms (SNPs)), different pre-translational mechanisms affecting mRNA (e.g., production of numerous mRNA variants by the alternative splicing and mRNA editing), and changes induced in proteins by various posttranslational modifications (PTMs) (Farrah et al., 2013; Farrah et al., 2014; Kim et al., 2014; Reddy et al., 2015; Smith et al., 2013; Uhlen et al., 2005), which represent specific means by which a single gene can encode not a single protein but multiple proteoforms, which are different protein products of a single gene (Smith et al., 2013). Later, additional means, such as intrinsic disorder,

increase in protein structural and functional diversity (Uversky, 2016d; 2019).

All these considerations indicate that the relationships between genes and proteins are better described by an "one-gene – many-proteins – many-functions" model (Uversky, 2016c; d) rather than by a classic "one gene – one enzyme" hypothesis, according to which each gene is responsible for producing a single enzyme that in turn affects a single step in a metabolic pathway (Beadle and Tatum, 1941). Furthermore, a "protein structure-function continuum" model, where a functional protein exists as a dynamic conformational ensemble containing multiple proteoforms of different origin characterized by a broad spectrum of structural features and possessing different functionalities, provides a global link between protein structure and function (Uversky, 2015).

structural flexibility, and functioning were included in the list of factors contributing to the

I.D. Intrinsic disorder and liquid-liquid phase separation

Recent years have witnessed a dramatic increase in the interest of researchers in the intriguing intracellular entities known as membrane-less organelles (MLOs) or biomolecular condensates (BCs) (Brangwynne, 2013; Brangwynne et al., 2009; Brangwynne et al., 2015; Dundr and Misteli, 2010; Feric et al., 2016; Mitrea and Kriwacki, 2016; Uversky, 2017b; c; Uversky et al., 2015; Zhu and Brangwynne, 2015). These cellular foci or dots are known by different names, such as ribonucleoprotein (RNP) bodies, or RNP droplets, or RNP granules. They extend the realm of the membrane-encapsulated eukaryotic organelles, such as chloroplasts, endoplasmic reticulum, Golgi apparatus, lysosomes, mitochondria, nucleus, and vacuoles. Although for the first time the nucleolus, which is the best known and the most studied

MLO, was described about 200 years ago (reviewed in (Pederson, 2011)), and although other

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

MLOs were regularly found in eukaryotic cells, these cellular bodies were mostly underappreciated by the scientific community, being often considered as obscure objects participating in completely different cellular processes. Furthermore, nobody even supposed that these highly diversified organelles could have common mechanical properties and share common mechanisms of formation (Antifeeva et al., 2022; Fonin et al., 2022). More than a hundred different MLOs were eventually found in the cytoplasm, nucleus, mitochondria (and chloroplasts) of eukaryotic cells, as well as in the cytoplasm of bacteria and archaea. The incomplete list of these biomolecular condensates in eukaryotic cells include cytoplasmic centrosomes (Decker et al., 2011), germline P-granules (germ cell granules or nuage) (Brangwynne et al., 2009; Chuma et al., 2009), neuronal RNA granules (Kiebler and Bassell, 2006), processing or P-bodies (Decker et al., 2007), stress granules (SGs) (Wippich et al., 2013), as well as chloroplast stress granules (cpSGs) (Uniacke and Zerges, 2008) and mitochondrial RNA granules (Antonicka and Shoubridge, 2015). In the nucleous, one can find Cajal bodies (CBs) (Strzelecka et al., 2010), chromatin (Li et al., 2007), cleavage bodies (Li et al., 2006), histone locus bodies (HLBs) (Nizami et al., 2010), nuclear gems or Gemini or coiled bodies (Gubitz et al., 2004; Matera and Frey, 1998), nuclear speckles or interchromatin granule clusters (Lamond and Spector, 2003), nuclear pores (Grossman et al., 2012), nuclear stress bodies (nSBs) (Biamonti, 2004; Biamonti and Vourc'h, 2010), nucleolus (Shav-Tal et al., 2005), Oct1/PTF/ transcription (OPT) domains (Harrigan et al., 2011), perinucleolar compartment (PNC) (Huang, 2000), paraspeckles (Fox et al., 2002), PML-bodies (PML oncogenic domains, PODs) (Maul et al., 2000), polycomb bodies (PcG bodies) (Pirrotta and Li, 2012), and Sam68 nuclear bodies (SNBs) (Huang,

514 2000).

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

MLOs are spherical micron-sized droplets (Nott et al., 2015) that have unique morphologies and specific distribution patterns. They typically contain both RNA and proteins, and structurally can include layers (i.e., might themseves represent phases in phases), which might have different biophysical properties and functions (Hirose et al., 2023). The importance of MLOs is defined by the fact that they represent "an intricate solution of the cellular need to facilitate and regulate molecular interactions by physically isolating target molecules in specialized compartments in a reversible and controllable way" (Uversky, 2017c). Despite their localization within the different cellular compartments, and desipte their very different functions, such as as microreactors-fermenters, network hubs controlling various cellular signaling pathways or as storages of target molecules, the biogenesis of MLOs/BCs is driven by a unique process of liquid-liquid phase separation (LLPS). Here, under the approproate condition (typically above a specific critical concentration of the molecules capable of LLPS) a homogeneous solution spontaneously separates into two distinct immiscible liquids, or "phases": a dense phase, and a dilute phase, both characterized by high water content and not separated by the membranes. Among the fundamental principles defining MLO formation is the critical involvement of the polyvalent stochastic proteinprotein interactions typical for IDPs/IDRs (Uversky, 2016b; 2017c; Uversky et al., 2015). Therefore, it is not surprising that although MLOs differ from each other by specific sets of their resident proteins, it seems that they always contain IDPs (Uversky, 2017c). In other words, MLOs/BCs often represent a way of the intracellular compartmentalization of IDPs/IDRs (Darling et al., 2018; Meng et al., 2015; Uversky, 2017b; c; d).

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

The characteristic features of MLOs are their cell size-dependent dimensions (Brangwynne, 2013) and liquid-like behavior (Brangwynne et al., 2009; Brangwynne et al., 2011; Feric and Brangwynne, 2013; Wippich et al., 2013), with MLOs typically being just slightly denser than the rest of the cytoplasm or nucleoplasm (Handwerger et al., 2005; Updike et al., 2011). MLOs are mesoscopic cellular compartments with highly dynamic nature, components of which are not protected from the environment, being in direct contact with the surrounding cytoplasm, nucleoplasm, mitochondrial matrix, or chloroplast stroma (Pederson, 2001; Phair and Misteli, 2000). The lack of encapsulating membranes also indicates that the structural integrity and biogenesis of MLOs are entirely controlled and regulated by protein-protein, protein–nucleic acid (Dundr and Misteli, 2010), and protein-membrane interactions (Nesterov et al., 2021). Being classified as liquid-droplet phases or different liquid state of the nucleoplasm, cytoplasm, matrix, or stroma, MLOs possess a high level of internal dynamics (Aggarwal et al., 2013; Brangwynne, 2013; Brangwynne et al., 2009; Brangwynne et al., 2011; Feric and Brangwynne, 2013; Li et al., 2012; Wippich et al., 2013), clearly representing characteristic examples of fluid, disorder-based ensembles. Depending on the place of their origin, MLOs are classified as 1D, 2D, or 3D assemblages, where 1D MLOs are found as logiod droplets on liner cellular sturcutres, such as chromatin and cytoskeleton, 2D MLOs originate as a result of the phase separation in/on the membranes, and 3D MLOs are formed via the LLPS in the bulk of the nucleoplasm/cytoplasm/matrix/stroma (Nesterov et al., 2021). The resulting 1D, 2D, and 3D MLOs can influence each other (Nesterov et al., 2021). It was also hypothesized that the LLPS, being triggered by environmental changes, can initiate propagation of 1D, 2D, and 3D MLOs within the cell interior or can be transmitted in a form

of an autowave, with both processes being characteried by low energy demand representing

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

an efficent way of the adjustustement of the cell signaling and metabolic systems to new demands (Nesterov et al., 2021). Such interconnection of phase separation at different dimensions might serve as an important means of intracellular communication and regulation (Nesterov et al., 2021). Since the formation of many (if not all) MLOs is diven by LLPS of specific IDPs (Csizmok et al., 2016; Elbaum-Garfinkle et al., 2015; Lin et al., 2015; Meng et al., 2015; Mitrea et al., 2016; Nott et al., 2015; Toretsky and Wright, 2014; Uversky, 2017c; Uversky et al., 2015), it is clear that the protein intrinsic disorder, biological phase separation, and MLO phenomena are interlinked (Antifeeva et al., 2022; Fonin et al., 2022; Nesterov et al., 2021; Turoverov et al., 2019; Uversky, 2017c). This interconnection redefines the organizational principles of living matter from a rather mechanistic model, where functions of proteins are determined by their rigid globular structures and where intracellular processes occur within the rigid membrane-encapsulated organelles, to a new model, where highly dynamic "biological soft matter" (IDPs and MLOs) positioned at the "edge of chaos" represents a critical foundation of life and defines the complexity and evolution of living things (Turoverov et al., 2019).

II. Diseases and disorder-based protein complexity: Too many ways to get something wrong

The facts assembled in previous sections indicate that the high abundance and enormous complexity of IDPs, combined with their crucial roles in various regulatory and signaling processes, have unique functional advantages (otherwise IDPs would not be commonly present

in all living things). However, the very same facts clearly suggest that this disorder-based complexity must be tightly controlled. Otherwise it might backfire, as within a complex and highly interconnected system, there are too many ways of getting something wrong. In fact, structural plasticity and binding promiscuity are crucial for protein multifunctionality. However, being taken out of control, they can easily promote a functional disaster (such as what would happen if a multifunctional IDP would exercise its promiscuous binding by interacting with the wrong partners at a wrong time in a wrong place). Similarly, uncontrolled assembly of promiscuous binders in a limited volume within a cell might create ideal conditions for pathological protein aggregation. Therefore, these different forms of deregulation of IDPs represent an important addition to the known arsenal of means associated with protein dysfunctions causing development of many pathological conditions.

In fact, the failure of a specific peptide or protein to adopt its functional conformational state accompanied by protein misfolding, loss of normal function, gain of toxic function, and/or protein aggregation are linked to a broad range of human diseases (Uversky, 2009a; 2010b).

Often, diseases are associated with dysfunction of a particular protein (or a set of proteins), and dysfunctions of different proteins might have different triggers. In fact, for some disease-related proteins, the formation of pathologic conformation(s) represents an intrinsic propensity. For other proteins, conformational changes leading to the increased propensity to misfold are triggered by mutations, or improper posttranslational modifications (acetylation, advanced glycation (i.e., the end-stage of the non-enzymatic glycosylation), deamidation, glycosylation, methylation, phosphorylation, or racemization), or impaired interactions with chaperones, or interactions with various intracellular or extracellular factors, such as other proteins, nucleic acids, and other endogenous factors or lost binding partners (including other proteins, small molecules, nucleic

acids, etc.). For still other proteins, misfolding and dysfunction are associated with exposure to internal or external toxins or are linked to oxidative damage. Furthermore, abnormal alternative splicing that commonly affects IDPs has been associated with numerous human diseases, such as Alzheimer's disease (Lovestone et al., 1994), azoospermia (Ma et al., 1993), cancers (Geng et al., 2024; Tao et al., 2024; Venables, 2004; Wojtys and Oron, 2023), cardiometabolic disorders (Miyazaki, 2023), genetic disorders (Shi et al., 2024), inflammatory bowel disease (Zou et al., 2023), inherited retinal diseases (Sundaresan et al., 2023), myotonic dystrophy (Roberts et al., 1997), and Parkinson's disease (Beyer et al., 2008a; Beyer et al., 2008b), to name a few. All these misfolding- and dysfunction-promoting factors can act additively, independently, or synergistically.

Altogether, there are hundreds of different maladies associated with protein dysfunction. These conformational diseases or proteinopathies (Walker and LeVine, 2000) can affect a single organ, or be spread through multiple tissues, and can be hereditary or sporadic. In various forms of amyloidosis, there are more than 50 different proteins, which prior to fibrillation have different structures (β -sheets, α -helices, or contain both α -helices and β -sheets). Such pathology-associated proteins can be globular or intrinsically disordered. The broad involvement of IDPs/IDRs in the pathology of different diseases is typically associated with their deregulated involvement in recognition, regulation, and cell signaling and is reflected in the "disorder in disorders" or D² concept (Uversky et al., 2008). In other words, proteinopathies may originate from the misfolding, misidentification, misregulation, and missignaling of causative IDPs/IDRs (Midic et al., 2009; Uversky, 2009a; 2010b; Uversky et al., 2008; Uversky et al., 2009). Despite the fact that IDPs/IDRs are commonly associated with various diseases, the IDRs themselves might not be directly responsible for increased disease risk (Pajkos et al., 2012; Tompa, 2009).

Although the countless roles of IDPs in the pathogenesis of various diseases undoubtedly represent an exciting subject, a detailed consideration of this phenomenon is outside the scope of this review, and interested readers are encouraged to look for recent studies focused on this subject (e.g., see (Alberti and Hyman, 2016; Ambadipudi and Zweckstetter, 2016; Choudhary et al., 2022; Darling and Uversky, 2017; 2018; Hivare et al., 2023; Pancsa et al., 2019; Popelka and Uversky, 2022; Raasakka and Kursula, 2020; Santofimia-Castano et al., 2020; Tsang et al., 2020; Uversky, 2013b; 2018)).

III. How to target a dancing protein cloud

III.A. Why one would want to target an IDP?

Should we consider IDPs/IDRs as potential drug targets? The answer is undoubtedly yes. In fact, there are multiple reasons to very seriously consider targeting IDPs and IDRs. The arguments supporting this statement were already emphasized in the previous sections of this review. How can one ignore proteins that constitute a very significant part of a human proteome, have numerous crucial functions, act as multifunctional promiscuous binders capable of binding and folding in a template-dependent manner, and are tightly involved in the pathogenesis of various human diseases (Cheng et al., 2006; Dunker and Uversky, 2010; Metallo, 2010; Uversky, 2012)? Therefore, it is absolutely clear that IDPs should be targeted (or at least, serious attempts should be made to develop drugs specifically targeting IDPs/IDRs). On the other hand, it is also absolutely clear that these proteins and protein regions cannot be subjected to the rational, structure-based drug design (which became an essential tool for fast and cost-efficient lead discovery for ordered proteins, and where prior knowledge of a target protein structure represents

the most important prerequisite for the successful development of a new drug), as they do not have stable structures. Therefore, the druggability of "protein clouds" that do not possess ordered structure and exist as highly flexible and extremely dynamic conformational ensembles is questionable (if not impossible) from the viewpoint of the traditional structure-based rational drug design approaches (Joshi and Vendruscolo, 2015). In fact, it seems that most of the prior knowledge of what should be done to find a small molecule capable of high affinity and selectivity binding to a specific "grove" or "cavity" on the surface of a "rock" would not work for a fuzzy cloud, and therefore, in the intrinsic disorder-based drug design, new approaches based on outside-the-box thinking are required to find drugs targeting IDPs/IDRs, affecting their interactions, and modulating their (multi)functionality (Uversky, 2012).

III.B. Some general strategies for targeting IDPs

In addition to the obvious complication of the lack of unique 3D structure, which makes IDPs/IDRs mostly unsuitable for rational drug design, where prior knowledge of a target protein structure represents the most important prerequisite for the successful development of a new drug, the use of IDPs/IDRs as drug targets is further complicated by another crucial hurdle, namely their binding promiscuity. In fact, depending on their interactions with specific partners, IDPs/IDRs, being neomorphic moonlighting proteins, can form both physiological and pathological complexes defining their ability to have physiological or pathological functions (Szenasi et al., 2017). This need to find a drug lead that would be capable of selective targeting of the pathological and not the physiological complexes of a given IDP represents a new type of challenge in drug development. A convincing illustration of this complexity is given by the

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

analysis of two IDPs involved in the pathogenesis of Parkinson's disease and other synucleinopathies, tubulin polymerization promoting protein (TPPP/p25) and α-synuclein (Szenasi et al., 2017). These two proteins are known to be co-enriched and co-localized in pathological brain inclusions (Szenasi et al., 2017). These highly disordered proteins are engaged in the broad spectrum of protein-protein interactions, both forming tightly connected PPI networks (see **Figure 5**). Consideration of all these PPIs to find which of them would lead to the formation of physiological or pathological complexes is a daunting task. However, the available information for TPPP/p25 indicated that this protein is able to form physiological (TPPP/p25tubulin) and pathological (TPPP/p25-α-synuclein) complexes. Analysis of these systems revealed that formation of these complexes relies on different parts of the TPPP/p25, a fact that should simplify the search for potential interaction inhibitors. However, TPPP/p25 showed exceptional functional resilience, where, due to its high conformational plasticity and chameleon nature, the removed binding segments were functionally replaced by other segments (Szenasi et al., 2017). Despite these challenges, this study concluded that the disorder-based interfaces can be accurately identified, and finding such interfaces represents a promising approach for targeting promiscuous IDPs/IDRs (Szenasi et al., 2017). Therefore, although the development of drugs targeting IDPs and IDRs represent a challenging task, the novel field of finding small molecules capable of modulation of the functionality of IDPs/IDRs is rapidly progressing, and several innovative strategies for the effective discovery and design of the drugs affecting the disorder-based interactions were successfully elaborated (Dunker and Uversky, 2010). Some of the currently available approaches for targeting IDPS/IDRS and disorder-based interactions are briefly outlined below, along with illustrative examples.

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

An obvious way to deal with IDPs is to use their structural heterogeneity, as many IDPs represent complex hybrid systems containing both ordered domains and IDRs. Here, ordered domains can be subjected to the traditional routine of drug discovery elaborated for ordered proteins, where the drugs blocking ligand binding sites in such ordered domains are found using either random screening of possible compounds or rational drug design based on the prior knowledge of the domain's 3D structure (Dunker and Uversky, 2010; Uversky, 2012). Drugs inhibiting interaction of IDPs/IDRs with ordered partners can also be identified by utilizing the available structural information for these ordered partners. If an IDR can fold at binding to its partner (i.e., if it operates via the coupled binding and folding mechanism) and if the resulting interaction sites are relatively small and compact, then they can be easily mimicked by small molecules. These approaches indicate that small molecules directly targeting IDP/IDR can be found using strategies that look similar to traditional drug discovery approaches. However, these forms of rational drug design are still disorder-based and therefore will clearly benefit from the prior knowledge of the intrinsically disordered nature of the binding partners (Dunker and Uversky, 2010; Uversky, 2012). It is known that for interaction with their partners, many IDPs/IDPRs use relatively short contiguous regions that become ordered upon binding (Garner et al., 1999; Oldfield et al., 2005b). Furthermore, IDPs/IDRs are capable of context- or template-dependent folding, forming very different structures in their bound forms complexed with different partners (Dunker et al., 2001; Hsu et al., 2012; Karush, 1950; Kriwacki et al., 1996; Oldfield et al., 2008). In such cases, successful inhibition of the disorder-based PPI interactions can be achieved via misfolding of the foldable binding sites into structures, which are unlike their structures in the bound states. In other words, small molecules would force folding-upon-binding IDRs to form ordered structures

incompatible with binding to a partner. Therefore, in these cases, the disorder-based functions and formation of biologically important protein-protein complexes are prevented by small molecules capable of inducing (wrong) order in the targeted IDPs/IDRs (Dunker and Uversky, 2010; Hammoudeh et al., 2009; Metallo, 2010; Uversky, 2012; Wang et al., 2007; Yin et al., 2003).

One of the ways for an IDP/IDR to escape unwanted interaction is to spontaneously form a non-interactive cage sequestering interaction-prone preformed fragments; i.e., to functionally misfold (Uversky, 2011a). This mechanism can be utilized to find small molecules capable of stabilization of the different members of such functionally misfolded conformational ensembles, and thereby precluding the targeted protein from biological interactions (Uversky, 2012).

III.C. Targeting transcription factors

III.C.1. General considerations

Both the control of the gene activity in response to the specific stimuli and the expression of specific gene are crucially dependent on the regulation of gene transcription (Latchman, 1997). Important players in the related processes are transcription factors (TFs). These sequence-specific DNA-binding factors have several important functions, such as recognition and binding of specific DNA sequences, recruitment of the RNA polymerase to specific genes, control of the genetic information transfer from DNA to mRNA, and acting as specific activators or repressors of transcription via positive or negative regulation of gene transcription. To conduct these numerous functions, TFs can either act alone or in a complex with other proteins that can activate or deactivate the TF action (Latchman, 1997). Depending on what they do and how they

are controlled, TFs are classified as general or basal TFs that form a pre-initiation complex and are needed for the transcription by RNA polymerase II, upstream TFs that stimulate or repress transcription by binding upstream of the initiation site, and inducible TFs (ITFs), which are products of the immediate-early genes capable of activation or repression of the transcription of the late-response genes via specific binding to the regulatory DNA sequences upstream of the initiation site. All ITFs and many other TFs can be rapidly induced in cells in response to activating stimuli (Ziólkowska and Przewlocki, 2002).

III.C.2. Crucial hybrids: Order and intrinsic disorder in transcription factors

TFs are characterized by functional modularity for which they contain one or more DNA-binding domains (DBDs), at least one transactivation domain, and signal sensing domain(s) (SSDs, such as ligand binding domains, LBDs) capable of recognition of the external signals and transmission them to the rest of the transcription complex, thereby leading to the up- or down-regulation of gene expression. Often, DBDs and SSDs reside on separate proteins that interact within the transcription complex to regulate gene expression.

The aforementioned multifunctionality and functional modularity of TFs also suggest that these important proteins might represent structural hybrids containing ordered domains and functional IDRs. In line with this hypothesis, the Protein Data Bank does not have 3-D structures of the whole eukaryotic TFs, but contains abundant structural information on the TF modules (e.g. DBDs and LBDs) (Minezaki et al., 2006). Furthermore, crucial roles of IDRs in TF functionality was demonstrated for some specific TFs (Dyson and Wright, 2002b; 2005), and, based on a comprehensive bioinformatics analysis, it was conceded that most TFs (82-94%) contain long

IDRs, with the eukaryotic TFs being significantly more disordered than the prokaryotic TFs (Liu et al., 2006a; Minezaki et al., 2006). For example, in human TFs, almost 50% of the amino acid sequences are occupied by IDRs, with more than half of the human TFs containing small DBDs and long IDRs (Minezaki et al., 2006). Intrinsic disorder is heterogeneously distributed within TFs, as their activation regions are typically essentially more disordered than the DBDs (Liu et al., 2006a). Furthermore, in addition to the ordered DBDs that are well-structured in the non-bound state, some DBDs can be considered as inducible foldons, as they are highly unstructured in the unbound form and undergo a disorder-to-order transition upon DNA binding (Liu et al., 2006a). Importantly, it was pointed out that TFs commonly contain inducible foldons (Liu et al., 2006a), also known as molecular recognition features, MoRFs (Oldfield et al., 2005b), and even inducible morphing foldons that can adopt different conformations when binding to different partners (Oldfield et al., 2008). Because of the abundant presence of functional disorder in TFs, it is not surprising to see that their functionality is regulated by alternative splicing (Hofstetter et al., 2010) and posttranslational modification (Avalos et al., 2002).

777 III.C.3. Transcription factors as potential and actual drug targets

Because of their crucial roles in a wide spectrum of physiological and pathological processes, TFs are commonly considered as promising drug targets (Latchman, 2000), and ~ 10% of currently prescribed drugs directly target TFs from the nuclear receptor family (Gronemeyer et al., 2004; Overington et al., 2006). Furthermore, it is clear that the functionality of TFs can be modulated indirectly via numerous signaling cascades. Being multifunctional structural hybrids, TFs represent important illustrative examples of the utilization of principally different molecular

mechanisms for (dis)order-based drug discovery. In fact, small molecules can be found that either block the ligand binding sites in ordered TF modules or inhibit interaction of the intrinsically disordered TF with the ordered TF partner by blocking the binding site of the ordered partner, or directly target IDRs in TFs.

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

784

785

786

787

III.C.4. Targeting ordered domains of transcription factors

DBDs or LBDs, which are often well-structured TF modules (e.g., in nuclear receptors), commonly serve as targets for the small molecules capable of recognition and blocking their specific DNA- or ligand-binding sites. For example, the LBDs of all nuclear receptors studied so far have similar 3-D structure, where a compact structure with a ligand-binding pocket is formed by 11 helices, and where the mobile twelfth helix acts as a movable lid over the ligand-binding pocket and controls the entrance to this pocket (Gronemeyer et al., 2004; Wurtz et al., 1996), the size of which varies between family members (Wurtz et al., 1996). Furthermore, the orientation of the twelfth helix relative to the reminder of an LBD is crucial for the LBD action as a signal transducer, where in the absence of ligands, LBDs bind to a set of transcriptional co-repressors, whereas in the ligand-bound form, LBDs specifically interact with transcriptional co-activators (Gronemeyer et al., 2004). The available structural information was used to develop small molecule pharmaceuticals with a large spectrum of agonist or antagonist activities, as well as a set of selective modulators of the nuclear receptors which were capable, in a targeted cell-typeselective manner, to modulate and control a subset of the functions of these important proteins (Gronemeyer et al., 2004).

805

III.C.5. Disorder-based rational drug design: the p53-Mdm2 story

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

One of the three potential targets of structure-aided drug design are ordered proteins interacting with IDRs of TFs. This type of interaction is commonly based on the insertion of a relatively short fragment of IDR to a groove or cavity on the surface of an ordered partner, which can be targeted by small molecules reasonably well (Cheng et al., 2006). Obviously, for the ordered proteins with known 3D structures, the use of special computational approaches from the realm of in silico screening tools can aid in finding the potential interaction surfaces that can be targeted by small molecules (Liang et al., 1998) capable of inhibition of protein-protein interactions (Joce et al., 2010). One of the most convincing examples of this approach for finding/designing drugs capable of inhibition of a disorder-based binding of a TF to an ordered partner is given by the successful development of the inhibitors of the interaction of the disordered fragment of the cellular tumor antigen p53 (residues 15-29) with the ordered domain of E3 ubiquitin-protein ligase Mdm2 (residues 17-125). With more than 120,000 papers in PubMed talking about it, transcription regulator p53 does not require a lengthy introduction. Activated p53 accumulates in the nucleus, where it causes induction or inhibition of over 150 genes via binding to specific DNA sequences (Balint and Vousden, 2001; Zhao et al., 2000). Therefore, it is not surprising that p53 is known as a caretaker, keeping other genes healthy (i.e. suppressing mutation) and helping the genome recover from damaging mutations, and also as a gatekeeper, controlling or inhibiting cell growth (Deininger, 1999). This protein, being a crucial tumor suppressor, also acts as a major contributor to the progression of various cancers, as it is mutated in over 50% of all human tumors (Deininger, 1999). Similar to other TFs, p53 has a modular structure possessing an Nterminal intrinsically disordered transactivation domain (TAD, which includes an

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

aforementioned Mdm2 binding region), the centrally-located mostly ordered DBD, and the Cterminal intrinsically disordered tetramerization and regulatory domain. Besides Mdm2, the Nterminal TAD of p53 can bind CBP/p300, CSN5/Jab1, RPA, TFIID, TFIIH, among many other proteins (Anderson and Appella, 2004). Similarly, the C-terminal regulatory domain is also a promiscuous binder interacting with 14-3-3, hGcn5, GSK3β, PARP-1, TAF1, TRRAP, and S100B(ββ) and many other proteins (Anderson and Appella, 2004). The intrinsically disordered p53 TAD binding to Mdm2 is accompanied by the disorder-to-order transition in the p53 TAD (Cheng et al., 2006) and has several crucial outputs, such as direct inhibition of the p53 functioning as an activator or inhibitor of other genes, proteasomal degradation of the p53 after the Mdm2-driven ubiquitination, and transport p53 out of the nucleus due to the presence of a nuclear export signal in Mdm2 (Anderson and Appella, 2004). Since all these outputs cause the shutting down of p53, an inhibition of the p53-Mdm2 interaction by small drug-like molecules capable of blocking the p53 binding site of Mdm2 represents a promising approach for restoring the crucial cellular p53 functions (Chene, 2004; Klein and Vassilev, 2004; Vassilev, 2004; Vassilev et al., 2004). Several such small molecules were found, and one of them, Nutlin-2, was shown to efficiently mimic the p53 residues crucial for the Mdm2 binding (Klein and Vassiley, 2004; Vassilev, 2004; Vassilev et al., 2004). **Figure 6** shows p53 and Mdm2 from an interesting angle, revealing that both proteins are expected to contain high levels of intrinsic disorder. In fact, predicted disordered residues constitute more than 65% of the sequences of these proteins. Figure 6 also shows that the p53-Mdm2 complex originates from the interaction of an inducible foldon of p53 (residues 15-29) with the ordered N-terminal domain of Mdm2 (residues 17-125, SWIB/MDM2). Based on the UniProt annotations, the intrinsically disordered N-terminal TAD of p53, besides binding to Mdm2, can interact with Mdm2, histone acetyltransferase p300,

CREB-binding protein (CBP), high mobility group protein B1 (HMGB1), and protein arginine

N-methyltransferase 1 (HRMT1L2) whereas SWIB/MDM2 domain binds p53, p73, and E2F1. This binding promiscuity of both partners clearly represents an additional level of complexity of the development of drugs targeting this complex. The molecular principles of the disorder-to-order transition-based interactions in one of the binding partners are understood rather well (Cheng et al., 2006; Oldfield et al., 2005b). In fact, the IDRs capable of undergoing disorder-to-order transitions at interaction with their binding partners are potentially predictable (Cheng et al., 2006; Dosztanyi et al., 2009; Fuxreiter et al., 2004; Fuxreiter et al., 2007a; Meszaros et al., 2009; Oldfield et al., 2005b). These bioinformatics tools developed for predicting foldable binding sites in disordered regions (Oldfield et al., 2005b) can be used to find potentially druggable short disordered binding regions (Cheng et al., 2006). Since as a result of the coupled binding and folding processes, these short disorder-based binding motifs fold into small and compact structures, they can be potentially mimicked by small molecules capable of inhibiting such interactions (Cheng et al., 2006). Therefore, in these cases, the small molecules mimic a critical motif of the disordered partner, which folds upon binding into a specific structural element, and competes with this region for its binding site on the structured partner.

III.C.6. cMyc-Max journey

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

The interaction between two intrinsically disordered TFs c-Myc and Max serves as a very important illustration of a danger of using prior knowledge accumulated while working on one set of systems on a system operating on different principles. The attractiveness of targeting this

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

complex stems from the fact that the proto-oncogene c-Myc (also known as Myc proto-oncogene protein, c-Myc, class E basic helix-loop-helix protein 39 (bHLHe39), and transcription factor p64), being involved in regulation of multiple genes controlling a wide spectrum of cellular processes ranging from apoptosis to cell growth, differentiation, and metabolism, is overexpressed in most human cancers (Dang, 1999) and that the c-Myc activation is driven by the heredimerization of this protein with its partner, Myc-associated factor X (Max, also known as class D basic helix-loop-helix protein 4 (bHLHd4)). The unbound forms of both Max and c-Myc are mostly disordered (see **Figure 7**), whereas interaction of their basic region/helix-loophelix/leucine zipper (bHLHZip) domains is accompanied by their mutual coupled binding and folding, leading to the formation of a helical coiled coil complex (see **Figure 7**) (Hammoudeh et al., 2009; Metallo, 2010). Therefore, disruption of this heterodimetic complex represents a reasonable strategy for c-Myc inhibition. However, using known structures of triple c-Myc-Max-DNA complexes in rational structure-based drug design was unsuccessful, as the small molecules identified by this approach failed to produce inhibitory effect. The mystery was resolved when several specific inhibitors of the c-Myc-Max interactions were identified using the traditional high throughput screening (Wang et al., 2007; Yin et al., 2003). Using solution NMR analysis of the monomeric c-Myc it was established that the identified inhibitors bind to one of three discrete sites within its bHLHZip domain (residues 366–375, 375–385, and 402–409). Importantly, all these binding sites were located within the C-terminal region of c-Myc that was disordered when not bound to Max. Interaction of these small molecules with the c-Myc bHLHZip domain induced local folding of binding regions into structures incompatible with the formation of the Myc-Max dimer; i.e., it promoted local misfolding that made the protein dysfunctional (Hammoudeh et al., 2009; Metallo, 2010). Therefore, this case revealed that the

locally induced misfolding might represent a principally new way of inhibition of the disorderbased interaction by small molecules.

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

It is important to emphasize here that although structure-based drug design is difficult for the Myc-Max system and IDPs generally, pharmacophore models have proven possible. For example, structural diversity of Myc-Max inhibitors was successfully extended using a pharmacophore-based in silico screen of a large compound library linked to a rapid in vivo screen (Han et al., 2019). Here, a pharmacophore model, which is a molecular framework describing the essential features of a compound that allow it to bind to a biological target, was created. To find compounds potentially targeting Myc-Max system, the model included 5 point pharmacophoric features, such as one aromatic hydrophobic, two hydrogen bond donors, one hydrogen bond acceptor, and one hydrophobic feature. This pharmacophore model was used to screen a 16 million compound library, and 61 potential hits were identified and tested for their possibility to affect Myc activity (Myc-Max-DNA complex formation, Myc transcriptional activity, and Myc-Max-dependent cell viability). As a result, a set of small molecule acting as Myc inhibitors was developed. The compounds were capable to engage Myc inside cells, disrupt Myc/Max dimers, and impair Myc-driven gene expression, indicating that the proposed approach of sampling a larger chemical space coupled with the rapid screening of candidates in mice provides a promising way for the discovery of small molecules affecting IDP functions (Han et al., 2019).

III.C.7. Targeting EWS-FLI1 and other oncogenic translocation-generated fusion proteins

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

Many types of cancer originate from the oncogenic chromosomal translocations, which is described as the exchange of genetic components between two non-homologous chromosomes (Nussenzweig and Nussenzweig, 2010), and if it happens across the coding regions of two genes, it generates a chimeric gene which can be translated into a chimeric protein. One of the illustrative examples of this type of cancer is given by a family of highly malignant tumors of bone and soft tissue known as the Ewing's sarcoma family of tumors (ESFT), the second-most common primary bone malignancy in children, adolescents, and young adults (Delattre et al., 1992; Erkizan et al., 2010). ESFT is believed to originate from the chromosomal translocation events, where the EWS breakpoint region 1 (EWSR1, or EWS) gene on the chromosome 22 is fused to one of the five ETS gene family members, FLI1, ERG, ETV1/ER81, E1AF/PEA3, and FEV, generating a set of the EWS-ETS chimeric proteins, 85% of which is EWS-FLI1 (Lawrence et al., 2014). The only genetic alteration in these pediatric tumors is the appearance of the EWS/ETS oncogenic fusion proteins, which function as aberrant transcription factors (Crompton et al., 2014; Tirode et al., 2014), and whose persistent expression is absolutely required for transformed phenotype maintenance (Kovar et al., 1996). As a result of the chromosomal translocation, the RNA-binding domain of EWS is replaced by the DNA-binding domain of FLI1 (Delattre et al., 1992), and the resulting EWS-FLI1 chimeric protein acts as a transcription factor modulating a diverse group of target genes (Uren et al., 2004). An IDR of EWS-FLI1 is required for maximal transactivation of transcription (Ng et al., 2007; Uren et al., 2004). Structurally, EWS-FLI1 can be divided to two domains, a highly disordered N-terminal domain of the EWS origin and a structured DBD of the FLI1 origin (see Figure 8). EWS-FLI1 binds to DNA as a part of ternary protein complexes, with the adjacent DNA sequences dictating the choice of the binding partners (Watson et al., 1997). Most of the

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

EWS-FLI1 protein-protein interactions happen within the disordered N-terminal domain, with some well-established protein partners of EWS-FLI1 being BARD1, CREB-binding protein, FOS-JUN dimers, hRPB3 subunit of RNA polymerase II, RNA helicase A (RHA), and TFIID (Erkizan et al., 2010). This binding promiscuity of EWS-FLI1 is responsible for the involvement of this protein in the formation of various nuclear complexes which are facilitated by the EWS-FLI1 IDR and lead to oncogenesis (Erkizan et al., 2010). However, the C-terminally located IDR of EWS-FLI1 was shown to drive some of the critical interaction of this TF with other transcriptional regulators and govern the binding of other proteins to the adjacent DNA regulatory elements (Erkizan et al., 2010). The oncogenic function and the neoplastic transformation potential of the fusion EWS-FLI1 protein is driven by interaction of this hybrid protein with RHA (Erkizan et al., 2009; Toretsky et al., 2006). Therefore, the finding of the inhibitors of this EWS-FLI1-RHA interaction represents a promising way of the anti-ESFT drug development. However, it is also recognized that the intrinsically disordered nature of the oncogenic EWS-ETS proteins and the lack of the small molecule recognizable pockets make these hybrid proteins (as well as TFs in general (Koehler, 2010)) difficult subjects for direct targeting [38], indicating that to mitigate the oncogenic functions of the oncogenic EWS-ETS proteins one should also identify and target functionally relevant EWS/ETS-associated factors (Gollavilli et al., 2018). Despite these concerns, a small molecule YK-4-279 capable of inhibiting the EWS-FLI1 interaction with RHA was found using a screen of a library of 3,000 compounds (Erkizan et al., 2009). This observation indicated that, likely similar to the aforementioned c-Myc-Max case, the found lead compound was able to bind to the intrinsically disordered protein-protein interaction site of EWS-FLI1 (Erkizan et al., 2009). An YK-4-279 derivative, TK-216, with demonstrated in vitro and in vivo antitumor activity in ESFT models

was developed for clinical trials (Federman et al., 2017; Selvanathan et al., 2017; Spriano et al., 2019).

III.C.8. Androgen receptor

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

An important example of drug development to target a complex, modular transcription factor is given by a set of small molecules interacting with an intrinsically disordered transactivation domain of the androgen receptor (AR) (Obst et al., 2024). AR is a modular, ligand-activated transcription factor from the super family of nuclear steroid receptors. Being activated by androgens, AR is involved in regulation of cardiovascular, musculoskeletal, and hematopoietic systems, whereas its misbehavior is associated with various pathologies including prostate cancer, where AR is commonly overexpressed (Davey and Grossmann, 2016). In AR, one can find three functional domains, the N-terminal intrinsically disordered transactivation domain (TAD, residues 1-557), the DNA-binding domain (DBD, residues 560-660) that contains two zinc-finger motifs (residues 560-580 and 596-620), and the C-terminal ligand-binding domain (LBD, residues 669-920). TAD, which is a primary driver of the AR transcriptional activity, is intrinsically disordered (Lavery and McEwan, 2005; McEwan et al., 2007; Tan et al., 2015). The intrinsically disordered nature of TAD defines the multifunctionality and binding promiscuity of AR, which is known to have almost 300 binding partners (Dai et al., 2023; Dai et al., 2017; Heemers and Tindall, 2007; Obst et al., 2024). It was also indicated that the ability of TAD to adopt numerous unique conformations enabling rapid and transient protein-protein interactions with many structurally diverse binding partners is defined by the conformational plasticity of its intrinsically disordered structure (Obst et al., 2024). This idea is illustrated by

Figure 9A representing the functional disorder profile generated for human AR by the D²P²

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

platform (Oates et al., 2013) and showing that the N-terminally-located TAD of this protein contains 11 MoRFs, as well as by Figure 9B representing the 3D model generated by AlphaFold (Jumper et al., 2021) and showing high overall prevalence of disorder in AR. It is therefore not surprising that AR transactivation domain inhibitors (ARTADIs) have attracted the attention of researchers, as these compounds can block AR activity potentially without the adverse effects associated with androgen deprivation therapy (ADT) (Ban et al., 2021; Banuelos et al., 2016; Obst et al., 2024; Sadar et al., 2008; Yi et al., 2024; Yi et al., 2023). It was found that ARTADIs can exclusively target intrinsically disordered TAD of AR and do not prevent ligands from binding to the AR-LBD. In particular, these compounds were effective in modulating AR activity when the structured portion of the receptor had been circumvented (e.g., in castration-resistant prostate cancer, CRPC) leaving the disordered TAD as the viable remaining target (Vaishampayan et al., 2017). The molecular mechanism of the ARTADI action was revealed by the all-atom molecular dynamics computer simulations, which showed that these compounds can bind at the interface of two transiently helical regions and induce the formation of partially folded collapsed helical states (Zhu et al., 2022). It was also shown that TAD is crucial for the AR activity as transcription factor, allowing AR translocation to the nucleus upon activation by androgens, where it undergoes LLPS and forms transcriptional condensates, mesoscale nuclear "speckles", associated with the key AR functions (Basu et al., 2023). Such function-related phase separation of AR was modulated by short transient helices found in the regions of a TAD sequence that are rich in aromatic residues. Importantly, ARTADIs were shown to partition into AR condensates, where they interacted with aromatic residues in the AR TAD, eventually trapping this domain in a conformation that disfavors

interactions with effector partners. These observations were then used to improve the ARTADI potency (Basu et al., 2023). As such, AR represents a noteworthy example of the importance of having means for targeting the IDRs of hybrid proteins containing ordered and intrinsically disordered domains.

III.D. Irrational drug design: Targeting functionally misfolded IDPs/IDRs

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

1029

1030

IDPs/IDRs, being characterized by high conformational dynamics and flexibility and the presence of highly interaction-prone binding elements, can escape unwanted interactions with non-native partners via the functional misfolding mechanism, where the interaction-prone elements are sequestered inside the non-interactive or less-interactive cage (Uversky, 2011a). In line with this hypothesis, it is known that, despite the absence of persistent structural elements in many IDPs/IDRs, their conformational space is not completely random but contains a rather limited set of preferential conformations, which can be structurally characterized by combining NMR spectroscopy with advanced structure determination/modeling techniques of computational biology (Allison et al., 2009; Bernado et al., 2005; Bertoncini et al., 2005; Dedmon et al., 2005; Jensen et al., 2009; Salmon et al., 2010; Sung and Eliezer, 2007; Vendruscolo, 2007; Wu et al., 2008; Wu et al., 2009). For example, in the case of a canonical IDP α -synuclein it was shown that the fluctuating structural ensemble of this protein in solution is characterized by the presence of a wide range of conformations, including relatively compact transient states originating from long-range contacts between the temporarily populated elements of the residual local structure (Bertoncini et al., 2005; Dedmon et al., 2005). These relatively compact transient conformations represent an illustrative example of the aforementioned functionally misfolded state of an IDP.

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

It seems that this functionally misfolded conformational ensemble represents an attractive drug target, assuming that small molecules can be found that would be capable of stabilization of different members of this ensemble, thereby precluding the targeted protein from making biological interactions. It is important to emphasize here that this approach is principally different from the aforementioned direct targeting of short IDRs, as here, a small molecule is expected to bind to a highly dynamic surface generated by the transient contacts between the interaction-prone elements. Within the context of the functionally misfolded conformational ensemble model, a search for such small molecules is more reminiscent of the well-established structure-based rational drug design approach elaborated for ordered proteins, assuming that the structures of the individual members of the ensemble can be guessed. In this case, tools originally developed for rational structure-based drug design for ordered proteins (e.g., in silico screening methods based on the high-throughput docking of large small molecule libraries to structured proteins (Lavecchia and Di Giovanni, 2013; McInnes, 2007)) can be utilized to find small molecules that are potentially able to interact with these guessed structures, thereby stabilizing them and locking the cage. The idea that the proposed approach might actually work was presented in a study by Toth et al., who used a complex combinatorial approach comprising a set of computational and experimental techniques to find a drug-like phenyl-sulfonamide compound (ELN484228) capable of targeting α-synuclein, and showing substantial biological activity in the cellular models of α -synuclein-mediated dysfunction (Toth et al., 2014). In their search for small molecules targeting intrinsically disordered α-synuclein, the authors first randomly selected 100

derived from comprehensive NMR analysis. Then, they selected 22 more compact structures and

structures from the conformational ensemble containing 40,000 α-synuclein structural models

used them as targets in the computational fragment probe mapping (Kortvelyesi et al., 2003) to identify potentially druggable hot spots (Toth et al., 2014). Based on this analysis, eight potential binding pockets, which were typically formed through relatively long-range tertiary contacts, were identified. Each of these pockets was located in a different member of the α -synuclein ensemble. In the next step, each of these binding pockets was used as a target for computational docking of a library of ~ 33,000 fragment-like compounds with molecular masses under 325 Da, leading to the identification of 89 potential ligands for these binding pockets (Toth et al., 2014). At the final stage, one of the identified in silico hits, ELN484228, was used in α -synuclein aggregation assays and in cellular models of α -synuclein malfunction (Toth et al., 2014). This analysis revealed the protective role of ELN484228 in cellular models of α-synuclein-mediated vesicular dysfunction (Toth et al., 2014). The importance of this study cannot be overestimated, as it serves as a solid proof of the idea that the dynamic and highly heterogeneous conformational ensembles of IDPs contain specific functionally misfolded members, which are relatively compact, contain small molecule binding pockets, and therefore can be targeted by drugs. These findings open intriguing and very promising possibilities in the field of drug discovery for pathology-related IDPs/IDRs.

III.E. Targeting aggregating IDPs/IDRs

1054

1055

1056

1057

1058

1059

1060

1061

1062

1063

1064

1065

1066

1067

1068

1069

1070

1071

1072

1073

1074

1075

Since protein misfolding diseases, including numerous neurodegenerative disorders, are characterized by the pathological aggregation of misfolded species that initiates an avalanche of events leading to neurodegeneration and death (Uversky, 2009a; 2010b), overpowering the pathological protein aggregation by small molecules is considered as a very promising research

1077

1078

1079

1080

1081

1082

1083

1084

1085

1086

1087

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

1098

area. However, protein aggregation involves multiple parallel assembly pathways and the simultaneous existence of various metastable structures, making this research a daunting task (Liu and Bitan, 2012). Furthermore, many conformational diseases are driven by the misbehavior of IDPs/IDRs (Gadhave et al., 2020; Uversky, 2009a; 2012; 2014; Wang et al., 2011). To deal with these challenges, several strategies were proposed to find small molecules that are able to (Uversky, 2012; 2014; Wang et al., 2011): (i) directly bind to IDRs and block their aggregation by keeping them in the interaction-incompetent conformation; or (ii) interact with IDP/IDR and promote formation and stabilization of non-toxic and non-amyloidogenic oligometric species; or (iii) interact with amyloidogenic protein and dramatically accelerate its aggregation to minimize the duration of the toxic oligomer formation stage. One of the ways to perturb the oligomerization and aggregation processes is the use of small molecules known as "molecular tweezers" (Fokkens et al., 2005; Prabhudesai et al., 2012; Sinha et al., 2011) capable of caging the reactive residues (lysines) of the aggregating proteins (such as amyloid β -protein (A β), tau, islet amyloid polypeptide, and α -synuclein) inside the electron-rich torus-shaped cavity decorated with two peripheral anionic phosphonate groups (Prabhudesai et al., 2012; Sinha et al., 2011). Formation of stable, nontoxic oligomers located off the fibrillation pathway was efficiently induced in an important IDP involved in the pathogenesis of Parkinson's disease, α -synuclein, by different various small molecules (including several polyphenols) (Ehrnhoefer et al., 2008; Uversky, 2007; 2010b; Uversky and Eliezer, 2009). The small molecule-induced formation of such oligomers was shown to inhibit fibrillation of α -synuclein (Masuda et al., 2006; Uversky, 2007; 2010b; Uversky and Eliezer, 2009; Yamaguchi et al., 2010). Similarly, a set of lead-like compounds and drug-like molecules was identified in a high-throughput chemical microarray

surface plasmon resonance imaging-based search for finding small molecules capable of binding to a monomeric tau protein, which is an important IDP involved in the pathogenesis of various neurodegenerative diseases collectively known as tauopathies (Pickhardt et al., 2015). Based on the premise that the mature amyloid fibrils are typically less toxic than some of the soluble oligomeric species transiently accumulating during the protein fibrillation process, it was hypothesized that the acceleration of the transition from oligomers to fibrils might represent an important, albeit an absolutely counter-intuitive, therapeutic strategy (Ross and Poirier, 2005). Systematic analyses of the consequences of the drug-accelerated aggregation of several proteins provided strong support to this hypothesis (Liu and Bitan, 2012).

Finally, information on the small molecules known to inhibit aggregation of IDPs related to the pathogenesis of neurodegenerative diseases was used to generate fragment-based libraries of IDP-specific drugs by screening the existing large generic libraries of small molecules (Joshi et al., 2016). The usefulness of this approach providing a way to generate molecular scaffolds of drugs potentially targeting neurodegeneration-related IDPs was illustrated by creating IDP-specific libraries of small molecules capable of targeting the IDPs related to the pathogenesis of the Alzheimer's and Parkinson's diseases, Aβ, tau, and α-synuclein (Joshi et al., 2016).

III.F. Disorder-based development of consensus interferons

Interferons (IFNs) are a group of signaling proteins produced and released by the host cells in response to the presence of different pathogens, such as bacteria, parasites, tumor cells, viruses, and their diverse products (De Andrea et al., 2002). Since the release of IFNs by the infected cells represents a unique signal to the neighboring cells aiming at triggering the protective

1122

1123

1124

1125

1126

1127

1128

1129

1130

1131

1132

1133

1134

1135

1136

1137

1138

1139

1140

1141

1142

1143

mechanisms used by the immune system to eradicate pathogens, IFNs serve as cytokines for inter-cell communication (Parkin and Cohen, 2001). There are three major types of human INFs that are grouped based on the receptors they use to trigger the subsequent signals. Type I represents the largest group of IFNs that includes a set of IFNs-α encoded by at least 23 genes with no intron sequences (Pestka et al., 1987), IFN-β, IFN-δ, IFN-ε, IFN-κ, IFN-τ, and IFN-ω (Liu, 2005; Platanias, 2005). Type I IFNs bind to a specific multichain IFN- α/β receptor IFNAR, which is a complex containing at least two subunits, IFNAR1 and IFNAR2 (de Weerd et al., 2007). The only type II IFN in humans is IFN- γ , which binds to the oligomeric IFN- γ receptor (IFNGR) consisting of IFNGR1 and IFNGR2 chains (Parkin and Cohen, 2001). Finally, for transduction of their signals, the type III IFNs use a receptor complex that comprises IL10R2 and IFNLR1 chains (Kalliolias and Ivashkiv, 2010). IFN-α, being discovered more than 50 years ago by Isaacs and Lindenmann (Isaacs and Lindenmann, 1957) as an anti-viral agent, is secreted by nearly all cell types following the stimulation by viruses, bacteria, nucleic acids, and protozoa (Sen and Lengyel, 1992). Therefore, it is not surprising that IFNs- α , which can be further subdivided into several subtypes (e.g., IFN- $\alpha 1$, $-\alpha 2$, $-\alpha 4$, $-\alpha 5$, $-\alpha 6$, $-\alpha 7$, $-\alpha 8$, $-\alpha 10$, $-\alpha 13$, $-\alpha 14$, $-\alpha 16$, $-\alpha 17$, and $-\alpha 21$), are among the best studied IFNs. Different IFNs-α show high levels of sequence similarity, and sequences of human IFNs-α share between 70 and 80% homology, and about 35% identity with human IFN-β (El-Baky and Redwan, 2015; Genin et al., 2009). In line with this sequence conservation, structural analysis revealed a high level of structural similarity between these proteins, where IFNs- α (IFN- α 1/13 and IFN- α 2) and IFN- β are characterized by a compact structure composed of five major α -helices (named helix A to E) connected by a long loop and three shorter loops (Radhakrishnan et al., 1996). However, although the global α-helical fold of IFNs is conserved,

1145

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

1162

1163

1164

1165

1166

the arrangements of their loops show some noticeable differences (see Figures 10A, 10B, and **10C**) (El-Baky et al., 2015b). Furthermore, analysis of the reported structures revealed the presence of noticeable structural flexibility in IFN-α proteins, suggesting that some of their regions can be intrinsically disordered (El-Baky et al., 2015b). This idea was further supported by the analysis of the per-residue intrinsic disorder propensity of 17 human IFNs-α, which clearly revealed the presence of several flexible or disordered regions, mostly within the Nterminal regions of these proteins (see Figure 10D) (El-Baky et al., 2015b). Recombinant IFN-α2 is the only interferon that is currently used for treatment of chronic hepatitis B and C, and leukemia (Borden et al., 2007; Gutterman, 1994). Furthermore, to improve the anti-viral efficiency of natural recombinant IFNs- α , a synthetic IFN- α , the consensus interferon cIFN-α, was created two decades ago (Blatt et al., 1996; Fish et al., 2008). This consensus interferon, being an artificial recombinant second-generation type I interferon, developed based on the sequence conservation among the fourteen natural human IFNs-α subtypes (Klein et al., 1988), was shown to possess 10- to 100-fold higher anti-viral and antiproliferative activities than the naturally occurring α -interferon subtypes in humans (Blatt et al., 1996; Keeffe et al., 1997; Ozes et al., 1992; Sjogren et al., 2005; Tong et al., 1997). This higher efficiency of the cIFN-α was linked to the higher affinity of this protein to the type I IFN receptors than the naturally occurring IFN- α (Blatt et al., 1996). Comparison of the disorder profiles generated for two consensus IFNs-α with the mean disorder profile calculated as averaged disorder predispositions of 17 human IFNs-α revealed a remarkable similarity between these three disorder profiles (El-Baky et al., 2015b) (see Figure 11). Furthermore, these three disorder profiles were closer to each other than the disorder profiles of most of the individual IFNs- α (cf. **Figure 10D**). Based on these observations it was

hypothesized that "if the peculiarities of disorder distribution within the protein sequence are related to protein functionality, then comparison of the disorder profiles of artificial proteins (query profiles) with the averaged disorder predisposition profile of human IFNs- α (target profile) can be used in the design of novel cIFNs. The goal here would be to achieve a close similarity between the query and target profiles by manipulating the cIFN sequence" (El-Baky et al., 2015b).

III.G. Unstructural vaccinology: Fighting fire with fire

1167

1168

1169

1170

1171

1172

1173

1174

1175

1176

1177

1178

1179

1180

1181

1182

1183

1184

1185

1186

1187

1188

1189

Despite intensive research spanning several decades, there has been no advancement in finding efficient vaccines against hepatitis C virus (HCV), human immunodeficiency virus-1 (HIV-1), and herpes simplex viruses (HSVs). In addition to the accepted objective reasons for such failure, such as the capability of HSVs to establish latency (Stanfield and Kousoulas, 2015), the high mutation rates of the HCV and HIV-1 RNA viruses (Goh et al., 2019; Goh, 2017b; Ward, 2007) leading to the presence of a complex mixture of heterogeneous viral strains, "quasispecies" in the HIV-1 infected persons (Meyerhans et al., 1989) or multiple HCV genotypes (Palladino et al., 2018; Smith et al., 2014), the presence of neotopes (Khattar et al., 2013), and the highly glycosylated nature of proteins used as primary vaccine targets against these viruses (see, e.g., (Chakraborty et al., 2020; Leonard et al., 1990; Vigerust and Shepherd, 2007)), an important but mostly overlooked factor is the presence of highly flexible regions and IDRs in human antibodies (Abs) and in the major HIV-1, HCV, and HSV immunogens (Uversky, 2022). Such structural flexibility prevents the utilization of structure-based reverse vaccinology and calls for utilization of tools designed for the analysis of disordered and flexible proteins, while looking at the intrinsically disordered viral antigens and their interactions with intrinsically disordered/flexible

1191

1192

1193

1194

1195

1196

1197

1198

1199

1200

1201

1202

1203

1204

1205

1206

1207

1208

1209

1210

1211

1212

Abs, i.e., unstructural vaccinology. In fact, the foundation of structure-based reverse vaccinology, which was successfully utilized for the identification of novel vaccine antigens and the improvement of the safety and immunogenicity of vaccine antigens (Burton, 2002; 2010; Masignani et al., 2002; Rappuoli, 2001; Rinaudo et al., 2009), is the use of information from the crystallographic structure of a complex between a neutralizing monoclonal antibody (mAb) and a complementary epitope to rationally design better antigens capable of acting as vaccine immunogens (Masignani et al., 2002; Rappuoli, 2001). However, considering antigen-antibody complexes as rigid, motionless structures with steric "lock-and-key"-type complementarity to each other is a clear oversimplification, as biological molecules are not crystals but represent dynamic conformational ensembles characterized by structural fluctuations of different amplitude happening at multiple time-scales. Furthermore, the binding sites of all the partners involved in the complex formation are not fixed in space and time, being instead relational entities engaged in mutual tuning, the scale of which ranges from rather minimal structural adjustments to global binding-induced folding (Uversky, 2022). Therefore, the "flexible keys and adjustable locks" model could provide a better description of the protein-based interactions that rely on the mutual adjustments of the partners via coordinated induced complementarity and fit (Edmundson et al., 1987). In line with these considerations, intrinsic disorder or structural flexibility is abundantly present on both sides of the Abs-antigen system, as antigen-binding sites of Abs are flexible/disordered, and many antigens contain noticeable levels of intrinsic disorder, or are at least characterized by high conformational plasticity (Uversky, 2022). For example, being one of the major HIV-1 antigens, gp120 contains multiple IDRs coinciding with, or located in close proximity to, the functional regions of this protein, such as highly genetically diverse variable regions, CD4-binding loop, and all N-linked glycosylation sites

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

1224

1225

1226

1227

1228

1229

1230

1231

1232

1233

1234

1235

(Uversky, 2022). Furthermore, although "crystallizable" variants of the HIV-1 glycoprotein gp120 (gp120 cores) were generated by removal of some disordered/flexible regions (see Figure 12), the resulting truncated forms were still characterized by noticeable structural variability, as between 20% and 30% of each structurally characterized gp120 core contained some unique structural features, not seen in other forms (Uversky, 2021). Similarly, a hypervariable region of the HCV envelope glycoprotein E2 (residues 1-27), which shields the more conserved epitopes of this protein from neutralizing antibodies (The Lancet Gastroenterology, 2021), and the Nlinked glycosylation sites of this protein were predicted to be disordered (Uversky, 2022). In the HSVs, all 12 surface glycoproteins were predicted to contain high levels of intrinsic disorder, with many important functional features of HSV glycoproteins and their N-glycosylation sites being overlapped or located within, or in close proximity to, the IDRs (Uversky, 2022). Taken together, these data for three viruses indicated the importance of intrinsic disorder in establishing a flexible glycan-IDR shield protecting potential epitopes from neutralizing antibodies (Uversky, 2022). Let's now look at another side of the dynamic antigen-antibody complex and briefly consider some of the key features of the highly flexible structure of Abs. For a detailed analysis of this structural flexibility, interested readers are encouraged to check reference (Uversky, 2021). In fact, structures of Abs are highly dynamic at multiple levels. For example, in the Y-shaped IgG, an obvious illustration of structural pliability is given by the flexible linkers/hinges between the antigen-binding fragments F_{ab} (arms) and the constant fragment F_c (stem). As a results of this high conformational flexibility of hinges, Abs exist as highly dynamic conformational ensembles, and the known crystal Ab structures represent "snapshots" of these ensembles (Saphire et al., 2001). Furthermore, the discontinuous "active sites" of Abs, which are formed by

1237

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

1249

1250

1251

1252

1253

1254

1255

1256

1257

1258

the 50-70 hypervariable residues containing paratopes (binding sub-sites chemically and structurally complementary to the epitopes), are characterized by high conformational dynamics as well. These antigen-binding sites of anti-protein Abs represent the short segments located within the six complementarity determining regions (CDRs), known as L1, L2, L3 on the light chain and H1, H2, and H3 on the heavy chain (Goldsby et al., 2003), and which are typically relatively flat. However, it was pointed out that human Abs are able to embed into the canyons and clefts on the antigen surface (Saphire et al., 2001; Smith et al., 1996) as their H3 loops located in the center of the binding sites are often extended (Barbas et al., 1993; Kunert et al., 1998; Sanna et al., 1995; Saphire et al., 2001), being characterized by a very broad spectrum of distinctive structural features containing on average 10 times more unique conformations than the other loops (Regep et al., 2017). The intrinsic disorder status of this loop in both heavy and light chains of a typical IgG was confirmed by a bioinformatics analysis (Uversky, 2022). The idea of high structural flexibility of the H3 loop was further supported by a comparative analysis of several anti-HIV Abs of human or bovine origin (Uversky, 2021), which revealed that the length of the H3 loop can vary in a very broad range, from 4 residues in a non-neutralizing HIV antibody 13H11 (PDB ID: 3MO1) to 16 residues in a broadly reactive and potent HIV-1 neutralizing human antibody PG9 (PDB ID: 3U1S; (McLellan et al., 2011)), and to 60 residues in a potent HIV-1 bNAb NC-Cow1 (PDB ID: 6000; (Stanfield et al., 2020)), which is folded into a mini domain (knob) on an extended stalk structure (Stanfield et al., 2020) (see Figure 13). The presence of the "knob on a stalk" structure within the exceptionally long CDR H3 of the NC-Cow1 bNAb (which protrude up to 40 Å above the tips of the other CDR loops) defines its ability to efficiently bind to the HIV Env trimer BG505 SOSIP, as the "knob on the stalk" can navigate "through the dense glycan shield on Env to target a small footprint on the gp120 CD4

1260

1261

1262

1263

1264

1265

1266

1267

1268

1269

1270

1271

1272

1273

1274

1275

1276

1277

1278

1279

1280

1281

receptor binding site with no contact of the other CDRs to the rest of the Env trimer" (Stanfield et al., 2020). In other words, the "knob on an extended stalk" structure makes an extra-long CDR H3 a perfect "penetrator" capable of traversing through the glycan shield on Env. It was also pointed out that the neutralization potential of a given Ab correlates with the length of its CDR H3 loop, and bNAbs, which are typically characterized by high neutralization potential, tend to have long CDR H3 loops (Purtscher et al., 1994; Zhou and Xu, 2018), which allow them to breach the dense glycan shield of HIV Env, thereby ensuring access to the protein surface of this viral glycoprotein (Kong et al., 2013; Zhou and Xu, 2018). One should also remember that the CDR H3 loops of different Abs were all predicted to be flexible or disordered, with the disorder degree being proportional to the length of the H3 loop (Uversky, 2021; Uversky, 2022). These observations not only indicate that the neutralizing efficiency of bNAbs is driven by intrinsic disorder, but also suggest that the structures reported for this region in different Abs are likely to represent snapshots of highly dynamic conformational ensembles, with some of these structures being induced by the crystal lattice or by the interactions of Abs with the antigens (Uversky, 2022). Taken together, these and many related observations suggest that intrinsic disorder and structural flexibility play crucial roles in immune response, where intrinsic disorder of viral antigens helps them evade at least some of the protective mechanisms of the hosts, and where, by having flexible/disordered antigen-binding sites of Abs, the "immune system follows the "if you can't fight them join them" principle and "fights fire with fire" by utilizing intrinsic disorder/structural flexibility of Abs to overcome intrinsic disorder-based "invisibility" of viral antigens" (Uversky, 2022). This also generates serious doubts about the overall applicability of the computational tools elaborated to be used in the rational structure-based reversed vaccinology. Since these

important considerations cannot be ignored, it was claimed: "We should stop playing with motionless toys, as the reality is much more complex than the static picture drawn by the classic "lock-and-key" model. In fact, it is even more complex than the complex interplay of "flexible keys and adjustable locks". It is time for the emergence of unstructural vaccinology, where the phenomenon of intrinsic disorder is taken into account while thinking about novel approaches for designing vaccines against "flexible" viruses that act as dynamic "shape-shifters" (Goh, 2017a). In other words, we need to start using experimental and computational tools designed for the analysis of disordered and flexible proteins, while looking at intrinsically disordered viral antigens and their interactions with intrinsically disordered/flexible Abs" (Uversky, 2022).

III.H. Targeting liquid-liquid phase separation

In addition to a broad spectrum of crucial roles in cellular organization, signaling, and regulation of various cellular processes, LLPS is involved in the pathogenesis of numerous diseases, thereby serving as an important novel subject of the research on disease biology and development of therapeutics (Alberti and Dormann, 2019; Wang et al., 2021; Zbinden et al., 2020). In fact, in neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) associated with the accumulation of neuropathological protein aggregates in the brain (Arai et al., 2006; Kosik et al., 1986; Masters et al., 1985; Spillantini et al., 1998), LLPS is recognized as the stage preceding aggregation that plays a number of significant roles in the pathogenesis of these diseases (Ambadipudi et al., 2017; Carey and Guo, 2022; Ray et al., 2020). Phase separation has been linked to cancer as well, with many oncogenic proteins undergoing LLPS and driving formations of MLOs and BCs involved in the promotion of tumor growth, survival, and metastasis (Kamagata et al., 2020;

- 1305 Mehta and Zhang, 2022; Ren et al., 2022; Shi et al., 2021; Tong et al., 2022; Xie et al., 2023; Zamudio et al., 2019; Zhang et al., 2020). The aforementioned hybrid oncoprotein EWS-FLI1 1306 contributes to the altered gene expression patterns resulting in oncogenic cell transformation by 1307 1308 undergoing LLPS and forming nuclear condensates (Ahmed et al., 2021; Boulay et al., 2017). 1309 Furthermore, oncogenesis is linked to dysregulation (El-Naggar and Sorensen, 2018; Song and 1310 Grabocka, 2023) and abnormal dynamics of SGs (Grabocka and Bar-Sagi, 2016; Gupta et al., 2017; Li et al., 2021; Somasekharan et al., 2015). Finally, pathogenesis of several metabolic 1311 1312 diseases, such as obesity, diabetes, and nonalcoholic fatty liver disease (NAFLD) is linked to 1313 protein LLPS (Fonteneau et al., 2022; Gao et al., 2022; Pytowski et al., 2020). Consequently, targeting phase-separating proteins and resulting MLOs/BCs might have great potential in the 1314 therapeutic interventions of various diseases, and therefore emerged as a promising strategy for 1315 1316 drug discovery (Mitrea et al., 2022; Vendruscolo and Fuxreiter, 2022). Among the approaches that can be utilized in the discovery of drug targeting phase-separated protein states or proteins 1317 undergoing LLPS are the use of small molecules as: 1318
- a) Inhibitors capable of modulating the LLPS of proteins involved in specific diseases

 (Babinchak et al., 2020; Dai et al., 2021; Fang et al., 2019; Girdhar et al., 2020; Oka et

 al., 2016; Pradhan et al., 2021; Ramesh et al., 2023; Richard et al., 2019; Sawner et al.,

 2021; Song et al., 2016; Takada and Makishima, 2020; Wang et al., 2022; Xu et al.,

 2022a; Xu et al., 2022b), or

1325

1326

1327

- b) A means to modulate the protein-protein interactions in condensates (Liu et al., 2023; White et al., 2019), or
- c) Specific IDR binders capable of altering the conformation or aggregation propensity of IDRs (Fang et al., 2019), or

d) A means to induce changes in the IDR energy landscape (Heller et al., 2018) or affecting interactions of IDRs with other proteins or cellular components involved in LLPS, or

- e) Modulators of the physicochemical properties of the cellular environment leading to the disruption of the formation or stability of liquid-like condensates (Patel et al., 2022), or
- f) Modulators of the cellular proteostasis and protein quality control systems affecting the functionality of chaperones (Baughman et al., 2018; Bruinsma et al., 2011; Wilhelmus et al., 2006; Zourlidou et al., 2004) and autophagy (Ma et al., 2022).

Ever-increasing understanding of the phase-separated protein states leads to the development of new approaches for their utilization in drug discovery (Mitrea et al., 2022; Richard et al., 2019; Vendruscolo and Fuxreiter, 2022). Small molecules or compounds capable of LLPS modulation can be identified through the development of assays that capture the dynamics and properties of phase-separated condensates (Zhou et al., 2020). The discovery of novel therapeutics that effectively modulate phase-separated protein states and provide new opportunities for treating LLPS-associated diseases are linked to emerging technologies, such as high-throughput screening (HTS) techniques, development of biomimetic systems that aim to recreate cellular environments and conditions in a controlled laboratory environment (Bina et al., 2022; Jobdeedamrong et al., 2023; Razzak and De Brabander, 2011), and the integration of artificial intelligence (AI) and machine learning (ML) to accelerate the identification and optimization of potential drug candidates (Dara et al., 2022; Jobdeedamrong et al., 2023; Paul et al., 2021; Zhou et al., 2020) and streamlining the drug discovery process by predicting the potential off-target or side effects and toxicity profiles (Dara et al., 2022; Paul et al., 2021).

III.I. Self-assembling "smart" IDP-based containers for targeted drug delivery

1352

1353

1354

1355

1356

1357

1358

1359

1360

1361

1362

1363

1364

1365

1366

1367

1368

1369

1370

1371

1372

1373

Importantly, IDPs have found specific applications in the form of self-assembling "smart" containers for targeted drug delivery. These new IDP-based materials utilize an intriguing possibility of extended IDPs to show a "turned out" response to heat reflected in the temperatureinduced formation of some residual secondary structure (Kim et al., 2000; Permyakov et al., 2003; Timm et al., 1992; Uversky et al., 2001; Uversky et al., 2002). In this context, the term "turned out" response is used to emphasize the specific response of extended IDPs (native coils and native pre-molten globules) to changes in their environment, which is different from that of ordered proteins. In fact, although extreme temperatures or pH act as denaturing factors leading to the disruption of ordered protein structures (i.e., their (at least partial) destructuration), these same conditions (elevated temperature or extremely acidic and/or alkaline conditions) would cause the appearance of more structure in IDPs, i.e., their partial folding (Uversky, 2009b; 2013d). Among important members of such proteins with the "turned out" response are elastinlike polypeptides (ELPs) consisting of repeats of the VPGXG pentapeptide with the "guest residue" X being any amino acid with the exception of proline. Deep understanding of the specific features determining the capability of ELP to undergo a reversible phase transition from the disordered, highly solvated conformation below the inverse transition temperature (T_t) to a new condensed phase comprising desolvated and aggregated polypeptides when the temperature is raised above T_t (Meyer and Chilkoti, 1999; Urry, 1988; 1992; 1997) resulted in the development of a unified model for accurate prediction of the T_1 values for different ELPs based on their composition, chain length, and concentration (McDaniel et al., 2013b). The T_t of an ELP is unique to each polymer and inversely related to the polypeptide concentration, number of monomer repeats, and hydrophobicity of the fourth or variable X residue of the pentapeptide repeat (Chilkoti et al., 2002; Meyer and Chilkoti, 2004; Urry, 1992; Urry et al., 1991).

1375

1376

1377

1378

1379

1380

1381

1382

1383

1384

1385

1386

1387

1388

1389

1390

1391

1392

1393

1394

1395

1396

Depending on the peculiarities of the ELP sequence, the resulting condensed phase can be either nanoscale particles (micelles), or micron-scale coacervates, or viscous gels (Hassouneh et al., 2012). Therefore, ELPs represent a unique system with a controllable separation to the mechanically different phases. Since ELPs are non-toxic, biodegradable biopolymers displaying good pharmacokinetics (Janib et al., 2013; Liu et al., 2006b; Paiva and Martins, 2011), they have found multiple uses in the development of various self-assembling drug-loaded nanoparticles. For example, fusing ELP to a cysteine-rich short peptide generated a chimeric polypeptide (CP) capable of covalent binding of various hydrophobic molecules including chemotherapeutics and undergoing a conjugation-induced spontaneous self-assembly into nanoparticles (MacKay et al., 2009; McDaniel et al., 2013a), which were able to effectively treat solid tumors upon intravenous injection, as illustrated by the doxorubicin-conjugated chimeric polypeptide (Dox-CP) (MacKay et al., 2009). In another application of this technology, ELP-based "heat seeking" polypeptide nanoparticles loaded with anticancer drugs were designed to thermally target solid tumors (McDaniel et al., 2014). Here, the CP possessing thermal sensitivity within the clinically relevant temperature interval was designed that formed CP-Dox nanoparticles at 40–45°C (McDaniel et al., 2014). It was also shown that the nanoparticles were able to reversibly aggregate in tumors in a temperature-dependent manner and that the thermal cycling of the tumors between 37 and 42°C represented an effective way of targeting the nanoparticles to tumors (McDaniel et al., 2014). Fusing specific cell penetrating peptides (CPPs) to ELPs allowed for controllable and rapid delivery of the cargo molecule to the target cells (Bidwell et al., 2009; Bidwell et al., 2007; Bidwell and Raucher, 2005; 2010; Massodi et al., 2005; Massodi et al., 2009), and, being combined with local hyperthermia, such peptides showed enhanced permeability and high retention effects (Ryu and Raucher, 2014). A logical extension of this idea

was design of thermally responsive delivery systems, where fusion of a selected bioactive peptide or protein to a peptide delivery vector containing CPP and ELP enhanced cellular uptake and resulted in a noticeable increase in the activity of this protein/peptide by the hyperthermia treatment (Bidwell and Raucher, 2005; Massodi et al., 2005; Massodi et al., 2010; Massodi and Raucher, 2007; Mikecin et al., 2014; Shamji et al., 2008).

III.J. Pharmacological chaperones

1397

1398

1399

1400

1401

1402

1403

1404

1405

1406

1407

1408

1409

1410

1411

1412

1413

1414

1415

1416

1417

1418

Pharmacological chaperones are small molecules capable of stabilization of a native protein conformation or native protein complex. The idea is based on the discovery and successful utilization of tafamidis, a small molecule capable of stabilizing the native homotetrameric form of transthyretin and preventing dissociation, misfolding, aggregation, and amyloid fibril formation of this protein related to the pathogenesis of familial amyloid polyneuropathy, as well as familial and sporadic amyloid cardiomyopathy (Bulawa et al., 2012; Miroy et al., 1996). This concept of pharmacological chaperones has gained the attention of the researchers (Chiti and Kelly, 2022; Ringe and Petsko, 2009; Vendruscolo, 2023), and several drugs acting via this mechanism have been approved by the FDA, and many other compounds with a similar mechanism of action are under development (see (Vendruscolo, 2023) for review). Although the idea of pharmacological chaperones was originally proposed as a means for stabilization of the native structure of ordered proteins, it was recognized that this principle can be used to target IDPs/IDRs as well (Biesaga et al., 2021; Follis et al., 2008; Heller et al., 2015; Lohr et al., 2022; Robustelli et al., 2022; Ruan et al., 2019; Vendruscolo, 2023). Despite the fact that IDPs/IDRs cannot form stable interactions with small molecules due to the lack of specific binding pockets,

1420

1421

1422

1423

1424

1425

1426

1427

1428

1429

1430

1431

1432

1433

1434

1435

1436

1437

1438

1439

1440

1441

several small molecules were shown to interact with IDPs/IDRs (Ban et al., 2017; Follis et al., 2008; Ruan et al., 2020; Toth et al., 2014; Zhu et al., 2022). The proposed mechanisms of action of pharmacological chaperones on IDPs/IDRs include induction of a population shift in the conformational landscape of an IDP/IDR (Ban et al., 2017), promotion of IDP folding reflected in the formation of a collapsed state (Zhu et al., 2022) or even formation of a well-defined binding pocket (Follis et al., 2008; Toth et al., 2014; Vendruscolo, 2023; Zhu et al., 2013). Pharmacological chaperones have also been reported that utilize entropy and not enthalpy and work via the "disordered binding mechanism" (Heller et al., 2020; Heller et al., 2015; Lohr et al., 2022). According to this mechanism, the complex between an IDP/IDR and a small molecule is stabilized by an increase in entropy. This is possible when the small molecule competes with the transient intramolecular interactions of the protein and makes it even more disordered. In other words, the binding of small molecules by IDPs/IDRs can affect their conformational space by creating an entropic expansion, where more protein conformations become populated, thereby emphasizing that the entropic contributions can act as the main driving force of protein-ligand interaction (Heller et al., 2015). Recently, it was demonstrated that the concept of pharmacological chaperones can also be applied to the discovery of a small molecule that modulates the LLPS driven by the pathologyrelated IDPs (Dada et al., 2024). Here, the idea was that pharmacological interventions can be utilized to inhibit aggregation of a target protein (α-synuclein) within the liquid-like condensates into solid-like amyloid fibrils. Experiments conducted in vitro and in a Caenorhabditis elegans model of Parkinson's disease revealed that a small molecule spermine-containing aminosterol claramine (which is structurally similar to two natural products isolated from the liver of dogfish sharkstrodusquemine and squalamine) can act as a pharmacological chaperone modulating the

aggregation behavior of α -synuclein within the condensed state (Dada et al., 2024). Analysis revealed that the aminosterol claramine modulate the α -synuclein phase separation by stabilizing α -synuclein condensates and inhibiting fibrillation of this protein (Dada et al., 2024). Based on these exciting observations, the authors concluded that the inhibition of protein aggregation within condensates represents a possible therapeutic route that can be relevant to the treatment of many neurodegenerative diseases, where aggregation of disease causing proteins is accelerated within the liquid condensates formed through phase separation (Dada et al., 2024).

IV. Concluding remarks: Clouds in clouds

Biologically active proteins without unique structures represent a new reality of molecular biology. There are multiple important reasons why IDPs/IDRs cannot be ignored anymore. First of all, they are vastly abundant in the protein universe (Dunker et al., 2000; Tokuriki et al., 2009; Uversky, 2010a; Ward et al., 2004; Xue et al., 2012; Xue et al., 2010), with highly disordered proteins (i.e., proteins, which are, based on the results of PONDR® VSL2 analysis, contain at least 50% the disordered residues and are characterized by mean disorder scores exceeding the 0.5 threshold) accounting for 36.3% of human proteome (Mohammed and Uversky, 2022). This high prevalence of IDPs/IDRs in the human proteome and the fact that disorder is evolutionary conserved (IDPs/IDRs are abundantly found in all the proteomes from all the kingdoms of life analyzed so far) embrace a very important message: disorder is important. This conjecture is supported by the fact that, being a highly conservative lady, nature would not waste time, energy, and resources, which are typically very scarce, to generate something useless. In line with these considerations, vast evidence is accumulated to show that IDPs/IDRs are biologically important,

1465

1466

1467

1468

1469

1470

1471

1472

1473

1474

1475

1476

1477

1478

1479

1480

1481

1482

1483

1484

1485

1486

possessing crucial cellular functions complementing the functional repertoire of ordered proteins. Furthermore, intrinsic disorder represents a means for the almost unlimited extension of the modes of protein action, control, and regulation. Among numerous ways of how disorder is used by proteins in their various biological activities, its roles in protein multifunctionality and protein-protein interactions are unsurpassed. If one could think of any very unusual and neverseen-before way of connecting proteins to their partners (other proteins, nucleic acids, other biopolymers, membranes, or small molecules), with a very high probability, such an interaction mode would be based on intrinsic disorder. Being "edge of chaos" systems (Uversky, 2013d)(Turoverov et al., 2019), IDPs/IDRs are extremely sensitive to their environment and can undergo fast conformational switching in response to subtle environmental changes, with the scale and direction of such conformational changes being dependent on the nature of the environmental stimuli. These high sensitivity and responsiveness define IDPs/IDRs as crucial cellular controllers, but also indicate that these controllers must be tightly controlled themselves. In fact, as was already emphasized, within a complex and highly interconnected system there are too many ways of getting something wrong. Therefore, it is not surprising that misregulation/dysregulation, deregulation, miscommunication, misfunction, and malfunction of IDPs/IDRs are commonly disastrous and linked to numerous human diseases. All this defines an ever-increasing desire of researchers to better understand these highly abundant multifunctional promiscuous binders in order to use IDPs/IDRs and disorder-based functionality as novel drug targets. However, all this also indicates that IDPs/IDRs and disorder-based functions are difficult drug targets, as well-established protocols of structure-based rational drug design cannot be directly

used to find drugs targeting structure-less and highly dynamic systems. As a result, a

1488

1489

1490

1491

1492

1493

1494

1495

1496

1497

1498

1499

1500

1501

1502

1503

1504

1505

1506

1507

1508

1509

comprehensive computational analysis of the current druggable human proteome, which includes 1027 human proteins known to be targeted by the existing drugs, revealed a low abundance of drugs targeting IDPs, with the druggable human proteome being heavily biased towards ordered proteins (Hu et al., 2016). Again, this bias is defined by a set of drug discovery techniques that were originally elaborated to find small molecules capable of modulating the functions of ordered proteins from limited set of functional families, such as cell surface receptors, enzymes, ion channels, nuclear hormone receptors, and transporters. Regardless of differences in the biological functions of these targets, the basic principles of their molecular mechanisms of action are similar – they all have structurally defined binding sites that specifically interact with the endogenous ligands or substrates. Therefore, the molecular mechanisms of action of smallmolecule drugs affecting these differently functioning ordered targets are rather similar, as drugs, being used as antagonists and inhibitors, achieve their effects by over competing those endogenous ligands or substrates. Consequently, traditional, structure-based rational drug design is deeply rooted in prior knowledge of the structural organization of a targeted protein and a deep understanding of the molecular mechanisms underlying its biological activity, as the goal here is to find a small molecule that is precisely positioned within the uniquely organized binding site of a targeted protein.

Because of the lack of ordered structures in their unbound states, the ability to fold in a context-dependent manner and preserve noticeable disorder and structural flexibility outside their binding site, IDPs/IDRs are considered as impossible targets for structure-based rational drug design. Further complication is given by the multitudes of ways by which small molecules can interact with IDPs/IDRs, where several chemically dissimilar small molecules can interact with one IDR binding site, and several different small molecules can bind to independent interaction

1511

1512

1513

1514

1515

1516

1517

1518

1519

1520

1521

1522

1523

1524

1525

1526

1527

1528

1529

1530

1531

1532

sites in one IDP, where the ability of IDPs/IDRs to interact with multiple structurally different proteins is paralleled by their ability to bind a variety of chemically different small molecules (Metallo, 2010), where the point-like, local folding can be induced in an IDP by binding of a small molecule with the remaining protein preserving disorder, and where the conformational plasticity and flexibility of the recognition/binding elements of IDPs/IDRs define the their ability to bind structurally different molecules with similar affinity (Metallo, 2010). To further illustrate complications associated with intrinsic disorder, the "cloud in cloud" or "ligand cloud around the protein cloud" binding mechanism is briefly outlined below. In the first case, the overall flexibility of the polypeptide chain containing well-defined binding sites defines a model that can be described as "fixed ligand cloud within protein cloud". Figure 14A shows the solution NMR structure of the metallothionein (MT) from the snail *Littorina littorea* (LlMT) in the complex with Cd²⁺ (Baumann et al., 2017). The conformational ensemble representing the solution structure of LIMT includes 20 structurally different models of a polypeptide chain coordinating 9 metal ions (thus, the entire ensemble includes 20 polypeptide structures and 180 Cd²⁺ ions). LIMT contains three individual domains, each comprising a single structurally welldefined three-metal cluster, where three Cd²⁺ ions are present in the (S-thiolate)₄-coordinated form (there are 27 Cys residues in LIMT capable of coordinating 9 metal ions) (Baumann et al., 2017). Although individual domains are well-folded (Baumann et al., 2017), they undergo rather substantial mutual movements, resulting in the overall structure of LIMT resembling a cloud. Since each structure included in the LIMT conformational ensemble contains 9 well-coordinated Cd²⁺ ions, we are dealing with the "fixed ligand cloud within protein cloud" model here. Importantly, MTs represent a class of cysteine-rich polypeptides that contain little secondary structure but are capable of binding a large number of metal ions, such as Zn²⁺, Cd²⁺, and Cu⁺

1534

1535

1536

1537

1538

1539

1540

1541

1542

1543

1544

1545

1546

1547

1548

1549

1550

1551

1552

1553

1554

1555

(Blindauer and Leszczyszyn, 2010; Henkel and Krebs, 2004; Kagi and Schaffer, 1988; Romero-Isart et al., 2010). It was also emphasized that the apo-forms of MTs are intrinsically disordered and undergo binding-induced folding at interaction with metal ions, such as Cd²⁺, Cu⁺, Hg⁺, and Zn²⁺ (Baumann et al., 2017). In line with these observations, **Figure 14B** represents a 3D structural model of LIMT generated by AlphaFold showing that this protein is expected to be mostly disordered. Further support of the highly disordered nature of LlMT is given by **Figure** 14C representing its intrinsic disorder profile. Therefore, the aforementioned "fixed ligand cloud within protein cloud" model originates from the local multi-site metal-ion-binding-induced folding of an IDP combined with the preservation of global structural flexibility. To illustrate another level of complexity associated with utilization of IDPs/IDRs as potential drug targets, Figure 15 represents the outputs of the comprehensive computational analysis of interaction between the c-Myc₃₇₀₋₄₀₉ (a ligand-binding element of the aforementioned intrinsically disordered proto-oncogene c-Myc) and its 10074-A4 ligand (Jin et al., 2013). This analysis revealed that the "protein cloud"-like structure of c-Myc₃₇₀₋₄₀₉ represents a complex conformational ensemble, in which one can find several structurally different clusters, members of which can efficiently bind ligands. Furthermore, Figure 15 shows that, contrary to the traditional binding of small molecules to ordered proteins, where a dominant binding structure is formed, the binding of the ligand to a given member of the c-Myc₃₇₀₋₄₀₉ conformational ensemble occurred at a broad set of sites, generating a "ligand cloud around the protein cloud" binding mode (Jin et al., 2013). It is clear that reality can be even more complex. In fact, for long IDPs, instead of being around a protein cloud, the ligand cloud can be located within a protein cloud as illustrated by Figure 14. Therefore, the rarity of drugs targeting IDPs/IDRs can be explained by global challenges associated with dealing with such "cloud-around-cloud" or

"cloud-in-cloud" binding scenarios. This also indicates that some new tricks should be developed

1556

to find a way to drug IDPs/IDRs. 1557 1558 To overcome at least some of these difficulties and challenges, several approaches were 1559 elaborated for disorder-based drug discovery (Ambadipudi and Zweckstetter, 2016; Arai et al., 2024; Chen and Tou, 2013; Cheng et al., 2006; Choudhary et al., 2022; Dunker and Uversky, 1560 1561 2010; Joshi and Vendruscolo, 2015; Metallo, 2010; Ruan et al., 2019; Ruan et al., 2020; Saikia 1562 and Baruah, 2024; Saurabh et al., 2023; Tsafou et al., 2018; Uversky, 2012; Uversky and 1563 Dunker, 2010a; Wang et al., 2023; Yu et al., 2016; Yu et al., 2024). Drug molecules can be 1564 designed that mimic a critical foldable region (inducible foldon) of the disordered partner that 1565 undergoes a binding-induced folding and successfully compete with this inducible foldon for its 1566 binding site on the ordered partner (Cheng et al., 2006; Kim et al., 2019). Other small molecules 1567 can induces local misfolding of IDR and make the corresponding region incapable of the protein-1568 protein interaction (Dunker and Uversky, 2010; Metallo, 2010; Tsafou et al., 2018). Other small 1569 molecules can stabilize different members of the functionally misfolded ensemble (Uversky, 1570 2011a), thereby preventing targeted protein from functional interactions (Uversky, 2012). Such 1571 small molecules acting as stabilizers of the non-functional misfolded members of the disordered 1572 conformational ensemble using an in silico structure-based computational docking screen, where the members of the conformational ensemble are treated as ordered proteins and are used in a 1573 1574 virtual screening to identify potential ligands (Toth et al., 2014). Furthermore, small molecules 1575 can inhibit or accelerate protein aggregation and modulate the LLPS potential of targeted 1576 IDPs/IDRs. Finally, IDPs can be utilized in the development of novel means for drug delivery. 1577 Concluding, although many approaches are currently used to discover small molecules affecting various disorder-based function of proteins, it is clear that innovative techniques are required to 1578

find and design drugs for successful modulation of the (multi)functions and dysfunctions of IDPs/IDRs. In fact, one should also keep in mind that most of the techniques currently used for discovering and designing drugs for IDPs/IDRs are, in one way or another, still rooted in the approaches originally elaborated for rational structure-based drug design. However, the molecular mechanisms of many disorder-based functions are unique to IDPs/IDRs and seem to be impossible from the viewpoint of order-based functions, indicating that finding novel ways to modulate such "impossible" functions requires outside the box thinking. Despite these shortcomings, it is clear that the intrinsic disorder-based functions are principally druggable and can be modulated by small molecules. Therefore, the future of this field is exciting, bright, and promising. It is expected that better understanding of the molecular mechanisms underlying multifunctionality of IDPs/IDRs, their binding promiscuity, and unusual binding modes will lead to the identification of unique targets and elaboration of novel approaches to design drugs affecting disorder-based functionalities.

Acknowledgments

Over the years, I have collaborated with more than 12,500 colleagues from more than 2,750 research organizations in 89 countries/territories. I extend my sincere gratitude to all of them, as the presented research would be impossible without them.

Funding

This work received no external funding.

1600	
1601	Conflict-of-interest statement
1602	The author has no an actual or perceived conflict of interest with the contents of this article.
1603	
1604	Data Availability Statement
1605	The author declares that all the data supporting the findings of this study are contained within the
1606	paper.
1607	
1608	Authorship Contributions
1609	Participated in research design, conducted research, performed literature analysis, wrote the
1610	manuscript: Uversky, V.N.
1611	
1612	References
1613 1614 1615 1616	Aggarwal S, Snaidero N, Pahler G, Frey S, Sanchez P, Zweckstetter M, Janshoff A, Schneider A, Weil MT, Schaap IA, Gorlich D and Simons M (2013) Myelin membrane assembly is driven by a phase transition of myelin basic proteins into a cohesive protein meshwork. <i>PLoS biology</i> 11:e1001577.
1617 1618	Ahmed NS, Harrell LM, Wieland DR, Lay MA, Thompson VF and Schwartz JC (2021) Fusion protein EWS-FLI1 is incorporated into a protein granule in cells. <i>Rna</i> 27 :920-932.
1619 1620	Alberti S and Dormann D (2019) Liquid-Liquid Phase Separation in Disease. <i>Annu Rev Genet</i> 53 :171-194.
1621 1622	Alberti S and Hyman AA (2016) Are aberrant phase transitions a driver of cellular aging? <i>Bioessays</i> 38 :959-968.
1623 1624 1625	Allison JR, Varnai P, Dobson CM and Vendruscolo M (2009) Determination of the free energy landscape of alpha-synuclein using spin label nuclear magnetic resonance measurements. <i>J Am Chem Soc</i> 131 :18314-18326.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- Ambadipudi S, Biernat J, Riedel D, Mandelkow E and Zweckstetter M (2017) Liquid–liquid phase separation of the microtubule-binding repeats of the Alzheimer-related protein Tau. *Nature Communications* 8:275.
- Ambadipudi S and Zweckstetter M (2016) Targeting intrinsically disordered proteins in rational drug discovery. *Expert Opin Drug Discov* **11**:65-77.
- Anderson CW and Appella E (2004) Signaling to the p53 tumor suppressor through pathways activated by genotoxic and nongenotoxic stress, in *Handbook of Cell Signaling* (Bradshaw RA and Dennis EA eds) pp 237-247, Academic Press, New York.
- Antifeeva IA, Fonin AV, Fefilova AS, Stepanenko OV, Povarova OI, Silonov SA, Kuznetsova IM,
 Uversky VN and Turoverov KK (2022) Liquid-liquid phase separation as an organizing principle
 of intracellular space: overview of the evolution of the cell compartmentalization concept. *Cell*Mol Life Sci 79:251.
- Antonicka H and Shoubridge EA (2015) Mitochondrial RNA Granules Are Centers for Posttranscriptional RNA Processing and Ribosome Biogenesis. *Cell Rep.*
- Arai M, Suetaka S and Ooka K (2024) Dynamics and interactions of intrinsically disordered proteins.

 *Curr Opin Struct Biol 84:102734.**
- Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y and Oda T (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Biochem Biophys Res Commun* **351**:602-611.
- Avalos JL, Celic I, Muhammad S, Cosgrove MS, Boeke JD and Wolberger C (2002) Structure of a Sir2 enzyme bound to an acetylated p53 peptide. *Mol Cell* **10**:523-535.
- Babinchak WM, Dumm BK, Venus S, Boyko S, Putnam AA, Jankowsky E and Surewicz WK (2020)

 Small molecules as potent biphasic modulators of protein liquid-liquid phase separation. *Nature Communications* 11:5574.
- Balint EE and Vousden KH (2001) Activation and activities of the p53 tumour suppressor protein. *Br J Cancer* **85**:1813-1823.
- Ban D, Iconaru LI, Ramanathan A, Zuo J and Kriwacki RW (2017) A Small Molecule Causes a Population Shift in the Conformational Landscape of an Intrinsically Disordered Protein. *J Am Chem Soc* **139**:13692-13700.
- Ban F, Leblanc E, Cavga AD, Huang CF, Flory MR, Zhang F, Chang MEK, Morin H, Lallous N, Singh
 K, Gleave ME, Mohammed H, Rennie PS, Lack NA and Cherkasov A (2021) Development of an
 Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for
 Treatment of Castration Resistant Prostate Cancer. Cancers (Basel) 13.
- Banuelos CA, Tavakoli I, Tien AH, Caley DP, Mawji NR, Li Z, Wang J, Yang YC, Imamura Y, Yan L,
 Wen JG, Andersen RJ and Sadar MD (2016) Sintokamide A Is a Novel Antagonist of Androgen
 Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain. *J Biol Chem* 291:22231-22243.
- Barbas CF, 3rd, Collet TA, Amberg W, Roben P, Binley JM, Hoekstra D, Cababa D, Jones TM, Williamson RA, Pilkington GR and et al. (1993) Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. *J Mol Biol* **230**:812-823.
- Basu S, Martinez-Cristobal P, Frigole-Vivas M, Pesarrodona M, Lewis M, Szulc E, Banuelos CA,
 Sanchez-Zarzalejo C, Bielskute S, Zhu J, Pombo-Garcia K, Garcia-Cabau C, Zodi L, Dockx H,
 Smak J, Kaur H, Batlle C, Mateos B, Biesaga M, Escobedo A, Bardia L, Verdaguer X, Ruffoni A,

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- Mawji NR, Wang J, Obst JK, Tam T, Brun-Heath I, Ventura S, Meierhofer D, Garcia J, Robustelli P, Stracker TH, Sadar MD, Riera A, Hnisz D and Salvatella X (2023) Rational optimization of a transcription factor activation domain inhibitor. *Nature structural & molecular biology* **30**:1958-1969.
- Baughman HER, Clouser AF, Klevit RE and Nath A (2018) HspB1 and Hsc70 chaperones engage distinct tau species and have different inhibitory effects on amyloid formation. *J Biol Chem* **293**:2687-2700.
- Baumann C, Beil A, Jurt S, Niederwanger M, Palacios O, Capdevila M, Atrian S, Dallinger R and Zerbe
 O (2017) Structural Adaptation of a Protein to Increased Metal Stress: NMR Structure of a
 Marine Snail Metallothionein with an Additional Domain. *Angewandte Chemie* **56**:4617-4622.
- Beadle GW and Tatum EL (1941) Genetic Control of Biochemical Reactions in Neurospora. *Proc Natl Acad Sci U S A* 27:499-506.
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN and Bourne PE (2000) The Protein Data Bank. *Nucleic Acids Res* **28**:235-242.
- Bernado P, Bertoncini CW, Griesinger C, Zweckstetter M and Blackledge M (2005) Defining long-range order and local disorder in native alpha-synuclein using residual dipolar couplings. *J Am Chem Soc* 127:17968-17969.
- Bertoncini CW, Jung YS, Fernandez CO, Hoyer W, Griesinger C, Jovin TM and Zweckstetter M (2005)
 Release of long-range tertiary interactions potentiates aggregation of natively unstructured alphasynuclein. *Proc Natl Acad Sci U S A* **102**:1430-1435.
- Beyer K, Domingo-Sabat M, Humbert J, Carrato C, Ferrer I and Ariza A (2008a) Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. *Neurogenetics* **9**:163-172.
- Beyer K, Domingo-Sabat M, Lao JI, Carrato C, Ferrer I and Ariza A (2008b) Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases.

 Neurogenetics 9:15-23.
- 1696 Biamonti G (2004) Nuclear stress bodies: a heterochromatin affair? *Nat Rev Mol Cell Biol* 5:493-498.
- 1697 Biamonti G and Vourc'h C (2010) Nuclear stress bodies. Cold Spring Harb Perspect Biol 2:a000695.
- Bidwell GL, 3rd, Davis AN and Raucher D (2009) Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. *J Control Release* **135**:2-10.
- Bidwell GL, 3rd, Fokt I, Priebe W and Raucher D (2007) Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. *Biochem Pharmacol* **73**:620-631.
- Bidwell GL, 3rd and Raucher D (2005) Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. *Mol Cancer Ther* **4**:1076-1085.
- Bidwell GL, 3rd and Raucher D (2010) Cell penetrating elastin-like polypeptides for therapeutic peptide delivery. *Adv Drug Deliv Rev* **62**:1486-1496.
- Bienkiewicz EA, Adkins JN and Lumb KJ (2002) Functional consequences of preorganized helical structure in the intrinsically disordered cell-cycle inhibitor p27(Kip1). *Biochemistry* **41**:752-759.
- Biesaga M, Frigole-Vivas M and Salvatella X (2021) Intrinsically disordered proteins and biomolecular condensates as drug targets. *Curr Opin Chem Biol* **62**:90-100.
- Bina M, Sciortino F and Mahrir AN (2022) Phase separation in polymer-based biomimetic structures containing planar membranes. *Biointerphases* 17.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- 1712 Blatt LM, Davis JM, Klein SB and Taylor MW (1996) The biologic activity and molecular 1713 characterization of a novel synthetic interferon-alpha species, consensus interferon. *Journal of* 1714 interferon & cytokine research: the official journal of the International Society for Interferon

and Cytokine Research **16**:489-499.

- Blindauer CA and Leszczyszyn OI (2010) Metallothioneins: unparalleled diversity in structures and functions for metal ion homeostasis and more. *Nat Prod Rep* **27**:720-741.
- Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR and Stark GR (2007) Interferons at age 50: past, current and future impact on biomedicine. *Nature Reviews Drug Discovery* **6**:975-990.
- Boulay G, Sandoval GJ, Riggi N, Iyer S, Buisson R, Naigles B, Awad ME, Rengarajan S, Volorio A, McBride MJ, Broye LC, Zou L, Stamenkovic I, Kadoch C and Rivera MN (2017) Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain. *Cell* **171**:163-178.e119.
- Bourhis JM, Canard B and Longhi S (2007) Predicting protein disorder and induced folding: from theoretical principles to practical applications. *Curr Protein Pept Sci* **8**:135-149.
- Brangwynne CP (2013) Phase transitions and size scaling of membrane-less organelles. *The Journal of cell biology* **203**:875-881.
- Brangwynne CP, Eckmann CR, Courson DS, Rybarska A, Hoege C, Gharakhani J, Julicher F and Hyman AA (2009) Germline P granules are liquid droplets that localize by controlled dissolution/condensation. *Science* **324**:1729-1732.
- Brangwynne CP, Mitchison TJ and Hyman AA (2011) Active liquid-like behavior of nucleoli determines their size and shape in Xenopus laevis oocytes. *Proc Natl Acad Sci U S A* **108**:4334-4339.
- Brangwynne CP, Tompa P and Pappu RV (2015) Polymer physics of intracellular phase transitions. *Nat Physics* **11**:899–904.
- Brown CJ, Takayama S, Campen AM, Vise P, Marshall TW, Oldfield CJ, Williams CJ and Dunker AK (2002) Evolutionary rate heterogeneity in proteins with long disordered regions. *J Mol Evol* **55**:104-110.
- Bruinsma IB, Bruggink KA, Kinast K, Versleijen AA, Segers-Nolten IM, Subramaniam V, Kuiperij HB,
 Boelens W, de Waal RM and Verbeek MM (2011) Inhibition of α-synuclein aggregation by small
 heat shock proteins. *Proteins* **79**:2956-2967.
- Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW and Labaudiniere R (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. *Proc Natl Acad Sci U S A* **109**:9629-9634.
- Burton DR (2002) Antibodies, viruses and vaccines. *Nat Rev Immunol* 2:706-713.
- Burton DR (2010) Scaffolding to build a rational vaccine design strategy. *Proc Natl Acad Sci U S A* **107**:17859-17860.
- 1748 Carey JL and Guo L (2022) Liquid-Liquid Phase Separation of TDP-43 and FUS in Physiology and Pathology of Neurodegenerative Diseases. *Front Mol Biosci* **9**:826719.
- 1750 Cary PD, Moss T and Bradbury EM (1978) High-resolution proton-magnetic-resonance studies of chromatin core particles. *Eur J Biochem* **89**:475-482.
- 1752 Chakraborty S, Berndsen ZT, Hengartner NW, Korber BT, Ward AB and Gnanakaran S (2020)
 1753 Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic
 1754 Detail. *iScience* 23:101836.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- 1755 Chen CY and Tou WI (2013) How to design a drug for the disordered proteins? *Drug Discov Today* 1756 18:910-915.
- 1757 Chen J, Liang H and Fernandez A (2008) Protein structure protection commits gene expression patterns.

 1758 *Genome Biol* 9:R107.
- 1759 Chene P (2004) Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. *Mol Cancer Res* **2**:20-28.
- 1761 Cheng Y, LeGall T, Oldfield CJ, Mueller JP, Van YY, Romero P, Cortese MS, Uversky VN and Dunker 1762 AK (2006) Rational drug design via intrinsically disordered protein. *Trends Biotechnol* **24**:435-1763 442.
- 1764 Cheng Y, Oldfield CJ, Meng J, Romero P, Uversky VN and Dunker AK (2007) Mining alpha-helix-1765 forming molecular recognition features with cross species sequence alignments. *Biochemistry* 1766 **46**:13468-13477.
- 1767 Chi SW, Kim DH, Lee SH, Chang I and Han KH (2007) Pre-structured motifs in the natively unstructured preS1 surface antigen of hepatitis B virus. *Protein Sci* **16**:2108-2117.
- 1769 Chilkoti A, Dreher MR and Meyer DE (2002) Design of thermally responsive, recombinant polypeptide carriers for targeted drug delivery. *Advanced Drug Delivery Reviews* **54**:1093-1111.
- 1771 Chiti F and Kelly JW (2022) Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation. *Curr Opin Struct Biol* **72**:267-278.
- 1773 Choudhary S, Lopus M and Hosur RV (2022) Targeting disorders in unstructured and structured proteins 1774 in various diseases. *Biophys Chem* **281**:106742.
- 1775 Chuma S, Hosokawa M, Tanaka T and Nakatsuji N (2009) Ultrastructural characterization of spermatogenesis and its evolutionary conservation in the germline: germinal granules in mammals. *Molecular and cellular endocrinology* **306**:17-23.
- 1778 Cortese MS, Uversky VN and Dunker AK (2008) Intrinsic disorder in scaffold proteins: getting more from less. *Prog Biophys Mol Biol* **98**:85-106.
- Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, Kiezun A, Carter SL, Shukla SA, Mehta SS, Thorner AR, de Torres C, Lavarino C, Sunol M, McKenna A, Sivachenko A, Cibulskis K, Lawrence MS, Stojanov P, Rosenberg M, Ambrogio L, Auclair D, Seepo S, Blumenstiel B, DeFelice M, Imaz-Rosshandler I, Schwarz-Cruz YCA, Rivera MN, Rodriguez-Galindo C, Fleming MD, Golub TR, Getz G, Mora J and Stegmaier K (2014) The genomic landscape of pediatric Ewing sarcoma. *Cancer Discov* 4:1326-1341.
- 1786 Csizmok V, Bokor M, Banki P, Klement É, Medzihradszky KF, Friedrich P, Tompa K and Tompa P 1787 (2005) Primary contact sites in intrinsically unstructured proteins: the case of calpastatin and 1788 microtubule-associated protein 2. *Biochemistry* 44:3955-3964.
- 1789 Csizmok V, Follis AV, Kriwacki RW and Forman-Kay JD (2016) Dynamic Protein Interaction Networks 1790 and New Structural Paradigms in Signaling. *Chem Rev*.
- Dada ST, Toprakcioglu Z, Cali MP, Rontgen A, Hardenberg MC, Morris OM, Mrugalla LK, Knowles
 TPJ and Vendruscolo M (2024) Pharmacological inhibition of alpha-synuclein aggregation within liquid condensates. *Nat Commun* 15:3835.
- Dai B, Zhong T, Chen ZX, Chen W, Zhang N, Liu XL, Wang LQ, Chen J and Liang Y (2021) Myricetin slows liquid-liquid phase separation of Tau and activates ATG5-dependent autophagy to suppress Tau toxicity. *J Biol Chem* **297**:101222.

Dai C, Dehm SM and Sharifi N (2023) Targeting the Androgen Signaling Axis in Prostate Cancer. *J Clin*

1798

Oncol 41:4267-4278.

- Dai C, Heemers H and Sharifi N (2017) Androgen Signaling in Prostate Cancer. *Cold Spring Harb*1800 *Perspect Med* 7.
- Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. *Mol Cell Biol* **19**:1-11.
- Dara S, Dhamercherla S, Jadav SS, Babu CM and Ahsan MJ (2022) Machine Learning in Drug Discovery: A Review. *Artif Intell Rev* **55**:1947-1999.
- Darling AL, Liu Y, Oldfield CJ and Uversky VN (2018) Intrinsically Disordered Proteome of Human Membrane-Less Organelles. *Proteomics* **18**:e1700193 (1700112 pages).
- Darling AL and Uversky VN (2017) Intrinsic Disorder in Proteins with Pathogenic Repeat Expansions. *Molecules* 22.
- Darling AL and Uversky VN (2018) Intrinsic Disorder and Posttranslational Modifications: The Darker Side of the Biological Dark Matter. *Front Genet* **9**:158.
- Daughdrill GW, Pielak GJ, Uversky VN, Cortese MS and Dunker AK (2005) Natively disordered proteins, in *Handbook of Protein Folding* (Buchner J and Kiefhaber T eds) pp 271-353, Wiley-VCH, Verlag GmbH & Co. KGaA, Weinheim, Germany.
- Davey RA and Grossmann M (2016) Androgen Receptor Structure, Function and Biology: From Bench to Bedside. *Clin Biochem Rev* **37**:3-15.
- Dayhoff GW, 2nd and Uversky VN (2022) Rapid prediction and analysis of protein intrinsic disorder.

 *Protein Sci 31:e4496.**
- De Andrea M, Ravera R, Gioia D, Gariglio M and Landolfo S (2002) The interferon system: an overview.

 Eur J Paediatr Neurol 6 Suppl A:A41-46; discussion A55-48.
- de Weerd NA, Samarajiwa SA and Hertzog PJ (2007) Type I interferon receptors: biochemistry and biological functions. *J Biol Chem* **282**:20053-20057.
- Decker CJ, Teixeira D and Parker R (2007) Edc3p and a glutamine/asparagine-rich domain of Lsm4p function in processing body assembly in Saccharomyces cerevisiae. *The Journal of cell biology* **179**:437-449.
- Decker M, Jaensch S, Pozniakovsky A, Zinke A, O'Connell KF, Zachariae W, Myers E and Hyman AA (2011) Limiting amounts of centrosome material set centrosome size in C. elegans embryos. *Current biology: CB* 21:1259-1267.
- Dedmon MM, Lindorff-Larsen K, Christodoulou J, Vendruscolo M and Dobson CM (2005) Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. *J Am Chem Soc* **127**:476-477.
- DeForte S and Uversky VN (2016) Order, Disorder, and Everything in Between. *Molecules* 21.
- Deininger P (1999) Genetic instability in cancer: caretaker and gatekeeper genes. *Ochsner J* 1:206-209.
- Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G and et al. (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. *Nature* **359**:162-165.
- Disfani FM, Hsu WL, Mizianty MJ, Oldfield CJ, Xue B, Dunker AK, Uversky VN and Kurgan L (2012)
 MoRFpred, a computational tool for sequence-based prediction and characterization of short disorder-to-order transitioning binding regions in proteins. *Bioinformatics* 28:i75-83.

1839 Dosztanyi Z, Chen J, Dunker AK, Simon I and Tompa P (2006) Disorder and sequence repeats in hub proteins and their implications for network evolution. J Proteome Res 5:2985-2995.

Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.

- Dosztanyi Z, Meszaros B and Simon I (2009) ANCHOR: web server for predicting protein binding 1841 1842 regions in disordered proteins. *Bioinformatics* **25**:2745-2746.
- 1843 Dosztanyi Z, Sandor M, Tompa P and Simon I (2007) Prediction of protein disorder at the domain level. 1844 Curr Protein Pept Sci 8:161-171.
- 1845 Dosztanyi Z and Tompa P (2008) Prediction of protein disorder. Methods Mol Biol 426:103-115.
- 1846 Dundr M and Misteli T (2010) Biogenesis of nuclear bodies. Cold Spring Harb Perspect Biol 2:a000711.
- 1847 Dunker AK, Babu MM, Barbar E, Blackledge M, Bondos SE, Dosztányi Z, Dyson HJ, Forman-Kay J, 1848 Fuxreiter M, Gsponer J, Han K-H, Jones DT, Longhi S, Metallo SJ, Nishikawa K, Nussinov R, 1849 Obradovic Z, Pappu R, Rost B, Selenko P, Subramaniam V, Sussman JL, Tompa P and Uversky 1850 VN (2013) What's in a name? Why these proteins are intrinsically disordered. Intrinsically
- Disordered Proteins 1:e24157. 1851

1840

- 1852 Dunker AK, Brown CJ, Lawson JD, Iakoucheva LM and Obradovic Z (2002a) Intrinsic disorder and 1853 protein function. Biochemistry 41:6573-6582.
- 1854 Dunker AK, Brown CJ and Obradovic Z (2002b) Identification and functions of usefully disordered proteins. Adv Protein Chem 62:25-49. 1855
- 1856 Dunker AK, Cortese MS, Romero P, Iakoucheva LM and Uversky VN (2005) Flexible nets. The roles of 1857 intrinsic disorder in protein interaction networks. Febs J 272:5129-5148.
- 1858 Dunker AK, Garner E, Guilliot S, Romero P, Albrecht K, Hart J, Obradovic Z, Kissinger C and 1859 Villafranca JE (1998) Protein disorder and the evolution of molecular recognition: theory, 1860 predictions and observations. Pac Symp Biocomput:473-484.
- 1861 Dunker AK, Lawson JD, Brown CJ, Williams RM, Romero P, Oh JS, Oldfield CJ, Campen AM, Ratliff 1862 CM, Hipps KW, Ausio J, Nissen MS, Reeves R, Kang C, Kissinger CR, Bailey RW, Griswold 1863 MD, Chiu W, Garner EC and Obradovic Z (2001) Intrinsically disordered protein. J Mol Graph Model 19:26-59. 1864
- Dunker AK and Obradovic Z (2001) The protein trinity--linking function and disorder. Nat Biotechnol 1865 1866 **19**:805-806.
- 1867 Dunker AK, Obradovic Z, Romero P, Garner EC and Brown CJ (2000) Intrinsic protein disorder in 1868 complete genomes. Genome Inform Ser Workshop Genome Inform 11:161-171.
- 1869 Dunker AK, Obradovic Z, Romero P, Kissinger C and Villafranca E (1997) On the importance of being disordered. PDB Newsletter 81:3-5. 1870
- 1871 Dunker AK, Oldfield CJ, Meng J, Romero P, Yang JY, Chen JW, Vacic V, Obradovic Z and Uversky VN (2008a) The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics 1872 1873 **9 Suppl 2**:S1.
- 1874 Dunker AK, Silman I, Uversky VN and Sussman JL (2008b) Function and structure of inherently disordered proteins. Curr Opin Struct Biol 18:756-764. 1875
- 1876 Dunker AK and Uversky VN (2010) Drugs for 'protein clouds': targeting intrinsically disordered 1877 transcription factors. Curr Opin Pharmacol 10:782-788.
- Duret L, Gasteiger E and Perriere G (1996) LALNVIEW: a graphical viewer for pairwise sequence 1878 1879 alignments. Comput Appl Biosci 12:507-510.

Dyson HJ and Wright PE (2002a) Coupling of folding and binding for unstructured proteins. *Curr Opin* Struct Biol 12:54-60.

- Dyson HJ and Wright PE (2002b) Coupling of folding and binding for unstructured proteins. *Curr Opin Struct Biol* **12**:54-60.
- Dyson HJ and Wright PE (2005) Intrinsically unstructured proteins and their functions. *Nat Rev Mol Cell Biol* **6**:197-208.
- Edmundson AB, Ely KR, Herron JN and Cheson BD (1987) The binding of opioid peptides to the Mcg light chain dimer: flexible keys and adjustable locks. *Mol Immunol* **24**:915-935.
- Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A and Wanker EE (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. *Nature structural & molecular biology* **15**:558-566.
- Ekman D, Light S, Bjorklund AK and Elofsson A (2006) What properties characterize the hub proteins of the protein-protein interaction network of Saccharomyces cerevisiae? *Genome Biol* 7:R45.
- 1893 El-Baky NA, Linjawi MH and Redwan EM (2015a) Auto-induction expression of human consensus interferon-alpha in Escherichia coli. *BMC biotechnology* **15**:14.
- El-Baky NA and Redwan EM (2015) Therapeutic alpha-interferons protein: structure, production, and biosimilar. *Prep Biochem Biotechnol* **45**:109-127.
- El-Baky NA, Uversky VN and Redwan EM (2015b) Human consensus interferons: Bridging the natural and artificial cytokines with intrinsic disorder. *Cytokine Growth Factor Rev* **26**:637-645.
- El-Naggar AM and Sorensen PH (2018) Translational control of aberrant stress responses as a hallmark of cancer. *J Pathol* **244**:650-666.
- 1901 Elbaum-Garfinkle S, Kim Y, Szczepaniak K, Chen CC, Eckmann CR, Myong S and Brangwynne CP 1902 (2015) The disordered P granule protein LAF-1 drives phase separation into droplets with tunable 1903 viscosity and dynamics. *Proc Natl Acad Sci U S A* **112**:7189-7194.
- Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH,
 Dakshanamurthy S, Brown ML, Uren A and Toretsky JA (2009) A small molecule blocking
 oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's
 sarcoma. *Nat Med* **15**:750-756.
- Erkizan HV, Uversky VN and Toretsky JA (2010) Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. *Clin Cancer Res* **16**:4077-4083.
- Esnouf RM, Hamer R, Sussman JL, Silman I, Trudgian D, Yang ZR and Prilusky J (2006) Honing the in silico toolkit for detecting protein disorder. *Acta Crystallogr D Biol Crystallogr* **62**:1260-1266.
- Fan X and Kurgan L (2014) Accurate prediction of disorder in protein chains with a comprehensive and empirically designed consensus. *J Biomol Struct Dyn* **32**:448-464.
- Fang MY, Markmiller S, Vu AQ, Javaherian A, Dowdle WE, Jolivet P, Bushway PJ, Castello NA, Baral A, Chan MY, Linsley JW, Linsley D, Mercola M, Finkbeiner S, Lecuyer E, Lewcock JW and Yeo GW (2019) Small-Molecule Modulation of TDP-43 Recruitment to Stress Granules Prevents Persistent TDP-43 Accumulation in ALS/FTD. *Neuron* 103:802-819.e811.
- Farrah T, Deutsch EW, Hoopmann MR, Hallows JL, Sun Z, Huang CY and Moritz RL (2013) The State of the Human Proteome in 2012 as Viewed through PeptideAtlas. *Journal of Proteome Research* 1920 12:162-171.
- Farrah T, Deutsch EW, Omenn GS, Sun Z, Watts JD, Yamamoto T, Shteynberg D, Harris MM and Moritz RL (2014) State of the Human Proteome in 2013 as Viewed through PeptideAtlas:

1923 Comparing the Kidney, Urine, and Plasma Proteomes for the Biology- and Disease-Driven Human Proteome Project. *Journal of Proteome Research* 13:60-75.

- Federman N, Meyers PA, Daw NC, Toretsky J, Breitmeyer JB, Singh AS, Miller LL, Oltersdorf T, Jezior
 D and Jessen KA (2017) A phase I, first-in-human, dose escalation study of intravenous TK216
 in patients with relapsed or refractory Ewing sarcoma, American Society of Clinical Oncology.
- Feric M and Brangwynne CP (2013) A nuclear F-actin scaffold stabilizes ribonucleoprotein droplets against gravity in large cells. *Nature cell biology* **15**:1253-1259.
- Feric M, Vaidya N, Harmon TS, Mitrea DM, Zhu L, Richardson TM, Kriwacki RW, Pappu RV and Brangwynne CP (2016) Coexisting Liquid Phases Underlie Nucleolar Subcompartments. *Cell* **165**:1686-1697.
- Ferron F, Longhi S, Canard B and Karlin D (2006) A practical overview of protein disorder prediction methods. *Proteins* **65**:1-14.
- 1935 Fink AL (2005) Natively unfolded proteins. Curr Opin Struct Biol 15:35-41.
- Fischer E (1894) Einfluss der configuration auf die wirkung der enzyme. *Ber Dt Chem Ges* **27**:2985-1937 2993.
- Fish EN, Harrison SA and Hassanein T (2008) The role of consensus interferon in the current treatment of chronic hepatitis C viral infection. *Gastroenterol Hepatol (N Y)* **4**:1-12.
- Fokkens M, Schrader T and Klarner FG (2005) A molecular tweezer for lysine and arginine. *J Am Chem* Soc 127:14415-14421.
- Follis AV, Hammoudeh DI, Wang H, Prochownik EV and Metallo SJ (2008) Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. *Chem Biol* **15**:1149-1155.
- Fonin AV, Antifeeva IA, Kuznetsova IM, Turoverov KK, Zaslavsky BY, Kulkarni P and Uversky VN (2022) Biological soft matter: intrinsically disordered proteins in liquid-liquid phase separation and biomolecular condensates. *Essays Biochem* **66**:831-847.
- Fonteneau G, Redding A, Hoag-Lee H, Sim ES, Heinrich S, Gaida MM and Grabocka E (2022) Stress
 Granules Determine the Development of Obesity-Associated Pancreatic Cancer. *Cancer Discov*1950
 12:1984-2005.
- Fox AH, Lam YW, Leung AK, Lyon CE, Andersen J, Mann M and Lamond AI (2002) Paraspeckles: a novel nuclear domain. *Current biology: CB* 12:13-25.
- Fuxreiter M, Simon I, Friedrich P and Tompa P (2004) Preformed structural elements feature in partner recognition by intrinsically unstructured proteins. *J Mol Biol* **338**:1015-1026.
- Fuxreiter M and Tompa P (2012) Fuzzy complexes: a more stochastic view of protein function. *Adv Exp Med Biol* **725**:1-14.
- Fuxreiter M, Tompa P and Simon I (2007a) Local structural disorder imparts plasticity on linear motifs. *Bioinformatics* 23:950-956.
- Fuxreiter M, Tompa P and Simon I (2007b) Structural disorder imparts plasticity on linear motifs. *Bioinformatics* 23:950-956.
- Fuxreiter M, Tompa P, Simon I, Uversky VN, Hansen JC and Asturias FJ (2008) Malleable machines take shape in eukaryotic transcriptional regulation. *Nat Chem Biol* **4**:728-737.
- Fuxreiter M, Toth-Petroczy A, Kraut DA, Matouschek A, Lim RY, Xue B, Kurgan L and Uversky VN (2014) Disordered proteinaceous machines. *Chem Rev* **114**:6806-6843.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- 1965 Gadhave K, Gehi BR, Kumar P, Xue B, Uversky VN and Giri R (2020) The dark side of Alzheimer's disease: unstructured biology of proteins from the amyloid cascade signaling pathway. *Cell Mol Life Sci* **77**:4163-4208.
- Gao XK, Rao XS, Cong XX, Sheng ZK, Sun YT, Xu SB, Wang JF, Liang YH, Lu LR, Ouyang H, Ge H,
 Guo J-s, Wu H-j, Sun QM, Wu H-b, Bao Z, Zheng LL and Zhou YT (2022) Phase separation of
 insulin receptor substrate 1 drives the formation of insulin/IGF-1 signalosomes. *Cell Discovery* 8:60.
- 1972 Garner E, Romero P, Dunker AK, Brown C and Obradovic Z (1999) Predicting binding regions within disordered proteins. *Genome Informatics* **10**:41-50.
- 1974 Geng DY, Chen QS, Chen WX, Zhou LS, Han XS, Xie QH, Guo GH, Chen XF, Chen JS and Zhong XP
 1975 (2024) Molecular targets and mechanisms of different aberrant alternative splicing in metastatic
 1976 liver cancer. *World J Clin Oncol* **15**:531-539.
- 1977 Genin P, Vaccaro A and Civas A (2009) The role of differential expression of human interferon--a genes 1978 in antiviral immunity. *Cytokine Growth Factor Rev* **20**:283-295.
- 1979 Girdhar A, Bharathi V, Tiwari VR, Abhishek S, Deeksha W, Mahawar US, Raju G, Singh SK,
 1980 Prabusankar G, Rajakumara E and Patel BK (2020) Computational insights into mechanism of
 1981 AIM4-mediated inhibition of aggregation of TDP-43 protein implicated in ALS and evidence for
 1982 in vitro inhibition of liquid-liquid phase separation (LLPS) of TDP-432C-A315T by AIM4.
 1983 International Journal of Biological Macromolecules 147:117-130.
- 1984 Goh GK (2017a) *Viral Shapeshifters: Strange Behaviors of HIV and Other Viruses*, Simplicity Research 1985 Institute.
- 1986 Goh GK, Dunker AK, Foster JA and Uversky VN (2019) HIV Vaccine Mystery and Viral Shell Disorder.
 1987 *Biomolecules* **9**:178.
- 1988 Goh GKM (2017b) *Viral Shapeshifters: Strange Behavoirs of HIV and Other Viruses*, Simplicity 1989 Research Institute, Singapore.
- Goldsby R, Kindt TJ, Osborne BA and Kuby J (2003) Antigens in *Immunology* (Goldsby R, Osborne BA, Kuby J, Kindt TJ, Marcus DA and Punt J eds) pp 57-75, W. H. Freeman and Company, New York.
- Gollavilli PN, Pawar A, Wilder-Romans K, Natesan R, Engelke CG, Dommeti VL, Krishnamurthy PM, Nallasivam A, Apel IJ, Xu T, Qin ZS, Feng FY and Asangani IA (2018) EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins. *Cancer research* **78**:4760-4773.
- 1996 Grabocka E and Bar-Sagi D (2016) Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress 1997 Granules. *Cell* **167**:1803-1813.e1812.
- Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR, Maguire D, Lattanze J, Franks CF, Zhao S, Ramachandren K, Bylebyl GR, Zhang M, Manthey CL, Petrella EC, Pantoliano MW, Deckman IC, Spurlino JC, Maroney AC, Tomczuk BE, Molloy CJ and Bone RF (2005) Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. *J Med Chem* 48:909-912.
- Gronemeyer H, Gustafsson JA and Laudet V (2004) Principles for modulation of the nuclear receptor superfamily. *Nat Rev Drug Discov* **3**:950-964.
- Grossman E, Medalia O and Zwerger M (2012) Functional architecture of the nuclear pore complex.
 Annu Rev Biophys 41:557-584.
- 2007 Gubitz AK, Feng W and Dreyfuss G (2004) The SMN complex. Exp Cell Res 296:51-56.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- Gupta N, Badeaux M, Liu Y, Naxerova K, Sgroi D, Munn LL, Jain RK and Garkavtsev I (2017) Stress granule-associated protein G3BP2 regulates breast tumor initiation. *Proceedings of the National Academy of Sciences* **114**:1033-1038.
- 2011 Gutterman JU (1994) Cytokine Therapeutics Lessons from Interferon-Alpha. *Proceedings of the National Academy of Sciences of the United States of America* **91**:1198-1205.
- Hammoudeh DI, Follis AV, Prochownik EV and Metallo SJ (2009) Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. *J Am Chem Soc* **131**:7390-7401.
- Han H, Jain AD, Truica MI, Izquierdo-Ferrer J, Anker JF, Lysy B, Sagar V, Luan Y, Chalmers ZR, Unno
 K, Mok H, Vatapalli R, Yoo YA, Rodriguez Y, Kandela I, Parker JB, Chakravarti D, Mishra RK,
 Schiltz GE and Abdulkadir SA (2019) Small-Molecule MYC Inhibitors Suppress Tumor Growth
 and Enhance Immunotherapy. *Cancer Cell* 36:483-497 e415.
- Handwerger KE, Cordero JA and Gall JG (2005) Cajal bodies, nucleoli, and speckles in the Xenopus oocyte nucleus have a low-density, sponge-like structure. *Mol Biol Cell* **16**:202-211.
- Harrigan JA, Belotserkovskaya R, Coates J, Dimitrova DS, Polo SE, Bradshaw CR, Fraser P and Jackson SP (2011) Replication stress induces 53BP1-containing OPT domains in G1 cells. *The Journal of cell biology* **193**:97-108.
- Hassouneh W, MacEwan SR and Chilkoti A (2012) Fusions of elastin-like polypeptides to pharmaceutical proteins. *Methods in enzymology* **502**:215-237.
- Haynes C, Oldfield CJ, Ji F, Klitgord N, Cusick ME, Radivojac P, Uversky VN, Vidal M and Iakoucheva LM (2006) Intrinsic disorder is a common feature of hub proteins from four eukaryotic interactomes. *PLoS Comput Biol* 2:e100.
- He B, Wang K, Liu Y, Xue B, Uversky VN and Dunker AK (2009) Predicting intrinsic disorder in proteins: an overview. *Cell Res* **19**:929-949.
- Heemers HV and Tindall DJ (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. *Endocr Rev* **28**:778-808.
- Heller GT, Aprile FA, Michaels TC, Limbocker R, Perni M, Ruggeri FS, Mannini B, Löhr T, Bonomi M and Camilloni C (2020) Small-molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer's disease. *Science advances* **6**:eabb5924.
- Heller GT, Bonomi M and Vendruscolo M (2018) Structural Ensemble Modulation upon Small-Molecule Binding to Disordered Proteins. *J Mol Biol* **430**:2288-2292.
- Heller GT, Sormanni P and Vendruscolo M (2015) Targeting disordered proteins with small molecules using entropy. *Trends Biochem Sci* **40**:491-496.
- Henkel G and Krebs B (2004) Metallothioneins: zinc, cadmium, mercury, and copper thiolates and selenolates mimicking protein active site features--structural aspects and biological implications.

 Chem Rev 104:801-824.
- Hirose T, Ninomiya K, Nakagawa S and Yamazaki T (2023) A guide to membraneless organelles and their various roles in gene regulation. *Nat Rev Mol Cell Biol* **24**:288-304.
- Hivare P, Mujmer K, Swarup G, Gupta S and Bhatia D (2023) Endocytic pathways of pathogenic protein aggregates in neurodegenerative diseases. *Traffic* **24**:434-452.
- Hofstetter G, Berger A, Fiegl H, Slade N, Zoric A, Holzer B, Schuster E, Mobus VJ, Reimer D, Daxenbichler G, Marth C, Zeimet AG, Concin N and Zeillinger R (2010) Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. *Oncogene* 29:1997-2004.

2051 Holt C and Sawyer L (1993) Caseins as rheomorphic proteins: interpretation of primary and secondary

structures of the as1-, b-, and k-caseins. J Chem Soc Faraday Trans 89:2683-2692.

Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.

- Hsu WL, Oldfield C, Meng J, Huang F, Xue B, Uversky VN, Romero P and Dunker AK (2012) Intrinsic protein disorder and protein-protein interactions. *Pac Symp Biocomput*:116-127.
- Hsu WL, Oldfield CJ, Xue B, Meng J, Huang F, Romero P, Uversky VN and Dunker AK (2013) Exploring the binding diversity of intrinsically disordered proteins involved in one-to-many binding. *Protein Sci* **22**:258-273.
- Hu G, Wu Z, Wang K, Uversky VN and Kurgan L (2016) Untapped Potential of Disordered Proteins in Current Druggable Human Proteome. *Curr Drug Targets* **17**:1198-1205.
- Huang F, Oldfield C, Meng J, Hsu WL, Xue B, Uversky VN, Romero P and Dunker AK (2012) Subclassifying disordered proteins by the ch-cdf plot method. *Pac Symp Biocomput*:128-139.
- Huang S (2000) Review: perinucleolar structures. *Journal of structural biology* **129**:233-240.

2052

- Huang X and Miller W (1991) A time-efficient, linear-space local similarity algorithm. *Advances in applied mathematics* **12**:337-357.
- Iakoucheva LM, Brown CJ, Lawson JD, Obradovic Z and Dunker AK (2002) Intrinsic disorder in cell-signaling and cancer-associated proteins. *J Mol Biol* **323**:573-584.
- Iakoucheva LM, Radivojac P, Brown CJ, O'Connor TR, Sikes JG, Obradovic Z and Dunker AK (2004)
 The importance of intrinsic disorder for protein phosphorylation. *Nucleic Acids Research*32:1037-1049.
- Isaacs A and Lindenmann J (1957) Virus interference. I. The interferon. *Proc R Soc Lond B Biol Sci* **147**:258-267.
- Janib SM, Liu S, Park R, Pastuszka MK, Shi P, Moses AS, Orosco MM, Lin YA, Cui H, Conti PS, Li Z and MacKay JA (2013) Kinetic quantification of protein polymer nanoparticles using noninvasive imaging. *Integr Biol (Camb)* **5**:183-194.
- Janin J and Sternberg MJE (2013) Protein flexibility, not disorder, is intrinsic to molecular recognition. *F1000 Biol Rep* **5**:2.
- Jensen MR, Markwick PR, Meier S, Griesinger C, Zweckstetter M, Grzesiek S, Bernado P and Blackledge M (2009) Quantitative determination of the conformational properties of partially folded and intrinsically disordered proteins using NMR dipolar couplings. *Structure* 17:1169-1185.
- Jin F, Yu C, Lai L and Liu Z (2013) Ligand clouds around protein clouds: a scenario of ligand binding with intrinsically disordered proteins. *PLoS Comput Biol* **9**:e1003249.
- Jobdeedamrong A, Cao S, Harley I, Crespy D, Landfester K and Caire da Silva L (2023) Assembly of biomimetic microreactors using caged-coacervate droplets. *Nanoscale* **15**:2561-2566.
- Joce C, Stahl JA, Shridhar M, Hutchinson MR, Watkins LR, Fedichev PO and Yin H (2010) Application of a novel in silico high-throughput screen to identify selective inhibitors for protein-protein interactions. *Bioorg Med Chem Lett* **20**:5411-5413.
- Joshi P, Chia S, Habchi J, Knowles TP, Dobson CM and Vendruscolo M (2016) A Fragment-Based Method of Creating Small-Molecule Libraries to Target the Aggregation of Intrinsically Disordered Proteins. *ACS Comb Sci* **18**:144-153.
- Joshi P and Vendruscolo M (2015) Druggability of Intrinsically Disordered Proteins. *Adv Exp Med Biol* **870**:383-400.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Zidek
 A, Potapenko A, Bridgland A, Meyer C, Kohl SAA, Ballard AJ, Cowie A, Romera-Paredes B,
 Nikolov S, Jain R, Adler J, Back T, Petersen S, Reiman D, Clancy E, Zielinski M, Steinegger M,
 Pacholska M, Berghammer T, Bodenstein S, Silver D, Vinyals O, Senior AW, Kavukcuoglu K,
 Kohli P and Hassabis D (2021) Highly accurate protein structure prediction with AlphaFold.
 Nature 596:583-589.
- 2099 Kagi JH and Schaffer A (1988) Biochemistry of metallothionein. *Biochemistry* 27:8509-8515.
- Kalliolias GD and Ivashkiv LB (2010) Overview of the biology of type I interferons. *Arthritis Res Ther* 12 Suppl 1:S1.
- Kamagata K, Kanbayashi S, Honda M, Itoh Y, Takahashi H, Kameda T, Nagatsugi F and Takahashi S (2020) Liquid-like droplet formation by tumor suppressor p53 induced by multivalent electrostatic interactions between two disordered domains. *Sci Rep* **10**:580.
- Karush F (1950) Heterogeneity of the binding sites of bovine serum albumin. *J Am Chem Soc* **72**:2705-2106 2713.
- Keeffe EB, Hollinger FB, Bailey R, Bain VG, Bala K, Balart L, Black M, Bonkovsky H, Cassidy W,
 Craig JR, Donovan J, Dusheiko GM, Ehrinpreis M, Everson G, Feinman S, Foust RT, Fromm H,
 Hauser S, Heathcote EJ, Hoefs JC, Hunter E, James S, Jensen DM, Killenberg P, Krawitt EL, Lee
 S, Lee WM, vanLeeuwen DJ, Lesesne H, Lieberman H, Lissoos T, Lumeng L, Lyche K,
 McHutchison JG, Minuk G, Mullen K, Payne KM, Pimstone N, Pockros PJ, Poterucha J, Reddy
 KR, Rosenblate H, Shafritz D, Smith C, Tong MJ, White H and Willems B (1997) Therapy of
 hepatitis C: Consensus interferon trials. Hepatology 26:S101-S107.
- 2114 Khattar SK, Samal S, LaBranche CC, Montefiori DC, Collins PL and Samal SK (2013) Comparative 2115 immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle 2116 disease virus vector. *PLoS One* **8**:e78521.
- 2117 Kiebler MA and Bassell GJ (2006) Neuronal RNA granules: movers and makers. Neuron 51:685-690.
- 2118 Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, Madugundu AK, Kelkar DS, 2119 Isserlin R, Jain S, Thomas JK, Muthusamy B, Leal-Rojas P, Kumar P, Sahasrabuddhe NA, 2120 Balakrishnan L, Advani J, George B, Renuse S, Selvan LDN, Patil AH, Nanjappa V, Radhakrishnan A, Prasad S, Subbannayya T, Raju R, Kumar M, Sreenivasamurthy SK, 2121 Marimuthu A, Sathe GJ, Chavan S, Datta KK, Subbannayya Y, Sahu A, Yelamanchi SD, 2122 Jayaram S, Rajagopalan P, Sharma J, Murthy KR, Syed N, Goel R, Khan AA, Ahmad S, Dey G, 2123 Mudgal K, Chatterjee A, Huang TC, Zhong J, Wu XY, Shaw PG, Freed D, Zahari MS, 2124 Mukherjee KK, Shankar S, Mahadevan A, Lam H, Mitchell CJ, Shankar SK, Satishchandra P, 2125 2126 Schroeder JT, Sirdeshmukh R, Maitra A, Leach SD, Drake CG, Halushka MK, Prasad TSK, Hruban RH, Kerr CL, Bader GD, Iacobuzio-Donahue CA, Gowda H and Pandey A (2014) A 2127 draft map of the human proteome. Nature 509:575-581. 2128
- 2129 Kim MY, Na I, Kim JS, Son SH, Choi S, Lee SE, Kim JH, Jang K, Alterovitz G, Chen Y, van der Vaart
 2130 A, Won HS, Uversky VN and Kim CG (2019) Rational discovery of antimetastatic agents
 2131 targeting the intrinsically disordered region of MBD2. *Sci Adv* 5:eaav9810.
- Kim TD, Ryu HJ, Cho HI, Yang CH and Kim J (2000) Thermal behavior of proteins: heat-resistant proteins and their heat-induced secondary structural changes. *Biochemistry* **39**:14839--14846.
- Klein C and Vassilev LT (2004) Targeting the p53-MDM2 interaction to treat cancer. *Br J Cancer* **91**:1415-1419.
- Klein ML, Bartley TD, Lai PH and Lu HS (1988) Structural Characterization of Recombinant Consensus
 Interferon-Alpha. *Journal of Chromatography* 454:205-215.

2138 Koehler AN (2010) A complex task? Direct modulation of transcription factors with small molecules.

Curr Opin Chem Biol 14:331-340.

2139

- Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB and Wilson IA (2013) Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. *Nature structural & molecular biology* **20**:796-803.
- Kortvelyesi T, Dennis S, Silberstein M, Brown L, 3rd and Vajda S (2003) Algorithms for computational solvent mapping of proteins. *Proteins* **51**:340-351.
- Kosik KS, Joachim CL and Selkoe DJ (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. *Proc Natl Acad Sci U S A* 83:4044-4048.
- Kovar H, Aryee DN, Jug G, Henockl C, Schemper M, Delattre O, Thomas G and Gadner H (1996)
 EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. *Cell Growth Differ* 7:429-437.
- 2153 Kriwacki RW, Hengst L, Tennant L, Reed SI and Wright PE (1996) Structural studies of p21^{Waf1/Cip1/Sdi1} in the free and Cdk2-bound state: conformational disorder mediates binding diversity. *Proc Natl Acad Sci U S A* **93**:11504-11509.
- Kunert R, Ruker F and Katinger H (1998) Molecular characterization of five neutralizing anti-HIV type 1
 antibodies: identification of nonconventional D segments in the human monoclonal antibodies
 2G12 and 2F5. AIDS Res Hum Retroviruses 14:1115-1128.
- 2159 Kyte J and Doolittle RF (1982) A simple method for displaying the hydropathic character of a protein. *J* 2160 *Mol Biol* **157**:105-132.
- Lamond AI and Spector DL (2003) Nuclear speckles: a model for nuclear organelles. *Nat Rev Mol Cell* Biol **4**:605-612.
- 2163 Latchman DS (1997) Transcription factors: an overview. *Int J Biochem Cell Biol* 29:1305-1312.
- Latchman DS (2000) Transcription factors as potential targets for therapeutic drugs. *Curr Pharm Biotechnol* 1:57-61.
- Lavecchia A and Di Giovanni C (2013) Virtual screening strategies in drug discovery: a critical review.
 Curr Med Chem 20:2839-2860.
- Lavery DN and McEwan IJ (2005) Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations. *Biochem J* **391**:449-464.
- Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES and Getz G (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature* **505**:495-501.
- Lee H, Mok KH, Muhandiram R, Park KH, Suk JE, Kim DH, Chang J, Sung YC, Choi KY and Han KH (2000) Local structural elements in the mostly unstructured transcriptional activation domain of human p53. *J Biol Chem* **275**:29426-29432.
- Lee SH, Kim DH, Han JJ, Cha EJ, Lim JE, Cho YJ, Lee C and Han KH (2012) Understanding prestructured motifs (PreSMos) in intrinsically unfolded proteins. *Curr Protein Pept Sci* **13**:34-54.
- Lemieux UR and Spohr U (1994) How Emil Fischer was led to the lock and key concept for enzyme specificity. *Adv Carbohydrate Chem Biochem* **50**:1-20.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN and Gregory TJ (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. *J Biol Chem* **265**:10373-10382.
- Li B, Carey M and Workman JL (2007) The role of chromatin during transcription. *Cell* **128**:707-719.
- Li H, Lin PH, Gupta P, Li X, Zhao SL, Zhou X, Li Z, Wei S, Xu L, Han R, Lu J, Tan T, Yang DH, Chen ZS, Pawlik TM, Merritt RE and Ma J (2021) MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer. *Mol Cancer* 20:118.
- Li L, Roy K, Katyal S, Sun X, Bleoo S and Godbout R (2006) Dynamic nature of cleavage bodies and their spatial relationship to DDX1 bodies, Cajal bodies, and gems. *Mol Biol Cell* **17**:1126-1140.
- Li P, Banjade S, Cheng HC, Kim S, Chen B, Guo L, Llaguno M, Hollingsworth JV, King DS, Banani SF, Russo PS, Jiang QX, Nixon BT and Rosen MK (2012) Phase transitions in the assembly of multivalent signalling proteins. *Nature* **483**:336-340.
- Liang J, Edelsbrunner H and Woodward C (1998) Anatomy of protein pockets and cavities: measurement of binding site geometry and implications for ligand design. *Protein Sci* **7**:1884-1897.
- Lin Y, Protter DS, Rosen MK and Parker R (2015) Formation and Maturation of Phase-Separated Liquid
 Droplets by RNA-Binding Proteins. *Mol Cell* 60:208-219.
- Linderstrom-Lang K and Schellman JA (1959) Protein structure and enzyme activity, in *The Enzymes* (Boyer PD, Lardy H and Myrback K eds) pp 443-510, Academic Press, New York.
- Linding R, Russell RB, Neduva V and Gibson TJ (2003) GlobPlot: Exploring protein sequences for globularity and disorder. *Nucleic Acids Res* **31**:3701-3708.
- Liu J, Perumal NB, Oldfield CJ, Su EW, Uversky VN and Dunker AK (2006a) Intrinsic disorder in transcription factors. *Biochemistry* **45**:6873-6888.
- Liu M, Wu C, Wang R, Qiu J, She Z, Qu J and Xia J (2023) Modulating Liquid–Liquid Phase Separation
 of Nck Adaptor Protein against Enteropathogenic Escherichia coli Infection. ACS Central Science
 9:2358-2368.
- Liu T and Bitan G (2012) Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms. *ChemMedChem* **7**:359-374.
- Liu W, Dreher MR, Furgeson DY, Peixoto KV, Yuan H, Zalutsky MR and Chilkoti A (2006b) Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. *J Control Release* **116**:170-178.
- Liu YJ (2005) IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. *Annu Rev Immunol* **23**:275-306.
- Livesay DR (2010) Protein dynamics: dancing on an ever-changing free energy stage. *Curr Opin Pharmacol* **10**:706-708.
- Lohr T, Kohlhoff K, Heller GT, Camilloni C and Vendruscolo M (2022) A Small Molecule Stabilizes the Disordered Native State of the Alzheimer's Abeta Peptide. *ACS Chem Neurosci* **13**:1738-1745.
- Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, Hanger D, Mulot S, Marquardt B, Stabel S and et al. (1994) Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. *Current biology: CB* 4:1077-1086.

Ma B, Kumar S, Tsai CJ and Nussinov R (1999) Folding funnels and binding mechanisms. *Protein Eng*

2223

12:713-720.

- Ma K, Inglis JD, Sharkey A, Bickmore WA, Hill RE, Prosser EJ, Speed RM, Thomson EJ, Jobling M, Taylor K and et al. (1993) A Y chromosome gene family with RNA-binding protein homology:
- candidates for the azoospermia factor AZF controlling human spermatogenesis. *Cell* **75**:1287-1295.
- Ma X, Lu C, Chen Y, Li S, Ma N, Tao X, Li Y, Wang J, Zhou M, Yan Y-B, Li P, Heydari K, Deng H, Zhang M, Yi C and Ge L (2022) CCT2 is an aggrephagy receptor for clearance of solid protein aggregates. *Cell* 185:1325-1345.e1322.
- MacKay JA, Chen M, McDaniel JR, Liu W, Simnick AJ and Chilkoti A (2009) Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection.

 Nature materials 8:993-999.
- Masignani V, Rappuoli R and Pizza M (2002) Reverse vaccinology: a genome-based approach for vaccine development. *Expert Opin Biol Ther* **2**:895-905.
- Massodi I, Bidwell GL, 3rd and Raucher D (2005) Evaluation of cell penetrating peptides fused to elastinlike polypeptide for drug delivery. *J Control Release* **108**:396-408.
- Massodi I, Moktan S, Rawat A, Bidwell GL, 3rd and Raucher D (2010) Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier. *Int J Cancer* **126**:533-544.
- Massodi I and Raucher D (2007) A thermally responsive Tat-elastin-like polypeptide fusion protein induces membrane leakage, apoptosis, and cell death in human breast cancer cells. *J Drug Target* 15:611-622.
- Massodi I, Thomas E and Raucher D (2009) Application of thermally responsive elastin-like polypeptide fused to a lactoferrin-derived peptide for treatment of pancreatic cancer. *Molecules* **14**:1999-2246 2015.
- Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL and Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci U S A* 82:4245-4249.
- Masuda M, Suzuki N, Taniguchi S, Oikawa T, Nonaka T, Iwatsubo T, Hisanaga S, Goedert M and Hasegawa M (2006) Small molecule inhibitors of alpha-synuclein filament assembly. *Biochemistry* 45:6085-6094.
- Matera AG and Frey MR (1998) Coiled bodies and gems: Janus or gemini? *Am J Hum Genet* **63**:317-321.
- Maul GG, Negorev D, Bell P and Ishov AM (2000) Review: properties and assembly mechanisms of ND10, PML bodies, or PODs. *Journal of structural biology* **129**:278-287.
- McDaniel JR, Bhattacharyya J, Vargo KB, Hassouneh W, Hammer DA and Chilkoti A (2013a) Selfassembly of thermally responsive nanoparticles of a genetically encoded peptide polymer by drug conjugation. *Angewandte Chemie* **52**:1683-1687.
- McDaniel JR, MacEwan SR, Li X, Radford DC, Landon CD, Dewhirst M and Chilkoti A (2014) Rational design of "heat seeking" drug loaded polypeptide nanoparticles that thermally target solid tumors.

 Nano Lett 14:2890-2895.
- McDaniel JR, Radford DC and Chilkoti A (2013b) A unified model for de novo design of elastin-like polypeptides with tunable inverse transition temperatures. *Biomacromolecules* **14**:2866-2872.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- McEwan IJ, Lavery D, Fischer K and Watt K (2007) Natural disordered sequences in the amino terminal domain of nuclear receptors: lessons from the androgen and glucocorticoid receptors. *Nucl Recept Signal* **5**:e001.
- McInnes C (2007) Virtual screening strategies in drug discovery. Curr Opin Chem Biol 11:494-502.
- McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA and Kwong PD (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. *Nature* 480:336-343.
- Mehta S and Zhang J (2022) Liquid–liquid phase separation drives cellular function and dysfunction in cancer. *Nature Reviews Cancer* **22**:239-252.
- Meng F, Na I, Kurgan L and Uversky VN (2015) Compartmentalization and Functionality of Nuclear Disorder: Intrinsic Disorder and Protein-Protein Interactions in Intra-Nuclear Compartments. *Int J Mol Sci* 17.
- Meszaros B, Simon I and Dosztanyi Z (2009) Prediction of protein binding regions in disordered proteins.
 PLoS Comput Biol 5:e1000376.
- Metallo SJ (2010) Intrinsically disordered proteins are potential drug targets. *Curr Opin Chem Biol* **14**:481-488.
- Meyer DE and Chilkoti A (1999) Purification of recombinant proteins by fusion with thermallyresponsive polypeptides. *Nature Biotechnology* **17**:1112-1115.
- Meyer DE and Chilkoti A (2004) Quantification of the effects of chain length and concentration on the thermal behavior of elastin-like polypeptides. *Biomacromolecules* **5**:846-851.
- Meyerhans A, Cheynier R, Albert J, Seth M, Kwok S, Sninsky J, Morfeldt-Manson L, Asjo B and Wain-Hobson S (1989) Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. *Cell* **58**:901-910.
- Midic U, Oldfield CJ, Dunker AK, Obradovic Z and Uversky VN (2009) Unfoldomics of human genetic diseases: illustrative examples of ordered and intrinsically disordered members of the human diseasome. *Protein Pept Lett* **16**:1533-1547.
- Mikecin AM, Walker LR, Kuna M and Raucher D (2014) Thermally targeted p21 peptide enhances bortezomib cytotoxicity in androgen-independent prostate cancer cell lines. *Anticancer Drugs* **25**:189-199.
- Minezaki Y, Homma K, Kinjo AR and Nishikawa K (2006) Human transcription factors contain a high fraction of intrinsically disordered regions essential for transcriptional regulation. *J Mol Biol* **359**:1137-1149.
- Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C and Kelly JW (1996) Inhibiting transthyretin amyloid fibril formation via protein stabilization. *Proc Natl Acad Sci U S A* **93**:15051-15056.
- Mitrea DM, Cika JA, Guy CS, Ban D, Banerjee PR, Stanley CB, Nourse A, Deniz AA and Kriwacki RW (2016) Nucleophosmin integrates within the nucleolus via multi-modal interactions with proteins displaying R-rich linear motifs and rRNA. *Elife* 5.
- Mitrea DM and Kriwacki RW (2016) Phase separation in biology; functional organization of a higher order. *Cell Commun Signal* **14**:1.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- Mitrea DM, Mittasch M, Gomes BF, Klein IA and Murcko MA (2022) Modulating biomolecular condensates: a novel approach to drug discovery. *Nature Reviews Drug Discovery* **21**:841-862.
- 2309 Miyazaki T (2023) Calpain and Cardiometabolic Diseases. Int J Mol Sci 24.
- Mohammed AS and Uversky VN (2022) Intrinsic Disorder as a Natural Preservative: High Levels of Intrinsic Disorder in Proteins Found in the 2600-Year-Old Human Brain. *Biology (Basel)* 11.
- Mohan A, Oldfield CJ, Radivojac P, Vacic V, Cortese MS, Dunker AK and Uversky VN (2006) Analysis of molecular recognition features (MoRFs). *J Mol Biol* **362**:1043-1059.
- Mohanram H, Kumar A, Verma CS, Pervushin K and Miserez A (2019) Three-dimensional structure of Megabalanus rosa Cement Protein 20 revealed by multi-dimensional NMR and molecular dynamics simulations. *Philos Trans R Soc Lond B Biol Sci* **374**:20190198.
- Mollica L, Bessa LM, Hanoulle X, Jensen MR, Blackledge M and Schneider R (2016) Binding
 Mechanisms of Intrinsically Disordered Proteins: Theory, Simulation, and Experiment. Front Mol
 Biosci 3:52.
- Nair SK and Burley SK (2003) X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. *Cell* **112**:193-205.
- Neduva V and Russell RB (2005) Linear motifs: evolutionary interaction switches. *FEBS Lett* **579**:3342-3345.
- Nesterov SV, Ilyinsky NS and Uversky VN (2021) Liquid-liquid phase separation as a common organizing principle of intracellular space and biomembranes providing dynamic adaptive responses. *Biochim Biophys Acta Mol Cell Res* **1868**:119102.
- Ng KP, Potikyan G, Savene RO, Denny CT, Uversky VN and Lee KA (2007) Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins. *Proc Natl Acad Sci U S A* **104**:479-484.
- Nizami Z, Deryusheva S and Gall JG (2010) The Cajal body and histone locus body. *Cold Spring Harb Perspect Biol* **2**:a000653.
- Nott TJ, Petsalaki E, Farber P, Jervis D, Fussner E, Plochowietz A, Craggs TD, Bazett-Jones DP, Pawson T, Forman-Kay JD and Baldwin AJ (2015) Phase transition of a disordered nuage protein generates environmentally responsive membraneless organelles. *Mol Cell* **57**:936-947.
- Nussenzweig A and Nussenzweig MC (2010) Origin of chromosomal translocations in lymphoid cancer. *Cell* **141**:27-38.
- Oates ME, Romero P, Ishida T, Ghalwash M, Mizianty MJ, Xue B, Dosztanyi Z, Uversky VN, Obradovic Z, Kurgan L, Dunker AK and Gough J (2013) D(2)P(2): database of disordered protein predictions. *Nucleic Acids Res* **41**:D508-516.
- Obst JK, Tien AH, Setiawan JC, Deneault LF and Sadar MD (2024) Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer. *Steroids* **210**:109482.
- Oka M, Mura S, Yamada K, Sangel P, Hirata S, Maehara K, Kawakami K, Tachibana T, Ohkawa Y, Kimura H and Yoneda Y (2016) Chromatin-prebound Crm1 recruits Nup98-HoxA9 fusion to induce aberrant expression of Hox cluster genes. *Elife* 5:e09540.
- Oldfield CJ, Cheng Y, Cortese MS, Brown CJ, Uversky VN and Dunker AK (2005a) Comparing and combining predictors of mostly disordered proteins. *Biochemistry* **44**:1989-2000.
- Oldfield CJ, Cheng Y, Cortese MS, Romero P, Uversky VN and Dunker AK (2005b) Coupled folding and binding with alpha-helix-forming molecular recognition elements. *Biochemistry* **44**:12454-12470.

- Oldfield CJ, Meng J, Yang MQ, Uversky VN and Dunker AK (2008) Flexible nets: disorder and induced fit in the associations of p53 and 14-3-3 with their partners. *BMC Genomics* **9 Suppl** 1:S1.
- Overington JP, Al-Lazikani B and Hopkins AL (2006) How many drug targets are there? *Nat Rev Drug Discov* **5**:993-996.
- Ozes ON, Reiter Z, Klein S, Blatt LM and Taylor MW (1992) A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. *Journal of interferon research* 12:55-59.
- Paiva LR and Martins ML (2011) A multiscale model to evaluate the efficacy of anticancer therapies based on chimeric polypeptide nanoparticles. *Applied Physics Letters* **98**.
- Pajkos M, Meszaros B, Simon I and Dosztanyi Z (2012) Is there a biological cost of protein disorder?

 Analysis of cancer-associated mutations. *Mol Biosyst* 8:296-307.
- Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Marinho RT,
 Borrego P and Taveira N (2018) Epidemic history of hepatitis C virus genotypes and subtypes in
 Portugal. *Sci Rep* 8:12266.
- Pancsa R, Schad E, Tantos A and Tompa P (2019) Emergent functions of proteins in non-stoichiometric supramolecular assemblies. *Biochim Biophys Acta Proteins Proteom* **1867**:970-979.
- Parkin J and Cohen B (2001) An overview of the immune system. *Lancet* **357**:1777-1789.
- Patel A, Mitrea D, Namasivayam V, Murcko MA, Wagner M and Klein IA (2022) Principles and functions of condensate modifying drugs. *Front Mol Biosci* **9**:1007744.
- Patil A and Nakamura H (2006) Disordered domains and high surface charge confer hubs with the ability to interact with multiple proteins in interaction networks. *FEBS Lett* **580**:2041-2045.
- Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K and Tekade RK (2021) Artificial intelligence in drug discovery and development. *Drug Discov Today* **26**:80-93.
- Peciak K, Tommasi R, Choi JW, Brocchini S and Laurine E (2014) Expression of soluble and active interferon consensus in SUMO fusion expression system in E. coli. *Protein expression and purification* **99**:18-26.
- 2377 Pederson T (2001) Protein mobility within the nucleus--what are the right moves? *Cell* **104**:635-638.
- Pederson T (2011) The nucleoulus. *Cold Spring Harbor perspectives in biology* **3**:a000638.
- Pejaver V, Hsu WL, Xin F, Dunker AK, Uversky VN and Radivojac P (2014) The structural and functional signatures of proteins that undergo multiple events of post-translational modification.

 Protein Sci 23:1077-1093.
- Peng K, Vucetic S, Radivojac P, Brown CJ, Dunker AK and Obradovic Z (2005) Optimizing long intrinsic disorder predictors with protein evolutionary information. *J Bioinform Comput Biol* 3:35-60.
- Peng ZL and Kurgan L (2012) Comprehensive comparative assessment of in-silico predictors of disordered regions. *Curr Protein Pept Sci* **13**:6-18.
- Permyakov SE, Millett IS, Doniach S, Permyakov EA and Uversky VN (2003) Natively unfolded Cterminal domain of caldesmon remains substantially unstructured after the effective binding to calmodulin. *Proteins* **53**:855--862.
- Pestka S, Langer JA, Zoon KC and Samuel CE (1987) Interferons and their actions. *Annual review of biochemistry* **56**:727-777.

Phair RD and Misteli T (2000) High mobility of proteins in the mammalian cell nucleus. *Nature* **404**:604-609.

- Pickhardt M, Neumann T, Schwizer D, Callaway K, Vendruscolo M, Schenk D, St George-Hyslop P,
 Mandelkow EM, Dobson CM, McConlogue L, Mandelkow E and Toth G (2015) Identification of
 Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential
 Therapeutic Approach for Tauopathies. *Curr Alzheimer Res* 12:814-828.
- 2398 Pirrotta V and Li HB (2012) A view of nuclear Polycomb bodies. Curr Opin Genet Dev 22:101-109.
- Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. *Nat Rev Immunol* 5:375-386.
- 2401 Plaxco KW and Gross M (1997) Cell biology. The importance of being unfolded. *Nature* **386**:657, 659.
- Pontius BW (1993) Close encounters: why unstructured, polymeric domains can increase rates of specific macromolecular association. *Trends Biochem Sci* **18**:181-186.
- Popelka H and Uversky VN (2022) Theater in the Self-Cleaning Cell: Intrinsically Disordered Proteins or Protein Regions Acting with Membranes in Autophagy. *Membranes (Basel)* **12**.
- Prabhudesai S, Sinha S, Attar A, Kotagiri A, Fitzmaurice AG, Lakshmanan R, Ivanova MI, Loo JA, Klarner FG, Schrader T, Stahl M, Bitan G and Bronstein JM (2012) A novel "molecular tweezer" inhibitor of alpha-synuclein neurotoxicity in vitro and in vivo. *Neurotherapeutics* 9: 464-476.
- Pradhan A, Mishra S, Surolia A and Panda D (2021) C1 Inhibits Liquid–Liquid Phase Separation and
 Oligomerization of Tau and Protects Neuroblastoma Cells against Toxic Tau Oligomers. ACS
 Chemical Neuroscience 12:1989-2002.
- Pullen RA, Jenkins JA, Tickle IJ, Wood SP and Blundell TL (1975) The relation of polypeptide hormone structure and flexibility to receptor binding: the relevance of X-ray studies on insulins, glucagon and human placental lactogen. *Mol Cell Biochem* **8**:5-20.
- Puntervoll P, Linding R, Gemund C, Chabanis-Davidson S, Mattingsdal M, Cameron S, Martin DM, Ausiello G, Brannetti B, Costantini A, Ferre F, Maselli V, Via A, Cesareni G, Diella F, Superti-Furga G, Wyrwicz L, Ramu C, McGuigan C, Gudavalli R, Letunic I, Bork P, Rychlewski L, Kuster B, Helmer-Citterich M, Hunter WN, Aasland R and Gibson TJ (2003) ELM server: A new resource for investigating short functional sites in modular eukaryotic proteins. *Nucleic Acids Res* 31:3625-3630.
- Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, Tauer C, Berger R, Barrett N, Jungbauer A and et al. (1994) A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. *AIDS Res Hum Retroviruses* **10**:1651-1658.
- Pytowski L, Lee CF, Foley AC, Vaux DJ and Jean L (2020) Liquid–liquid phase separation of type II diabetes-associated IAPP initiates hydrogelation and aggregation. *Proceedings of the National Academy of Sciences* 117:12050-12061.
- Raasakka A and Kursula P (2020) Flexible Players within the Sheaths: The Intrinsically Disordered Proteins of Myelin in Health and Disease. *Cells* 9.
- 2429 Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushan TL and Walter MR (1996)
 2430 Zinc mediated dimer of human interferon-alpha(2b) revealed by X-ray crystallography. *Structure*2431 **4**:1453-1463.
- Radivojac P, Iakoucheva LM, Oldfield CJ, Obradovic Z, Uversky VN and Dunker AK (2007) Intrinsic
 disorder and functional proteomics. *Biophys J* 92:1439-1456.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- Ramelot TA, Gentile LN and Nicholson LK (2000) Transient structure of the amyloid precursor protein cytoplasmic tail indicates preordering of structure for binding to cytosolic factors. *Biochemistry* **39**:2714-2725.
- Ramesh M, Balachandra C, Baruah P and Govindaraju T (2023) Cyclic dipeptide-based small molecules modulate zinc-mediated liquid-liquid phase separation of tau. *J Pept Sci* **29**:e3465.
- Rao JN, Jao CC, Hegde BG, Langen R and Ulmer TS (2010) A combinatorial NMR and EPR approach for evaluating the structural ensemble of partially folded proteins. *J Am Chem Soc* **132**:8657-8668.
- Rappuoli R (2001) Reverse vaccinology, a genome-based approach to vaccine development. *Vaccine* **19**:2688-2691.
- Ray S, Singh N, Kumar R, Patel K, Pandey S, Datta D, Mahato J, Panigrahi R, Navalkar A, Mehra S, Gadhe L, Chatterjee D, Sawner AS, Maiti S, Bhatia S, Gerez JA, Chowdhury A, Kumar A, Padinhateeri R, Riek R, Krishnamoorthy G and Maji SK (2020) α-Synuclein aggregation nucleates through liquid–liquid phase separation. *Nature Chemistry* 12:705-716.
- Razzak M and De Brabander JK (2011) Lessons and revelations from biomimetic syntheses. *Nature Chemical Biology* **7**:865-875.
- Reddy PJ, Ray S and Srivastava S (2015) The Quest of the Human Proteome and the Missing Proteins:
 Digging Deeper. *Omics-a Journal of Integrative Biology* **19**:276-282.
- Regep C, Georges G, Shi J, Popovic B and Deane CM (2017) The H3 loop of antibodies shows unique structural characteristics. *Proteins* **85**:1311-1318.
- Ren J, Zhang Z, Zong Z, Zhang L and Zhou F (2022) Emerging Implications of Phase Separation in Cancer. *Advanced Science* **9**:2202855.
- Richard JW, Hyun OL, Ina P, Arun P, Thom D, Satoshi K, Sukhleen K, Eric Nathaniel A, Lara M,
 Anastasia CM, Marcus J, Xiaojie Z, Edgar B, Anatol F, Nicolas LF, Jared S, Udai P, Della CD,
 Benjamin GD, Andrew JB, Andreas H, Marc B, Simon A and Anthony AH (2019) Small
 molecules for modulating protein driven liquid-liquid phase separation in treating
 neurodegenerative disease. *bioRxiv*:721001.
- 2461 Rinaudo CD, Telford JL, Rappuoli R and Seib KL (2009) Vaccinology in the genome era. *J Clin Invest* 2462 119:2515-2525.
- Ringe D and Petsko GA (2009) Q&A: What are pharmacological chaperones and why are they interesting? *Journal of biology* **8**:1-4.
- Roberts R, Timchenko NA, Miller JW, Reddy S, Caskey CT, Swanson MS and Timchenko LT (1997)
 Altered phosphorylation and intracellular distribution of a (CUG)n triplet repeat RNA-binding protein in patients with myotonic dystrophy and in myotonin protein kinase knockout mice. *Proc Natl Acad Sci U S A* **94**:13221-13226.
- 2469 Robustelli P, Ibanez-de-Opakua A, Campbell-Bezat C, Giordanetto F, Becker S, Zweckstetter M, Pan AC 2470 and Shaw DE (2022) Molecular Basis of Small-Molecule Binding to alpha-Synuclein. *J Am* 2471 *Chem Soc* 144:2501-2510.
- Romero-Isart N, Oliva B and Vašák M (2010) Influence of bonding interactions on the structure and dynamics of metallothioneins. *Journal of molecular modeling* **16**:387-394.
- Romero P, Obradovic Z, Li X, Garner EC, Brown CJ and Dunker AK (2001) Sequence complexity of disordered protein. *Proteins* **42**:38-48.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- Ross CA and Poirier MA (2005) Opinion: What is the role of protein aggregation in neurodegeneration?

 Nat Rev Mol Cell Biol 6:891-898.
- Ruan H, Sun Q, Zhang W, Liu Y and Lai L (2019) Targeting intrinsically disordered proteins at the edge of chaos. *Drug Discov Today* **24**:217-227.
- Ruan H, Yu C, Niu X, Zhang W, Liu H, Chen L, Xiong R, Sun Q, Jin C, Liu Y and Lai L (2020)
 Computational strategy for intrinsically disordered protein ligand design leads to the discovery of p53 transactivation domain I binding compounds that activate the p53 pathway. *Chem Sci* 12:3004-3016.
- 2484 Ryu JS and Raucher D (2014) Elastin-like polypeptides: The influence of its molecular weight on local hyperthermia-induced tumor accumulation. *Eur J Pharm Biopharm*.
- Sadar MD, Williams DE, Mawji NR, Patrick BO, Wikanta T, Chasanah E, Irianto HE, Soest RV and Andersen RJ (2008) Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. *Org Lett* **10**:4947-4950.
- Saikia B and Baruah A (2024) Recent advances in de novo computational design and redesign of intrinsically disordered protein and intrinsically disordered protein regions. *Arch Biochem Biophys* **752**:109857.
- Salmon L, Nodet G, Ozenne V, Yin G, Jensen MR, Zweckstetter M and Blackledge M (2010) NMR characterization of long-range order in intrinsically disordered proteins. *J Am Chem Soc* 132:8407-8418.
- Sanna PP, Williamson RA, De Logu A, Bloom FE and Burton DR (1995) Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries. *Proc Natl Acad Sci U S A* **92**:6439-6443.
- Santofimia-Castano P, Rizzuti B, Xia Y, Abian O, Peng L, Velazquez-Campoy A, Neira JL and Iovanna J (2020) Targeting intrinsically disordered proteins involved in cancer. *Cell Mol Life Sci* **77**:1695-1707.
- Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR and Wilson IA (2001) Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. *Science* **293**:1155-1159.
- Saurabh S, Nadendla K, Purohit SS, Sivakumar PM and Cetinel S (2023) Fuzzy Drug Targets: Disordered Proteins in the Drug-Discovery Realm. *ACS Omega* **8**:9729-9747.
- Sawner AS, Ray S, Yadav P, Mukherjee S, Panigrahi R, Poudyal M, Patel K, Ghosh D, Kummerant E,
 Kumar A, Riek R and Maji SK (2021) Modulating α-Synuclein Liquid-Liquid Phase Separation.
 Biochemistry 60:3676-3696.
- Sayers EW, Gerstner RB, Draper DE and Torchia DA (2000) Structural preordering in the N-terminal region of ribosomal protein S4 revealed by heteronuclear NMR spectroscopy. *Biochemistry* **39**:13602-13613.
- Schluter H, Apweiler R, Holzhutter HG and Jungblut PR (2009) Finding one's way in proteomics: a protein species nomenclature. *Chem Cent J* 3:11.
- Schulz GE (1979) Nucleotide Binding Proteins, in *Molecular Mechanism of Biological Recognition* (Balaban M ed) pp 79-94, Elsevier/North-Holland Biomedical Press, New York.
- Schweers O, Schonbrunn-Hanebeck E, Marx A and Mandelkow E (1994) Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. *J Biol Chem* **269**:24290-24297.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- Selvanathan SP, Moseley E, Graham GT, Jessen K, Lannutti B, Üren A and Toretsky JA (2017) TK-216:
 A novel, first-in-class, small molecule inhibitor of EWS-FLI1 in early clinical development, for the treatment of Ewing Sarcoma. *Cancer research* 77:694-694.
- Sen GC and Lengyel P (1992) The interferon system. A bird's eye view of its biochemistry. *J Biol Chem* **267**:5017-5020.
- Shamji MF, Chen J, Friedman AH, Richardson WJ, Chilkoti A and Setton LA (2008) Synthesis and characterization of a thermally-responsive tumor necrosis factor antagonist. *J Control Release* **129**:179-186.
- Shav-Tal Y, Blechman J, Darzacq X, Montagna C, Dye BT, Patton JG, Singer RH and Zipori D (2005)

 Dynamic sorting of nuclear components into distinct nucleolar caps during transcriptional inhibition. *Mol Biol Cell* **16**:2395-2413.
- Shi Q, Kang K and Chen YG (2021) Liquid-liquid phase separation drives the β-catenin destruction complex formation. *Bioessays* **43**:e2100138.
- Shi W, Tang J and Xiang J (2024) Therapeutic strategies for aberrant splicing in cancer and genetic disorders. *Clin Genet* **105**:345-354.
- Sickmeier M, Hamilton JA, LeGall T, Vacic V, Cortese MS, Tantos A, Szabo B, Tompa P, Chen J, Uversky VN, Obradovic Z and Dunker AK (2007) DisProt: the Database of Disordered Proteins.

 Nucleic Acids Res 35:D786-793.
- Singh GP, Ganapathi M and Dash D (2007) Role of intrinsic disorder in transient interactions of hub proteins. *Proteins* **66**:761-765.
- Sinha S, Lopes DH, Du Z, Pang ES, Shanmugam A, Lomakin A, Talbiersky P, Tennstaedt A, McDaniel
 K, Bakshi R, Kuo PY, Ehrmann M, Benedek GB, Loo JA, Klarner FG, Schrader T, Wang C and
 Bitan G (2011) Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly
 and toxicity of amyloid proteins. J Am Chem Soc 133:16958-16969.
- Sjogren MH, Sjogren R, Holtzmuller K, Winston B, Butterfield B, Drake S, Watts A, Howard R and Smith M (2005) Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. *Digestive Diseases and Sciences* **50**:727-732.
- Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT and Simmonds P (2014) Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. *Hepatology* **59**:318-327.
- Smith LM, Kelleher NL and Consortium for Top Down P (2013) Proteoform: a single term describing protein complexity. *Nat Methods* **10**:186-187.
- Smith TJ, Chase ES, Schmidt TJ, Olson NH and Baker TS (1996) Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon. *Nature* **383**:350-354.
- Somasekharan SP, El-Naggar A, Leprivier G, Cheng H, Hajee S, Grunewald TG, Zhang F, Ng T, Delattre
 O, Evdokimova V, Wang Y, Gleave M and Sorensen PH (2015) YB-1 regulates stress granule
 formation and tumor progression by translationally activating G3BP1. *The Journal of cell biology*208:913-929.
- Song GJ, Nam Y, Jo M, Jung M, Koo JY, Cho W, Koh M, Park SB and Suk K (2016) A novel small-molecule agonist of PPAR-γ potentiates an anti-inflammatory M2 glial phenotype.

 Neuropharmacology 109:159-169.
- Song MS and Grabocka E (2023) Stress Granules in Cancer. *Rev Physiol Biochem Pharmacol* **185**:25-52.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- Spillantini MG, Crowther RA, Jakes R, Hasegawa M and Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

 Proc Natl Acad Sci U S A 95:6469-6473.
- Spolar RS and Record MT, Jr. (1994) Coupling of local folding to site-specific binding of proteins to DNA. *Science* **263**:777-784.
- Spriano F, Chung EYL, Gaudio E, Tarantelli C, Cascione L, Napoli S, Jessen K, Carrassa L, Priebe V,
 Sartori G, Graham G, Selvanathan SP, Cavalli A, Rinaldi A, Kwee I, Testoni M, Genini D, Ye
 BH, Zucca E, Stathis A, Lannutti B, Toretsky JA and Bertoni F (2019) The ETS Inhibitors YK-4 279 and TK-216 Are Novel Antilymphoma Agents. *Clin Cancer Res* 25:5167-5176.
- Stanfield B and Kousoulas KG (2015) Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections. *Curr Clin Microbiol Rep* **2**:125-136.
- Stanfield RL, Berndsen ZT, Huang R, Sok D, Warner G, Torres JL, Burton DR, Ward AB, Wilson IA and Smider VV (2020) Structural basis of broad HIV neutralization by a vaccine-induced cow antibody. *Sci Adv* **6**:eaba0468.
- Strzelecka M, Trowitzsch S, Weber G, Luhrmann R, Oates AC and Neugebauer KM (2010) Coilindependent snRNP assembly is essential for zebrafish embryogenesis. *Nature structural & molecular biology* **17**:403-409.
- Sundaresan Y, Banin E and Sharon D (2023) Exonic Variants that Affect Splicing An Opportunity for "Hidden" Mutations Causing Inherited Retinal Diseases. *Adv Exp Med Biol* **1415**:183-187.
- Sung YH and Eliezer D (2007) Residual structure, backbone dynamics, and interactions within the synuclein family. *J Mol Biol* **372**:689-707.
- Szenasi T, Olah J, Szabo A, Szunyogh S, Lang A, Perczel A, Lehotzky A, Uversky VN and Ovadi J (2017) Challenging drug target for Parkinson's disease: Pathological complex of the chameleon TPPP/p25 and alpha-synuclein proteins. *Biochim Biophys Acta* **1863**:310-323.
- Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT,
 Morris JH, Bork P, Jensen LJ and Mering CV (2019) STRING v11: protein-protein association
 networks with increased coverage, supporting functional discovery in genome-wide experimental
 datasets. *Nucleic Acids Res* 47:D607-d613.
- Takada I and Makishima M (2020) Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present). *Expert Opin Ther Pat* **30**:1-13.
- Tan MH, Li J, Xu HE, Melcher K and Yong EL (2015) Androgen receptor: structure, role in prostate cancer and drug discovery. *Acta Pharmacol Sin* **36**:3-23.
- Tao Y, Zhang Q, Wang H, Yang X and Mu H (2024) Alternative splicing and related RNA binding proteins in human health and disease. *Signal Transduct Target Ther* **9**:26.
- The Lancet Gastroenterology H (2021) The hunt for a vaccine for hepatitis C virus continues. *Lancet Gastroenterol Hepatol* **6**:253.
- Timm DE, Vissavajjhala P, Ross AH and Neet KE (1992) Spectroscopic and chemical studies of the interaction between nerve growth factor (NGF) and the extracellular domain of the low affinity NGF receptor. *Protein Sci* 1:1023--1031.
- Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, Zhang Z, Lapouble E, Grossetete Lalami S, Rusch M, Reynaud S, Rio-Frio T, Hedlund E, Wu G, Chen X, Pierron G, Oberlin O,
 Zaidi S, Lemmon G, Gupta P, Vadodaria B, Easton J, Gut M, Ding L, Mardis ER, Wilson RK,
 Shurtleff S, Laurence V, Michon J, Marec-Berard P, Gut I, Downing J, Dyer M, Zhang J, Delattre
 O, St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome P and

the International Concer Concern C (2014) Concerns landscore of Evving concerns defines an

- the International Cancer Genome C (2014) Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. *Cancer Discov* **4**:1342-1353.
- Tokuriki N, Oldfield CJ, Uversky VN, Berezovsky IN and Tawfik DS (2009) Do viral proteins possess unique biophysical features? *Trends Biochem Sci* **34**:53-59.
- 2611 Tompa P (2002a) Intrinsically unstructured proteins. Trends Biochem Sci 27:527-533.
- Tompa P (2002b) Intrinsically unstructured proteins. *Trends Biochem Sci* **27**:527-533.
- Tompa P (2005) The interplay between structure and function in intrinsically unstructured proteins. *FEBS Lett* **579**:3346-3354.
- Tompa P (2009) Structural disorder in amyloid fibrils: its implication in dynamic interactions of proteins. *Febs J* **276**:5406-5415.
- Tompa P and Csermely P (2004) The role of structural disorder in the function of RNA and protein chaperones. *FASEB J* **18**:1169-1175.
- Tompa P and Fuxreiter M (2008) Fuzzy complexes: polymorphism and structural disorder in proteinprotein interactions. *Trends Biochem Sci* **33**:2-8.
- Tompa P, Szasz C and Buday L (2005) Structural disorder throws new light on moonlighting. *Trends Biochem Sci* **30**:484-489.
- Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, Hathcote EJ, White H, 2623 2624 Foust RT, Jensen DM, Krawitt EL, Fromm H, Black M, Blatt LM, Klein M, Lubina J, Bailey R, 2625 Bala K, Balart L, Bonkovsky H, Cassidy W, Craig JR, Donovan J, Dusheiko GM, Ehrinpreis M, Everson G, Feinman S, Hauser S, Hunter E, James S, Killenberg P, Lee S, vanLeeuwen DJ, 2626 Lesesne H, Lieberman H, Lissoos T, Lumeng L, Lyche K, Minuk G, Mullen K, Payne KM, 2627 2628 Pimstone N, Poterucha J, Rosenblate H, Shafritz D, Smith C and Willems B (1997) Treatment of 2629 chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. 2630 Hepatology 26:747-754.
- Tong X, Tang R, Xu J, Wang W, Zhao Y, Yu X and Shi S (2022) Liquid–liquid phase separation in tumor biology. *Signal Transduction and Targeted Therapy* 7:221.
- Toretsky JA, Erkizan V, Levenson A, Abaan OD, Parvin JD, Cripe TP, Rice AM, Lee SB and Uren A (2006) Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. *Cancer research* 66:5574-5581.
- Toretsky JA and Wright PE (2014) Assemblages: functional units formed by cellular phase separation.

 The Journal of cell biology 206:579-588.
- Toth G, Gardai SJ, Zago W, Bertoncini CW, Cremades N, Roy SL, Tambe MA, Rochet JC, Galvagnion C, Skibinski G, Finkbeiner S, Bova M, Regnstrom K, Chiou SS, Johnston J, Callaway K, Anderson JP, Jobling MF, Buell AK, Yednock TA, Knowles TP, Vendruscolo M, Christodoulou J, Dobson CM, Schenk D and McConlogue L (2014) Targeting the Intrinsically Disordered Structural Ensemble of alpha-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson's Disease. *PLoS One* 9:e87133.
- Tsafou K, Tiwari PB, Forman-Kay JD, Metallo SJ and Toretsky JA (2018) Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm. *J Mol Biol* **430**:2321-2341.
- Tsang B, Pritisanac I, Scherer SW, Moses AM and Forman-Kay JD (2020) Phase Separation as a Missing Mechanism for Interpretation of Disease Mutations. *Cell* **183**:1742-1756.

Tsvetkov P, Asher G, Paz A, Reuven N, Sussman JL, Silman I and Shaul Y (2008) Operational definition of intrinsically unstructured protein sequences based on susceptibility to the 20S proteasome.

Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.

Turoverov KK, Kuznetsova IM, Fonin AV, Darling AL, Zaslavsky BY and Uversky VN (2019)
Stochasticity of Biological Soft Matter: Emerging Concepts in Intrinsically Disordered Proteins and Biological Phase Separation. *Trends Biochem Sci* 44:716-728.

2650

Proteins 70:1357-1366.

- Turoverov KK, Kuznetsova IM and Uversky VN (2010) The protein kingdom extended: ordered and intrinsically disordered proteins, their folding, supramolecular complex formation, and aggregation. *Prog Biophys Mol Biol* **102**:73-84.
- 2657 Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, 2658 Asplund A, Asplund C, Berglund L, Bergstrom K, Brumer H, Cerjan D, Ekstrom M, Elobeid A, 2659 Eriksson C, Fagerberg L, Falk R, Fall J, Forsberg M, Bjorklund MG, Gumbel K, Halimi A, Hallin I, Hamsten C, Hansson M, Hedhammar M, Hercules G, Kampf C, Larsson K, Linskog M, 2660 2661 Lodewyckx W. Lund J. Lundeberg J. Magnusson K. Malm E. Nilsson P. Odling J. Oksvold P. 2662 Olsson I, Oster E, Ottosson J, Paavilainen L, Persson A, Rimini R, Rockberg J, Runeson M, Sivertsson A, Skollermo A, Steen J, Stenvall M, Sterky F, Stromberg S, Sundberg M, Tegel H, 2663 2664 Tourle S, Wahlund E, Walden A, Wan JH, Wernerus H, Westberg J, Wester K, Wrethagen U, Xu 2665 LL, Hober S and Ponten F (2005) A human protein atlas for normal and cancer tissues based on antibody proteomics. Molecular & Cellular Proteomics 4:1920-1932. 2666
- Uniacke J and Zerges W (2008) Stress induces the assembly of RNA granules in the chloroplast of Chlamydomonas reinhardtii. *The Journal of cell biology* **182**:641-646.
- Updike DL, Hachey SJ, Kreher J and Strome S (2011) P granules extend the nuclear pore complex environment in the C. elegans germ line. *The Journal of cell biology* **192**:939-948.
- Uren A, Tcherkasskaya O and Toretsky JA (2004) Recombinant EWS-FLI1 oncoprotein activates transcription. *Biochemistry* **43**:13579-13589.
- Urry DW (1988) Entropic elastic processes in protein mechanisms. I. Elastic structure due to an inverse temperature transition and elasticity due to internal chain dynamics. *J Protein Chem* **7**:1-34.
- Urry DW (1992) Free energy transduction in polypeptides and proteins based on inverse temperature transitions. *Prog Biophys Mol Biol* **57**:23-57.
- Urry DW (1997) Physical chemistry of biological free energy transduction as demonstrated by elastic protein-based polymers. *Journal of Physical Chemistry B* **101**:11007-11028.
- Urry DW, Luan CH, Parker TM, Gowda DC, Prasad KU, Reid MC and Safavy A (1991) Temperature of
 Polypeptide Inverse Temperature Transition Depends on Mean Residue Hydrophobicity. *Journal* of the American Chemical Society 113:4346-4348.
- Uversky VN (2002a) Natively unfolded proteins: a point where biology waits for physics. *Protein Sci* **11**:739-756.
- 2684 Uversky VN (2002b) What does it mean to be natively unfolded? Eur J Biochem 269:2-12.
- Uversky VN (2003a) A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. *J Biomol Struct Dyn* **21**:211-234.
- Uversky VN (2003b) Protein folding revisited. A polypeptide chain at the folding-misfolding-nonfolding cross-roads: which way to go? *Cell Mol Life Sci* **60**:1852-1871.
- Uversky VN (2007) Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. *J Neurochem* **103**:17-37.

Uversky VN (2009a) Intrinsic disorder in proteins associated with neurodegenerative diseases. *Front Biosci* **14**:5188-5238.

- Uversky VN (2009b) Intrinsically disordered proteins and their environment: effects of strong denaturants, temperature, pH, counter ions, membranes, binding partners, osmolytes, and macromolecular crowding. *Protein J* 28:305-325.
- Uversky VN (2010a) The mysterious unfoldome: structureless, underappreciated, yet vital part of any given proteome. *J Biomed Biotechnol* **2010**:568068.
- Uversky VN (2010b) Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept. *Expert Rev Proteomics* **7**:543-564.
- Uversky VN (2011a) Intrinsically disordered proteins may escape unwanted interactions via functional misfolding. *Biochim Biophys Acta* **1814**:693-712.
- Uversky VN (2011b) Multitude of binding modes attainable by intrinsically disordered proteins: a portrait gallery of disorder-based complexes. *Chem Soc Rev* **40**:1623-1634.
- Uversky VN (2012) Intrinsically disordered proteins and novel strategies for drug discovery. *Expert Opin Drug Discov* 7:475-488.
- Uversky VN (2013a) A decade and a half of protein intrinsic disorder: biology still waits for physics. *Protein Sci* 22:693-724.
- Uversky VN (2013b) Intrinsic disorder-based protein interactions and their modulators. *Curr Pharm Des* **19** 4191-4213.
- Uversky VN (2013c) Intrinsic disorder-based protein interactions and their modulators. *Curr Pharm Des* **19**:4191-4213.
- Uversky VN (2013d) Unusual biophysics of intrinsically disordered proteins. *Biochim Biophys Acta* **1834** 932-951.
- Uversky VN (2014) The triple power of D(3): protein intrinsic disorder in degenerative diseases. *Front Biosci (Landmark Ed)* **19**:181-258.
- Uversky VN (2015) Functional roles of transiently and intrinsically disordered regions within proteins. *FEBS J* **282**:1182-1189.
- Uversky VN (2016a) Dancing Protein Clouds: The Strange Biology and Chaotic Physics of Intrinsically Disordered Proteins. *J Biol Chem* **291**:6681-6688.
- Uversky VN (2016b) Intrinsically disordered proteins in overcrowded milieu: Membrane-less organelles, phase separation, and intrinsic disorder. *Curr Opin Struct Biol* **44**:18-30.
- Uversky VN (2016c) (Intrinsically disordered) splice variants in the proteome: implications for novel drug discovery. *Genes Genom* **38**:577-594.
- Uversky VN (2016d) p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure-Function Continuum Concept. *Int J Mol Sci* **17**:1874.
- Uversky VN (2016e) Paradoxes and wonders of intrinsic disorder: Complexity of simplicity. *Intrinsically Disord Proteins* 4:e1135015.
- Uversky VN (2017a) How to Predict Disorder in a Protein of Interest. *Methods Mol Biol* **1484**:137-158.
- Uversky VN (2017b) Intrinsically disordered proteins in overcrowded milieu: Membrane-less organelles, phase separation, and intrinsic disorder. *Curr Opin Struct Biol* **44**:18-30.

2731 Uversky VN (2017c) Protein intrinsic disorder-based liquid-liquid phase transitions in biological systems:

Complex coacervates and membrane-less organelles. Adv Colloid Interface Sci 239:97-114.

Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.

Uversky VN (2017d) The roles of intrinsic disorder-based liquid-liquid phase transitions in the "Dr. Jekyll-Mr. Hyde" behavior of proteins involved in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. *Autophagy* **13**:2115-2162.

2732

- Uversky VN (2018) Intrinsic Disorder, Protein-Protein Interactions, and Disease. *Adv Protein Chem Struct Biol* **110**:85-121.
- Uversky VN (2019) Protein intrinsic disorder and structure-function continuum. *Prog Mol Biol Transl Sci* **166**:1-17.
- Uversky VN (2021) On the irrationality of rational design of an HIV vaccine in light of protein intrinsic disorder. *Arch Virol* **166**:1283-1296.
- Uversky VN (2022) Fight fire with fire: the need for a vaccine based on intrinsic disorder and structural flexibility. *Exploration of Immunology* **2**:731-748.
- Uversky VN (2024) Functional unfoldomics: Roles of intrinsic disorder in protein (multi)functionality.

 Adv Protein Chem Struct Biol 138:179-210.
- Uversky VN and Dunker AK (2010a) Understanding protein non-folding. *Biochim Biophys Acta* **1804**:1231-1264.
- Uversky VN and Dunker AK (2010b) Understanding protein non-folding. *Biochim Biophys Acta* **1804**:1231-1264.
- Uversky VN and Dunker AK (2013) The case for intrinsically disordered proteins playing contributory roles in molecular recognition without a stable 3D structure. *F1000 Biol Rep* **5**:1.
- Uversky VN and Eliezer D (2009) Biophysics of Parkinson's disease: structure and aggregation of alphasynuclein. *Curr Protein Pept Sci* **10**:483-499.
- Uversky VN, Gillespie JR and Fink AL (2000a) Why are "natively unfolded" proteins unstructured under physiologic conditions? *Proteins* **41**:415-427.
- Uversky VN, Gillespie JR and Fink AL (2000b) Why are "natively unfolded" proteins unstructured under physiologic conditions? *Proteins* **41**:415-427.
- Uversky VN, Kuznetsova IM, Turoverov KK and Zaslavsky B (2015) Intrinsically disordered proteins as crucial constituents of cellular aqueous two phase systems and coacervates. *FEBS Lett* **589**:15-22.
- Uversky VN, Li J and Fink AL (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. *J Biol Chem* **276**:10737--10744.
- Uversky VN, Oldfield CJ and Dunker AK (2005) Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling. *J Mol Recognit* **18**:343-384.
- Uversky VN, Oldfield CJ and Dunker AK (2008) Intrinsically disordered proteins in human diseases: introducing the D2 concept. *Annu Rev Biophys* **37**:215-246.
- Uversky VN, Oldfield CJ, Midic U, Xie H, Xue B, Vucetic S, Iakoucheva LM, Obradovic Z and Dunker
 AK (2009) Unfoldomics of human diseases: linking protein intrinsic disorder with diseases. *BMC Genomics* 10 Suppl 1:S7.
- Uversky VN, Permyakov SE, Zagranichny VE, Rodionov IL, Fink AL, Cherskaya AM, Wasserman LA and Permyakov EA (2002) Effect of zinc and temperature on the conformation of the gamma subunit of retinal phosphodiesterase: a natively unfolded protein. *J Proteome Res* 1:149--159.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- Vacic V, Oldfield CJ, Mohan A, Radivojac P, Cortese MS, Uversky VN and Dunker AK (2007a)
 Characterization of molecular recognition features, MoRFs, and their binding partners. *J Proteome Res* **6**:2351-2366.
- Vacic V, Uversky VN, Dunker AK and Lonardi S (2007b) Composition Profiler: a tool for discovery and visualization of amino acid composition differences. *BMC Bioinformatics* **8**:211.
- Vaishampayan U, Montgomery R, Gordon M, Smith D, Barber K, de Haas-Amatsaleh A, Thapar N, Chandhasin C, Perabo F and Chi K (2017) EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy. *Annals of Oncology* 28:v274.
- Vassilev LT (2004) Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. *Cell Cycle* **3**:419-421.
- Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N and Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. *Science* **303**:844-848.
- Venables JP (2004) Aberrant and alternative splicing in cancer. *Cancer research* **64**:7647-7654.
- Vendruscolo M (2007) Determination of conformationally heterogeneous states of proteins. *Curr Opin Struct Biol* **17**:15-20.
- Vendruscolo M (2023) Thermodynamic and kinetic approaches for drug discovery to target protein misfolding and aggregation. *Expert Opin Drug Discov* **18**:881-891.
- Vendruscolo M and Fuxreiter M (2022) Protein condensation diseases: therapeutic opportunities. *Nature Communications* **13**:5550.
- Vigerust DJ and Shepherd VL (2007) Virus glycosylation: role in virulence and immune interactions. *Trends Microbiol* **15**:211-218.
- Vucetic S, Xie H, Iakoucheva LM, Oldfield CJ, Dunker AK, Obradovic Z and Uversky VN (2007)
 Functional anthology of intrinsic disorder. 2. Cellular components, domains, technical terms,
 developmental processes, and coding sequence diversities correlated with long disordered
 regions. *J Proteome Res* **6**:1899-1916.
- 2800 Walker LC and LeVine H, 3rd (2000) The cerebral proteopathies. *Neurobiol Aging* **21**:559-561.
- Wang B, Zhang L, Dai T, Qin Z, Lu H, Zhang L and Zhou F (2021) Liquid–liquid phase separation in human health and diseases. *Signal Transduction and Targeted Therapy* **6**:290.
- Wang C, Lu H, Liu X, Gao X, Tian W, Chen H, Xue Y and Zhou Q (2022) A natural product targets BRD4 to inhibit phase separation and gene transcription. *iScience* **25**:103719.
- Wang H, Hammoudeh DI, Follis AV, Reese BE, Lazo JS, Metallo SJ and Prochownik EV (2007) Improved low molecular weight Myc-Max inhibitors. *Mol Cancer Ther* **6**:2399-2408.
- Wang H, Xiong R and Lai L (2023) Rational drug design targeting intrinsically disordered proteins. Wiley
 Interdisciplinary Reviews: Computational Molecular Science 13:e1685.
- Wang J, Cao Z, Zhao L and Li S (2011) Novel strategies for drug discovery based on Intrinsically Disordered Proteins (IDPs). *Int J Mol Sci* **12**:3205-3219.
- Ward B (2007) Antiviral Vaccines, in *Fundamentals of Molecular Virology* (Acheson NH ed) pp 428-455, Wiley, Hoboken, NJ, USA.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- Ward JJ, Sodhi JS, McGuffin LJ, Buxton BF and Jones DT (2004) Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. *J Mol Biol* **337**:635-645.
- Wathen B and Jia Z (2009) Folding by numbers: primary sequence statistics and their use in studying protein folding. *Int J Mol Sci* **10**:1567-1589.
- Watson DK, Robinson L, Hodge DR, Kola I, Papas TS and Seth A (1997) FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements. *Oncogene* **14**:213-221.
- Weinreb PH, Zhen W, Poon AW, Conway KA and Lansbury PT, Jr. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. *Biochemistry* **35**:13709-13715.
- White MR, Mitrea DM, Zhang P, Stanley CB, Cassidy DE, Nourse A, Phillips AH, Tolbert M, Taylor JP and Kriwacki RW (2019) C9orf72 Poly(PR) Dipeptide Repeats Disturb Biomolecular Phase Separation and Disrupt Nucleolar Function. *Mol Cell* **74**:713-728.e716.
- Wilhelmus MM, Otte-Höller I, Wesseling P, de Waal RM, Boelens WC and Verbeek MM (2006)
 Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains. *Neuropathol Appl Neurobiol* **32**:119-130.
- Williams RM, Obradovic Z, Mathura V, Braun W, Garner EC, Young J, Takayama S, Brown CJ and Dunker AK (2001) The protein non-folding problem: amino acid determinants of intrinsic order and disorder. *Pac Symp Biocomput*:89-100.
- Wippich F, Bodenmiller B, Trajkovska MG, Wanka S, Aebersold R and Pelkmans L (2013) Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling. *Cell* **152**:791-805.
- Wojtys W and Oron M (2023) How Driver Oncogenes Shape and Are Shaped by Alternative Splicing Mechanisms in Tumors. *Cancers (Basel)* **15**.
- Wright PE and Dyson HJ (1999a) Intrinsically unstructured proteins: re-assessing the protein structurefunction paradigm. *J Mol Biol* **293**:321-331.
- Wright PE and Dyson HJ (1999b) Intrinsically unstructured proteins: re-assessing the protein structurefunction paradigm. *J Mol Biol* **293**:321-331.
- Wu KP, Kim S, Fela DA and Baum J (2008) Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: implication for aggregation. *J Mol Biol* **378**:1104-1115.
- Wu KP, Weinstock DS, Narayanan C, Levy RM and Baum J (2009) Structural reorganization of alphasynuclein at low pH observed by NMR and REMD simulations. *J Mol Biol* **391**:784-796.
- Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D and Gronemeyer H (1996) A canonical structure for the ligand-binding domain of nuclear receptors. *Nat Struct Biol* **3**:87-94.
- 2847 Xie H, Vucetic S, Iakoucheva LM, Oldfield CJ, Dunker AK, Uversky VN and Obradovic Z (2007)
 2848 Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with
 2849 long disordered regions. *J Proteome Res* **6**:1882-1898.
- Xie Q, Cheng J, Mei W, Yang D, Zhang P and Zeng C (2023) Phase separation in cancer at a glance.

 Journal of Translational Medicine 21:237.
- Xu B, Chen J and Liu Y (2022a) Curcumin Interacts with α-Synuclein Condensates To Inhibit Amyloid Aggregation under Phase Separation. *ACS Omega* **7**:30281-30290.
- Xu B, Mo X, Chen J, Yu H and Liu Y (2022b) Myricetin Inhibits α-Synuclein Amyloid Aggregation by Delaying the Liquid-to-Solid Phase Transition. *Chembiochem* **23**:e202200216.

- Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version.
- 2856 Xue B, Dunker AK and Uversky VN (2012) Orderly order in protein intrinsic disorder distribution:
 2857 Disorder in thirty five hundred proteomes from viruses and the three domains of life. *Journal of Biomolecular Structure and Dynamics* **30**:137-149.
- Xue B, Williams RW, Oldfield CJ, Dunker AK and Uversky VN (2010) Archaic chaos: intrinsically disordered proteins in Archaea. *BMC Syst Biol* **4 Suppl 1**:S1.
- Yamaguchi Y, Masuda M, Sasakawa H, Nonaka T, Hanashima S, Hisanaga S, Kato K and Hasegawa M (2010) Characterization of inhibitor-bound alpha-synuclein dimer: role of alpha-synuclein N-terminal region in dimerization and inhibitor binding. *J Mol Biol* **395**:445-456.
- Yi Q, Han X, Yu HG, Chen HY, Qiu D, Su J, Lin R, Batist G and Wu JH (2024) SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain. *Oncogene* **43**:1522-1533.
- Yi Q, Liu W, Seo JH, Su J, Alaoui-Jamali MA, Luo J, Lin R and Wu JH (2023) Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer. *Mol Cancer Ther* 22:570-582.
- Yin X, Giap C, Lazo JS and Prochownik EV (2003) Low molecular weight inhibitors of Myc-Max interaction and function. *Oncogene* **22**:6151-6159.
- Yu C, Niu X, Jin F, Liu Z, Jin C and Lai L (2016) Structure-based Inhibitor Design for the Intrinsically Disordered Protein c-Myc. *Sci Rep* **6**:22298.
- Yu Q, Wang Z, Tu Y, Cao Y, Zhu H, Shao J, Zhuang R, Zhou Y and Zhang J (2024) Proteasome activation: A novel strategy for targeting undruggable intrinsically disordered proteins. *Bioorg Chem* **145**:107217.
- Zamudio AV, Dall'Agnese A, Henninger JE, Manteiga JC, Afeyan LK, Hannett NM, Coffey EL, Li CH,
 Oksuz O, Sabari BR, Boija A, Klein IA, Hawken SW, Spille JH, Decker TM, Cisse, II, Abraham
 BJ, Lee TI, Taatjes DJ, Schuijers J and Young RA (2019) Mediator Condensates Localize
 Signaling Factors to Key Cell Identity Genes. *Mol Cell* 76:753-766.e756.
- Zbinden A, Pérez-Berlanga M, De Rossi P and Polymenidou M (2020) Phase Separation and Neurodegenerative Diseases: A Disturbance in the Force. *Developmental Cell* **55**:45-68.
- Zhang JZ, Lu TW, Stolerman LM, Tenner B, Yang JR, Zhang JF, Falcke M, Rangamani P, Taylor SS,
 Mehta S and Zhang J (2020) Phase Separation of a PKA Regulatory Subunit Controls cAMP
 Compartmentation and Oncogenic Signaling. *Cell* 182:1531-1544.e1515.
- Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH and Levine AJ (2000) Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. *Genes Dev* **14**:981-993.
- Zhou M, Li W, Li J, Xie L, Wu R, Wang L, Fu S, Su W, Hu J, Wang J and Li P (2020) Phase-separated condensate-aided enrichment of biomolecular interactions for high-throughput drug screening in test tubes. *J Biol Chem* **295**:11420-11434.
- Zhou T and Xu K (2018) Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine. *Adv Exp Med Biol* **1075**:73-95.
- Zhu J, Salvatella X and Robustelli P (2022) Small molecules targeting the disordered transactivation domain of the androgen receptor induce the formation of collapsed helical states. *Nat Commun* **13**:6390.
- Zhu L and Brangwynne CP (2015) Nuclear bodies: the emerging biophysics of nucleoplasmic phases.
 Curr Opin Cell Biol 34:23-30.

2899 2900 2901	Zhu M, De Simone A, Schenk D, Toth G, Dobson CM and Vendruscolo M (2013) Identification of small-molecule binding pockets in the soluble monomeric form of the Abeta42 peptide. <i>J Chem Phys</i> 139 :035101.
2902 2903 2904	Ziólkowska B and Przewlocki R (2002) Chapter I Methods used in inducible transcription factor studies: focus on mRNA, in <i>Handbook of Chemical Neuroanatomy</i> (Kaczmarek L and Robertson HA eds) pp 1-38, Elsevier.
2905 2906 2907	Zitzewitz JA, Ibarra-Molero B, Fishel DR, Terry KL and Matthews CR (2000) Preformed secondary structure drives the association reaction of GCN4-p1, a model coiled-coil system. <i>J Mol Biol</i> 296 :1105-1116.
2908 2909 2910	Zou C, Zan X, Jia Z, Zheng L, Gu Y, Liu F, Han Y, Xu C, Wu A and Zhi Q (2023) Crosstalk between alternative splicing and inflammatory bowel disease: Basic mechanisms, biotechnological progresses and future perspectives. <i>Clin Transl Med</i> 13 :e1479.
2911 2912 2913	Zourlidou A, Payne Smith MD and Latchman DS (2004) HSP27 but not HSP70 has a potent protective effect against alpha-synuclein-induced cell death in mammalian neuronal cells. <i>J Neurochem</i> 88 :1439-1448.
2914	

2915

Figure legends

2916

2917

2918

2919

2920

2921

2922

2923

2924

2925

2926

2927

2928

2929

2930

2931

2932

2933

2934

2935

2936

2937

2938

Figure 1. NMR solution structure of barnacle (Megabalanus rosa) cement protein MrCP20 (PDB ID: 6LEK; (Mohanram et al., 2019)), where 10 models are overlaid generating a complex conformational ensemble that clearly resembles a fuzzy cloud. Figure 2. Schematic representation of major functional advantages of IDPs/IDRs over ordered proteins and domains. Modified from (Uversky, 2018). **Figure 3.** Peculiarities of the amino acid sequences of intrinsically disordered proteins. A. Amino acid determinants defining structural and functional differences between the ordered and intrinsically disordered proteins. Fractional difference in the amino acid composition (compositional profile) between the typical IDPs from the DisProt database (Sickmeier et al., 2007) and a set of completely ordered proteins (Berman et al., 2000) calculated for each amino acid residue. The fractional difference was evaluated as (C_{DisProt}-C_{PDB})/C_{PDB}, where C_{DisProt} is the content of a given amino acid in a DisProt database (Sickmeier et al., 2007), and C_{PDB} is the corresponding content in the dataset of fully ordered proteins from PDB select 25 (Berman et al., 2000). Positive bars colored in red and pink correspond to residues found more abundantly in IDPs, whereas negative bars colored in blue and cyan show residues, in which IDPs are depleted. Amino acid types are ranked according to their increasing disorder-promoting potential (Radivojac et al., 2007). Fractional differences are shown for proteins in DisProt 3.4 (cyan and pink bars) and DisProt release 2023 12 (blue and red bars). B. Evaluation of the chargehydropathy space available for mouse proteins. The space accessible to the sequences encoding compact proteins is shown as a light cyan area, whereas the space accessible to sequences encoding IDPs is depicted as light red area. These two areas are defined by four boundaries, (i) the known boundary separating compact proteins and extended IDPs ($\langle R \rangle = 2.785 \langle H \rangle - 1.151$, 2939

2940

2941

2942

2943

2944

2945

2946

2947

2948

2949

2950

2951

2952

2953

2954

2955

2956

2957

2958

2959

2960

2961

where $\langle R \rangle$ and $\langle H \rangle$ correspond to the absolute mean charge and mean hydropathy, respectively (Uversky et al., 2000b)); (ii) the mirror image of this boundary ($\langle R \rangle = -2.785 \langle H \rangle + 1.151$, where $\langle R \rangle$ and $\langle H \rangle$ correspond to the mean charge and mean hydropathy, respectively); (iii) two boundaries showing logical limits of the CH-space ($\langle R \rangle = -1.125 + 1.125 \langle H \rangle$ and $\langle R \rangle =$ $1.00 - \langle H \rangle$, evaluated for a series of hypothetical polypeptides containing different proportions of Ile (which is, according to the Kyte and Doolittle scale, is the most hydrophobic residue with the normalized hydropathy of 1 (Kyte and Doolittle, 1982)) and a negatively charged Asp (which is characterized by the normalized Kyte and Doolittle hydropathy of 0.1111 (Kyte and Doolittle, 1982)) or a positively charged Arg (which is characterized by the normalized Kyte and Doolittle hydropathy of 0.0 (Kyte and Doolittle, 1982)). Vertical dashed line represents a hypothetical boundary separating soluble compact proteins and membrane proteins. **Figure 4**. Schematic representation of the mosaic nature of the protein structure-function space. Differently (dis)ordered segments (foldons, semi-foldons, inducible foldons, inducible morphing foldons, non-foldons, and unfoldons) might have different functions. Being found within one protein, these pieces of structural mosaic define protein multifunctionality. Figure 5. Structural and functional characterization of TPPP/p25 (A, B) and α -synuclein (C, D) known to be involved in the pathogenesis of Parkinson's disease and other synucleinopathies. A. 3D model generated for human TPPP/p25 by AlphaFold (Jumper et al., 2021). Structure is colored based on the AlphaFold-generated per-residue confidence score (pLDDT) that between 0 and 100, where regions with very high confidence score (pLDDT > 90) are shown by blue color, confidently predicted regions (90 > pLDDT > 70) are shown by cyan color, whereas regions

predicted with low (70 > pLDDT > 50) and very low confidence (pLDDT < 50) are shown by

2963

2964

2965

2966

2967

2968

2969

2970

2971

2972

2973

2974

2975

2976

2977

2978

2979

2980

2981

2982

2983

2984

vellow and orange color, respectively. Some regions with low pLDDT may be unstructured in isolation. **B.** Protein-protein interaction network centered at human TPPP/p25 (UniProt: O94811) generated by the Search Tool for the Retrieval of Interacting Genes (STRING, which a qualitycontrolled database that uses experimentally and computationally derived data to detail functional interactions between proteins (Szklarczyk et al., 2019)) using a default medium confidence of 0.4 for the minimum required interaction score. This network includes 41 nodes connected by 139 edges. It is characterized by the average node degree of 6.78 and the average local clustering coefficient of 0.839. Since the expected number of edges for the random set of proteins of the same size and degree distribution drawn from the genome is 57, this network has significantly more interactions than expected and is characterized by the PPI enrichment p-value < 10⁻¹⁶. C. NMR solution structure of the SLAS-micelle bound human α-synuclein (PDB ID: 2KKW, (Rao et al., 2010)) showing an octopus-like appearance of this IDP. **D**. STRINGgenerated PPI network of human α-synuclein (UniProt: O94811) with a high confidence of 0.7 for the minimum required interaction score. Network includes 122 nodes connected by 768 edges, which is significantly higher than the expected number of edges (259), indicating that this network has significantly more interactions than expected and is characterized by the PPI enrichment p-value < 10⁻¹⁶. With the average node degree of 12.6 and the average local clustering coefficient of 0.69, this α-synuclein-centered network is highly connected. **Figure 6**. Intrinsic disorder and binding-induced folding of human p53 (UniProt ID: P04637) and Mdm2 (UniProt ID: Q00987). A. AlphaFold-generated model of the 3D structure of human p53. Note that this static structure represents a snapshot of a highly dynamic conformational ensemble, as structures of regions shown by orange and yellow colors are predicted with low and very low confidence and therefore are disordered. **B.** Intrinsic disorder profile of human p53

2986

2987

2988

2989

2990

2991

2992

2993

2994

2995

2996

2997

2998

2999

3000

3001

3002

3003

3004

3005

3006

3007

generated by the RIDAO platform (Dayhoff and Uversky, 2022). Here, residues with the disorder scores above the threshold of 0.5 (this threshold is shown by thin black solid line) are considered disordered, whereas residues with disorder scores between 0.15 (this threshold is shown by thin dashed black line) and 0.5 are considered flexible. C. AlphaFold-generated model of the 3D structure of human Mdm2. **D**. RIDAO-generated intrinsic disorder profile of human Mdm2. Note the extremely high level of intrinsic disorder in this protein. E. Crystal structure of the human Mdm2 (blue structure) in a complex with a p53 peptide (red structure) (PDB ID: 1T4F; (Grasberger et al., 2005)). Positions of the regions of these proteins used in the crystallization experiments within their amino acid sequences are shown in plot **D**. **Figure 7**. Intrinsic disorder and binding-induced folding of human c-Myc (UniProt ID: P01106) and Max (UniProt ID: P61244). A. AlphaFold-generated model of the 3D structure of human C-Myc. Note that long α-helices that correspond to the basic region/helix-loop-helix/leucine zipper (bHLHZip) domain cannot exist in solution as they are not involved in formation of any hydrophobic core, and therefore they represent regions with very strong helical propensity and high binding potential. Such long standing alone α-helical regions predicted by AlphFold typically correspond to coiled-coil domains of proteins. **B.** Intrinsic disorder profile of human c-Muc generated by the RIDAO platform (Dayhoff and Uversky, 2022). C. AlphaFold-generated model of the 3D structure of human Max. **D**. RIDAO-generated intrinsic disorder profile of human Max. Note that this protein is also predicted to have two long α-helices corresponding to its coiled-coil domain. E. Crystal structure of the Myc-Max recognizing DNA (PDB ID: 1NKP; (Nair and Burley, 2003)). Structures of C-Myc and Max are shown by orange and red colors, whereas DNA is shown in blue and light-blue. Positions of the regions of these proteins used in the crystallization experiments within their amino acid sequences are shown in plot **D**.

Figure 8. Intrinsic disorder profiles of human EWS (top plot), FLI1 (bottom plot), and the EWS-FLI1 chimeric protein (middle plot) generated by the RIDAO platform (Dayhoff and Uversky, 3009 3010 2022). Regions of the EWS and FLI1 incorporated to the EWS-FLI1 chimera are shown by gray 3011 and cyan shades, respectively. 3012 Figure 9. Modular structure and functional intrinsic disorder of human androgen receptor (UniProt ID: P10275). A. Functional disorder profile generated by the D²P² platform (Oates et 3013 3014 al., 2013) showing the outputs of several disorder predictors, such as VLXT, VSL2b, PrDOS, 3015 IUPred and Espritz. Position of conserved functional domains are shown below the bars with the 3016 intrinsic disorder prediction outputs. The colored bar containing blue and green shades represents 3017 the consensus disorder prediction, whereas yellow zigzagged bars show positions of MoRFs. **B**. 3018 3D model generated by AlphaFold (Jumper et al., 2021). 3019 Figure 10. Structural alignment of human IFN-α1/13 (PDB ID: 3ux9, yellow ribbon), IFN-α2 3020 (PDB IDs: 3s9D, chain A, gray ribbon; 3s9D, chain C, orange ribbon; and 1itf, red ribbon) and 3021 human IFN-β (PDB ID: 1au1, blue ribbon). Images A, B, and C correspond to the different 3022 views (left-side, central and right-side) of the aligned structures. D. Evaluation of intrinsic disorder propensities of various subtypes of human IFN-α by the PONDR® VSL2 algorithm 3023 3024 (Peng et al., 2005), which, based on the comprehensive assessment of in silico predictors of 3025 intrinsic disorder, is one of the more accurate stand-alone disorder predictors (Fan and Kurgan, 3026 2014; Peng and Kurgan, 2012). Data for different subtypes are represented by curves of different 3027 color (see the corresponding keys on the plot). Dashed, thick, dark pink line represents the 3028 consensus disorder plot, where the disorder propensity was calculated by averaging the disorder 3029 propensity data for the individual IFNs- α . Position of known α -helices and regions of missing electron density are also indicated. Shaded light pink area shows the position of the signal 3030

peptide (residues 1-23). Residues with the PONDR® VSL2 values above the threshold of 0.5

3031

(this threshold is shown by thin black solid line) are considered disordered, whereas residues 3032 3033 with disorder scores between 0.15 (this threshold is shown by thin dashed black line) and 0.5 are 3034 considered flexible. 3035 Figure 11. Comparison of the intrinsic disorder propensities of consensus interferons and the 3036 mean disorder propensity evaluated for 17 human IFN-α proteins. Plot represents disorder profiles calculated for two consensus interferons, cIFN-α2 (El-Baky et al., 2015a) and IFN-con 3037 (Peciak et al., 2014) and the mean disorder profile based on the data shown in **Figure 10**. Shaded 3038 gray area shows the position of the signal peptide (residues 1-23). 3039 3040 **Figure 12.** Comparison of the HIV-1 glycoprotein gp120 (residues 33-516 of the UniProt ID: 3041 P03377) and a gp120 core (UniProt ID: A0A0M3KKW8). A. Pairwise sequence alignment conducted by an alignment tool for protein sequences, SIM (https://web.expasy.org/sim/) (Huang 3042 3043 and Miller, 1991). Results of the alignment were visualized using LALNVIEW, a graphical 3044 viewer program for pairwise alignments (Duret et al., 1996)Intrinsic disorder profiles of gp120 3045 (**B**) and gp120 core (**C**) generated by the RIDAO platform (Dayhoff and Uversky, 2022). Figure 13. Multiple structure alignment of the heavy chains of Fab of the anti-HIV Abs of human 3046 3047 or bovine origin: Non-neutralizing HIV antibody 13H11 (PDB ID: 3MO1; orange structure); 3048 broadly reactive and potent HIV-1 neutralizing human antibody PG9 (PDB ID: 3U1S; blue 3049 structure) (McLellan et al., 2011); potent HIV-1 broadly neutralizing antibody NC-Cow1 (PDB ID: 6000; green structure) (Stanfield et al., 2020). 3050 3051 Figure 14. Structural characterization of the metallothionein from the snail *Littorina littorea* 3052 (LIMT). A. Illustration of the "clouds in cloud" model. NMR solution structure of the LIMT

3053	(gray structures) in complex with Cd2+ (small pink spheres) (PDB ID: 5ML1; (Baumann et al.,
3054	2017)). This conformational ensemble includes 20 structural models, with each chain binding
3055	nine metal ions. B . Alpha-Fold generated 3D structural model of LIMT. C . Intrinsic disorder
3056	profile of LlMT generated by several commonly used disorder predictors.
3057	Figure 15. Illustration of the ligand cloud concept. Figure represent the first eight clustering
3058	groups of the ligand-bound conformations of c-Myc _{370–409} fragment from the explicit solvent
3059	simulations together with the clouds of bound 10074-A4 ligand. In each cluster, the N- and C-
3060	termini of the c-Myc ₃₇₀₋₄₀₉ fragment are shown by blue and red colors, whereas the structures of
3061	10074-A4 ligand in the each group are depicted as green dots positioned at the centers of mass.
3062	The fractional cluster populations are: A : 14.3%, B : 13.9%, C : 13.7%, D : 10.4%, E : 7.5%, F :
3063	6.9%, G : 5.4%, and H : 5.2%. Figure is reproduced with permission from Jin F., Yu C., Lai L.,
3064	Liu Z. (2013) Ligand clouds around protein clouds: A scenario of ligand binding with
3065	intrinsically disordered proteins. PLoS Comput Biol. 9 (10): e1003249. doi:
3066	10.1371/journal.pcbi.1003249 (57).

Greater capture radius Faster interaction Ability to spatially search kinetics through interaction space Increased interaction area Formation of Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This article has not been copyedited and formatted. The final version may differ from this version. per residue very stable intertwined Larger interaction surfaces complexes in disorder-based complexes **Functional** Regulation **One-to-many interactions** advantages **Specific** efficiency of intrinsic interaction Many-to-one interactions disorder with different partners Presence of overlapping binding sites Interaction Ability to mask (or not) of Formation of Alternative spicing degradation the interaction sites efficiency **Posttranslational** proteinaceous modifications Ability to be involved in complexes cascade interactions Strengthened encounter complex **Binding plasticity** Template-Rapid dependent Less stringent spatial Ability to fold differently at folding orientation requirements bigding to diverse partners Ability to overcome steric Local stabilization of bindingrestrictions **e**competent elements **Signaling Decoupled binding affinity Establishing long-range** interactions and specificity electrostatic interactions **Binding fuzziness** Transient physical contacts with the partner **Ability to interact without** any apparent ordering Figure 2




Figure 3







Figure 4












Figure 8









Figure 10








Figure 13

Pharmrev Fast Forward. Published on 21 October 2024 as DOI 10.1124/pharmrev.124.001113 This are has not been copyedited and formatted. The final version may differ from this version. Α В 1.00 Disorder score 0.75 0.50 PONDR VSL2 PONDR VL3 PONDR FIT 0.25 IUPred_Redox MDP 0.00 20 60 80 0 40 100 Residue number

Figure 14

